Final program

October 24-27, 2023
Boston, MA - USA

www.ctad-alzheimer.com
Email: ctad@ant-congres.com
CTAD 2023: What is coming next in Alzheimer's Disease clinical research?

The 16th Clinical Trials on Alzheimer's Disease conference (CTAD), is held in Boston, Massachusetts (USA) on October 24-27, 2023.

Last November, in San Francisco, California, CTAD 2022 attracted over 2,800 international leaders to discuss the future of Alzheimer’s disease clinical research with pivotal readouts from major pharmaceutical companies and new avenues of treatment beyond Amyloid and Tau.

This year has already seen more breakthrough advances in anti-amyloid treatments, the emergence of diagnostic blood-based biomarkers and encouraging results from other Phase 1 to Phase 3 AD clinical trials.

At CTAD 2023, the scientific program focuses on bringing cutting edge clinical research, thought-provoking roundtable and symposia on the latest advances in AD clinical research. CTAD 2023 brings together leaders from academic research centers, patient advocacy groups, international research coalitions and pharmaceutical companies.

CTAD is also committed to exploring new avenues beyond amyloid-clearing immunotherapy including combination trials of disease-modifying agents, gene therapy, vaccines and multimodal interventions.

The CTAD scientific program is based on a strict peer-review abstract selection process. CTAD 2023 is a great opportunity for clinical and research teams around the world to showcase their work in AD clinical trials.

Boston has long been a hub of laboratory, translational and clinical neuroscience research, and is thrilled to host CTAD this year.

Welcome to Boston!

Editorial

Reisa Sperling, MD
President of the CTAD23 Scientific Committee
President of the CTAD23 Scientific Committee

Reisa Sperling, MD
Harvard Medical School
and Brigham and Women's Hospital, Boston, MA (USA)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Gainesville, USA); Michael C DONOHUE (San Diego, USA); Rachelle DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New-York, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germanu); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON* (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesot, USA); Michael S. RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member
This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Randall J. Bateman, MD in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics.

Randall J. Bateman, MD

Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Tracy Family SILQ Center and Bateman Lab for Neurodegenerative Biology, the Dominantly Inherited Alzheimer Network (DIAN), and the Knight Family DIAN Trials Unit (DIAN-TU), Washington University in St. Louis, St. Louis, MO (United States)

Dr. Bateman’s research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer’s disease. Dr. Bateman’s lab accomplishments include pioneering Stable Isotope Labeling Kinetics (SILK), furthering insights of human circadian patterns, and human in vivo control of the processing of amyloid-beta, apolipoprotein E, tau, and neurofilaments. His lab reported a highly accurate amyloid-beta blood test for Alzheimer’s disease amyloid plaques and also identified specific tau species in blood for accurate quantitation of amyloid pathology, has described the biology and pathophysiology of tau species in brain, CSF and blood, discovered unique soluble tau species that correlate with tau pathology, and also discovered that tau production is increased in Alzheimer’s disease. Dr. Bateman has received awards including the Beeson Award for Aging Research, Alzheimer’s Association Zenith Award, Scientific American top innovator, the Glenn Award for Aging Research, the Metlife Foundation Award for Medical Research, the Potamkin Prize, and is a member of the National Academy of Inventors and the National Academy of Medicine.
“Clinical Trials in Alzheimer’s Disease Prevention”

Sandrine Andrieu, MD, PhD
Professor of Public Health, Clinical Epidemiology and Public Health Department, Toulouse University Hospital, Toulouse (France)

Dr. Sandrine Andrieu is professor of public health of the clinical epidemiology and public health department at the Toulouse University Hospital (France) and adjunct professor at the University of New Mexico (United States). Since 2009 she has been in charge of the Aging Research team at the Center for Epidemiology and Research in Population Health. She served as the Director of the Research Center for Epidemiology and Research in Population Health (UMR1295 INSERM - University Paul Sabatier) from 2011 to 2020. She has published more than 250 international papers and book chapters in the field of aging. She is involved in large prevention studies in neurodegenerative diseases (GuidAge, MAPT) and in European projects (HATICE study, MIND-AD, PRODEMOS). Her main topic of research is Alzheimer’s Disease and prevention of age-related loss of functions and healthy aging. She is the past president of the French National Society of Geriatrics and Gerontology.

“Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer’s disease”

Randall J. Bateman, MD
Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Tracy Family SILQ Center and Bateman Lab for Neurodegenerative Biology, the Dominantly Inherited Alzheimer Network (DIAN), and the Knight Family DIAN Trials Unit (DIAN-TU), Washington University in St. Louis, St. Louis, MO (United States)

Dr. Bateman’s research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer’s disease. Dr. Bateman’s lab accomplishments include pioneering Stable Isotope Labeling Kinetics (SILK), furthering insights of human circadian patterns, and human in vivo control of the processing of amyloid-beta, apolipoprotein E, tau, and neurofilaments. His lab reported a highly accurate amyloid-beta blood test for Alzheimer’s disease amyloid plaques and also identified specific tau species in blood for accurate quantitation of amyloid pathology, has described the biology and pathophysiology of tau species in brain, CSF and blood, discovered unique soluble tau species that correlate with tau pathology, and also discovered that tau production is increased in Alzheimer’s disease. Dr. Bateman has received awards including the Beeson Award for Aging Research, Alzheimer’s Association Zenith Award, Scientific American top innovator, the Glenn Award for Aging Research, The MetLife Foundation Award for Medical Research, the Potamkin Prize, and is a member of the National Academy of Inventors and the National Academy of Medicine.
“What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials”

Cynthia A. Lemere, PhD
Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (United States)

Dr. Lemere is a Scientist in the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital (BWH) and an Associate Professor of Neurology at Harvard Medical School in Boston, MA USA. Her research focuses on understanding and using the immune system therapeutically to prevent and treat Alzheimer’s disease. Dr. Lemere earned a bachelor’s degree in psychology and education from Mount Holyoke College and a master’s in neurobiology from SUNY Albany. Dr. Lemere examined Alzheimer’s-related brain changes in people with Down syndrome in the Selkoe Laboratory at BWH while pursuing her doctorate in pathology at Boston University School of Medicine. Her current research involves: 1. Non-clinical studies of antibody treatments targeting a pathogenic form of amyloid-beta protein found in plaques in Alzheimer’s disease brain; 2. The role of the innate immune system’s complement signaling in aging and Alzheimer’s disease; and 3. The effects of deep space galactic cosmic radiation on brain aging and the risk of Alzheimer’s disease in studies in mouse models and human neural cells in preparation for NASA’s upcoming missions to the moon and Mars. Her lab is funded by NIH and NASA. Dr. Lemere serves as an advisor to the Alzheimer’s Association, the BrightFocus Foundation, the Cure Alzheimer’s Fund, and the AD/PD International Meeting. In addition, she serves as a consultant for several companies.

“Alzheimer’s Disease: the Drug Development Pipeline and Emerging Therapies”

Jeffrey Cummings, MD, ScD
Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)

Dr. Cummings is globally known for his contributions to Alzheimer’s research, drug development, and clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through many awards including the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017), Distinguished Scientist Award of the American Association of Geriatric Psychiatry (2010), Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association (2019), and the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.” Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London. Dr. Cummings was formerly Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He has authored or edited 43 books and published over 800 peer-reviewed papers.
“Creating more Equitable and Valid Alzheimer’s Clinical Trials for the 21st Century”

Monica Rivera-Mindt, PhD

Professor of Psychology, Latinx Studies, and African & African American Studies, Fordham University and joint appointment in Neurology, Icahn School of Medicine at Mount Sinai, New York NY (United States)

Dr. Mónica Rivera Mindt, a board-certified neuropsychologist, is Past-President of the Hispanic Neuropsychological Society and a tenured Professor of Psychology, Latinx Studies, and African & African American Studies at Fordham University with a joint appointment in Neurology at the Icahn School of Medicine at Mount Sinai. Her multidisciplinary, community-based research is funded by the NIH/National Institute of Aging (NIA), the Alzheimer’s Association, NSF, and Genentech. Her work primarily focuses on the intersection between cultural neuroscience and health inequities in cognitive aging. Her current studies are examining genetic, cerebrovascular, and sociocultural risk factors for cognitive impairment and dementia in ethnoculturally diverse populations, as well as ways to increase diverse representation in cognitive aging and dementia research. She has authored more than 100+ peer-reviewed publications and book chapters. In addition, she is Co-Lead of the NIA-funded Alzheimer’s Disease Neuroimaging Initiative’s (ADNI) Engagement Core. At the national level, Dr. Rivera Mindt recently served as Chair of NIH/NIA’s AGCD-4 Study Section, and is a member of the CDC’s BOLD Public Health Center of Excellence on Dementia Risk Reduction Expert Panel, and the CDC/National Alzheimer’s Project Act’s (NAPA) Physical Activity, Tobacco Use, and Alcohol Workgroup. Locally, she serves as a Board Member for the Alzheimer’s Association’s NYC Chapter and a Treasurer for the Harlem Community & Academic Partnership (HCAP). As a bilingual (Spanish/English), Afro-Latinx/Indigenous neuroscientist, she brings a unique perspective to her research and is the recipient of several awards for her research, teaching, and contributions to the field, including the 2020 Martha Bernal Award for the Advancement of Diversity Training and Education in Clinical Psychology from the Council of University Directors of Clinical Psychology (CUDCP) and 2019 Hispanic Health Leadership Award from the National Hispanic Medical Association. She is also a Fellow of the American Psychological Association (Division 40, Society for Clinical Neuropsychology), the National Academy of Neuropsychology, and Hispanic Neuropsychological Society.
IN-PERSON PROGRAM
in Boston
Available via livestream on the CTAD23 digital platform
Tuesday, OCTOBER 24

4.00 p.m. Welcome ceremony and CTAD Lifetime Achievement Award
4.30 p.m. KEYNOTE 1: Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer’s disease
4.55 p.m. SYMPOSIUM 1: The Effects of Race and Gender on Amyloid Positivity
5.35 p.m. LATE BREAKING COMMUNICATIONS
6.50 p.m. CTAD Welcome Reception
7.50 p.m. End of conference day

Wednesday, OCTOBER 25

7.30 a.m. POSTER WALKING TOUR
8.30 a.m. LATE BREAKING COMMUNICATIONS
9.00 a.m. KEYNOTE 2: Creating more Equitable and Valid Alzheimer’s Clinical Trials for the 21st Century
9.25 a.m. SYMPOSIUM 2: Donanemab in Early Symptomatic Alzheimer’s Disease: Additional Insights from TRAILBLAZER-ALZ 2
10.05 a.m. Coffee break and poster session
10.35 a.m. LATE BREAKING COMMUNICATIONS
11.20 a.m. ORAL COMMUNICATIONS
12.35 p.m. Lunch and poster sessions
1.40 p.m. LATE BREAKING SYMPOSIUM 3: Clinical and ATN Biomarker Findings on the Impact of Amyloid Removal in a 10 year prevention trial – the DIAN-TU-001
2.20 p.m. ORAL COMMUNICATIONS
3.20 p.m. LATE BREAKING ROUNDTABLE 1: NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer’s disease
3.50 p.m. Coffee break and poster session
4.20 p.m. KEYNOTE 3: Alzheimer’s Disease: The Drug Development Pipeline and Emerging Therapies
4.55 p.m. LATE BREAKING COMMUNICATIONS
5.25 p.m. LATE BREAKING SYMPOSIUM 4: Lecanemab for Early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration
6.05 p.m. End of conference day

Thursday, OCTOBER 26

7.30 a.m. POSTER WALKING TOUR
8.30 a.m. LATE BREAKING COMMUNICATIONS
9.00 a.m. ORAL COMMUNICATIONS
10.00 a.m. LATE BREAKING ORAL COMMUNICATIONS
10.30 a.m. Coffee break and poster session
11.00 a.m. KEYNOTE 4: Clinical Trials in Alzheimer’s Disease Prevention
11.25 a.m. SYMPOSIUM 5: What can we LEARN from the A4 Study? Associations among longitudinal cognitive, functional, biomarker and imaging outcomes
12.05 p.m. Lunch and poster session
1.20 p.m. ROUNDTABLE 2: Forging the Path Forward: Capitalizing on Recent Alzheimer’s Momentum through Strategic Investments in Novel Therapeutics
1.50 p.m. ORAL COMMUNICATIONS
3.05 p.m. ROUNDTABLE 3: What is meaningful enough for CMS to cover? – What is reasonable and necessary?
3.35 p.m. Coffee break and poster session
4.05 p.m. ORAL COMMUNICATIONS
5.05 p.m. LATE BREAKING SYMPOSIUM 6: Implementing blood biomarkers in clinical practice and trials
5.45 p.m. End of conference day

Friday, OCTOBER 27

7.30 a.m. POSTER WALKING TOUR
8.30 a.m. LATE BREAKING COMMUNICATIONS
9.00 a.m. KEYNOTE 5: What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials
9.25 a.m. LATE BREAKING SYMPOSIUM 7: INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers
10.05 a.m. Coffee break and poster session
10.30 a.m. ORAL COMMUNICATIONS
12.15 p.m. Lunch and poster sessions
1.15 p.m. LATE BREAKING ORAL COMMUNICATIONS
2.15 p.m. ORAL COMMUNICATIONS’ FOCUS SESSION: Phase 1 Clinical Trials
3.05 p.m. Coffee break and poster session
3.30 p.m. LATE BREAKING ORAL COMMUNICATIONS
5.00 p.m. End of the conference
Welcome ceremony and CTAD Lifetime Achievement Award Alzheimer’s Disease Therapeutic Research
Presented to Randall J. Bateman, MD in recognition for his pioneering work in Alzheimer’s Disease Research and Plasma Biomarkers in AD diagnostics
Introduction by Reisa Sperling, President of the CTAD23 Scientific Committee and the CTAD Organizing Committee

KEYNOTE 1
Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer’s disease
Introduction by Reisa Sperling, President of the CTAD23 Scientific Committee
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (United States)

SYMPOSIUM 1
The Effects of Race and Gender on Amyloid Positivity
Chair: Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)
Introduction: Determining amyloid status in different racial, ethnic, and gender groups
Suzanne Schindler, Washington University St. Louis, St. Louis, MO (United States)
Presentation 1: Amyloid PET results from the GAP Bio-Hermes study: initial findings on differences between racial and ethnic groups
Robin Wolz 1, Lynne Hughes 2, Richard Manber 1, Richard Mohs 3, John Dwyer 4, Douglas Beauregard 2
1IXICO - London (United Kingdom), 2Global Alzheimer’s Foundation - Washington (United States)
Presentation 2: Race and Sex Effects on Rates of Amyloid Positivity in Real-World Memory Care: Insights from IDEAS and New IDEAS
Charles Windon 1, Maria Carillo 2, Peggye Dilworth-Anderson 1, Constantine Gatsonis 4, Emily Glavin 4, Lucy Hanna 4, Bruce Hillner 2, Andrew March 2, Sid O’bryant 2, Robert Rissman 2, Barry Siegel 1, Consuelo Wilkins 1, Gil Rabinovici 1
1Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), 2Alzheimer’s Association - Chicago (United States), 3Gillings School of Public Health, University of North Carolina-Chapel Hill - Chapel Hill (United States), 4Department of Epidemiology and Biostatistics, Brown University School of Public Health - Providence (United States), 5American College of Radiology - Reston (United States), 6Center for Statistical Sciences, Brown University School of Public Health - Providence (United States), 7Department of Medicine, Virginia Commonwealth University - Richmond (United States), 8Institute for Translational Research, University of North Texas Health Science Center at Fort Worth - Fort Worth (United States), 9Department of Physiology and Neuroscience, Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States), 10Mallinckrodt Institute of Radiology, Washington University in St Louis - St. Louis (United States), 11Department of Medicine, Division of Geriatric Medicine, Vanderbilt University Medical Center - Nashville (United States)
Questions and Answers

LATE BREAKING COMMUNICATIONS
Moderators: Howard Feldman, University of California San Diego (United States) and Suzanne Schindler, Washington University St. Louis (United States)

LBI - Baseline levels and longitudinal changes in plasma Aβ42/40 among self-identified black and white individuals
Chengjie Xiong 1, Jingqin Luo 1, David Wolk 2, Leslie Shaw 2, Erik Roberson 3, Rachel Henson 1, Tammie Benzinger 1, Quoc Bui 1, Folasade Agboola 1, Elizabeth Grant 1, Emily Gremminger 1, Krista Moulder 1, David Holtzman 1, John Morris 1, Suzanne Schindler 1
1Washington University - St. Louis (United States), 2University of Pennsylvania - Philadelphia (United States), 3University of Alabama - Birmingham (United States)
Tuesday, October 24

> **Conference Room:** All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> **Overflow room:** Due to space constraints in the ballroom, a live feed is available in Avenue 34 at Lobby Level (Floor 1)

**5:50 p.m.**

**LB2 - Plasma MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease**

Kanta Horie 1, 2, 3, Rama Koppisetty 1, 2, Shothi Janelidze 4, Erik Stomrud 4, 5, Nicolas Barthélemy 1, 2, Chihiro Sato 1, 2, Tammie Benzinger 6, David Holtzman 2, John Morris 2, Nicklas Mattsson-Carlgren 4, 5, Sebastian Palmqvist 4, 5, Suzanne Schindler 7, Oskar Hansson 4, 5, Randall Bateman 1, 2

1Tracy Family SILQ Center, Washington University School of Medicine - St. Louis (United States), 2Department of Neurology, Washington University School of Medicine - St. Louis (United States), 3Eisai Inc - Nutley (United States), 4Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), 5Memory Clinic, Skåne University Hospital - Malmö (Sweden), 6Department of Radiology, Washington University School of Medicine - St. Louis (United States)

**6:05 p.m.**

**LB3 - Topline Results From the Phase 2 PIONEER Trial of Oral T3D-959 for the Treatment of Patients Diagnosed With Mild-to-Moderate Alzheimer’s Disease**

Jessica Stanek 1, Stanley Chamberlain 1, Chris Coutlee 1, Warren Strittmatter 1, Charles Lineberry 1, Blake Swearengen 1, John Didsbury 1

1T3D Therapeutics, Inc. - Research Triangle Park (United States)

**6:20 p.m.**

**LB4 - Safety, immunogenicity, clinical efficacy and biomarkers of ABvac40, an active vaccine anti-Aβ40 in patients with amnestic mild cognitive impairment or very mild Alzheimer’s disease: final results of a phase 2 randomized study**

Jose Terencio 1, 2, María Pascual-Lucas 3, Ana María Lacosta 3, María Montañés 3, Jesús Canudas 3, José Antonio Allué 3, Leticia Sarasa 1, Noelia Fandos 1, Judith Romero 1, Elisabet Molina 1, Manuel Sarasa 1, Merce Boada 4

1Grifols - Barcelona (Spain), 2Araclon Biotech-Grifols - Zaragoza (Spain), 3Araclon-Biotech - Zaragoza (Spain), 4Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain)

**6:35 p.m.**

**LB5 - Tau vaccine AADvac1 demonstrates clinical and biomarker efficacy on patients with plasma p-tau217 defined Alzheimer’s disease in Phase II clinical trial: post hoc analysis**

Branislav Kovacech 1, Nicolas Cullen 1, Petr Novak 1, Jozef Hanes 1, Eva Kontsekova 1, Michal Fresser 1, Jeroen Vanbrabant 1, Howard Feldman 1, Bengt Winblad 1, Eric Stoops 1, Eugen Vanmechelen 1, Norbert Zilka 1

1Axon Neuroscience R&D Services - Bratislava (Slovakia), 2Department of Clinical Sciences, Lund University - Lund (Sweden), 3Axon Neuroscience SE - Lamaca (Cyprus), 4Axon NeuroSciences NV, Technologiepark 94 - Bio Incubator - Gent (Belgium), 5Department of Neurosciences, University of California San Diego - La Jolla (United States), 6Karolinska Institutet, Dept IVS, Center for Alzheimer Research, Division of Neurogeriatrics - Solna (Sweden)

**6:50 - 7:50 p.m.**

**CTAD Welcome Reception with the Support of the Alzheimer’s Association**
Wednesday, October 25

> Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

7:30 a.m.

POSTER WALKING TOUR - Poster Hall

8:30 a.m.

LATE BREAKING COMMUNICATIONS
Moderators: Rebecca Amariglio, Harvard Medical School - Boston (United States) and John O’Gorman, Biogen - Cambridge (United States)

8:30 a.m.

LB6 - Pooled ENGAGE/EMERGE Integrated Placebo-controlled Period and Long-Term Extension (LTE) Topline Results: Slower Clinical Progression at Week 134 in Aducanumab-treated Patients that Became Amyloid PET Negative at Week 78
John O’Gorman 1, Jennifer Murphy 1, Philip Montenigro 1, Shardae Showell 1, Gersham Dent 1, Carrie Rubel 1, R. Matthew Hutchison 1, Tianle Chen 1, Kumar Kandadi Muralidharan 1, Kate Dawson 1
1Biogen - Cambridge (United States)

8:45 a.m.

LB7 - PrecivityAD2 blood test: An analytically and clinically validated test combining p-tau217/np-tau217 and Aβ42/40 ratios to identify brain amyloid
Kristopher Kirmess 1, Matthew Meyer 1, Traci Wente-Roth 1, Faith Irwin 1, Mary Holubasch 1, Stephanie Eastwood 1, Venky Venkatesh 1, Michael Irizarry 2, David Verbel 2, Pallavi Sachdev 2, Satoshi Ito 2, Kevin Yarasheski 1, Joel Braunstein 1, Philip Verghese 1, Tim West 1
1C2N Diagnostics - St. Louis (United States), 2Eisai Inc. - Nutley (United States)

9:00 a.m.

KEYNOTE 2
Creating more Equitable and Valid Alzheimer’s Clinical Trials for the 21st Century
Introduction: Mike Weiner, University of California San Francisco (United States)
Monica Rivera-Mindt, Icahn School of Medicine at Mount Sinai, New York, NY (United States)

9:25 a.m.

SYMPOSIUM 2
Donanemab in Early Symptomatic Alzheimer’s Disease: Additional Insights from TRAILBLAZER-ALZ 2
Chair: Takeshi Iwatsubo, The University of Tokyo, Tokyo (Japan)

Presentation 1: Safety Insights from the Donanemab Trials
Steve Greenberg, Harvard Medical School and Massachusetts General Hospital, Boston, MA (United States)

Presentation 2: Predicting Efficacy in Donanemab-Treated Participants
Mark Mintun, Eli Lilly and Company, Indianapolis, IN and Avid Radiopharmaceuticals, Inc. Philadelphia, PA (United States)

Presentation 3: Clinical Meaningfulness of Donanemab Treatment
Alireza Atri, Banner Sun Health Research Institute, Sun City, AZ (United States)

10:05 a.m. Coffee break and poster session

10:35 a.m.

LATE BREAKING COMMUNICATIONS
Moderators: Gad Marshall, Massachusetts General Hospital, Harvard Medical School - Boston (United States), and Catherine Mummer, University College London - London (United Kingdom)

10:35 a.m.

LB8 - Efficacy of Donanemab by APOE4 Carrier Status in TRAILBLAZER-ALZ 2, a Phase 3 Randomized Clinical Trial in Early Symptomatic Alzheimer’s Disease
Cynthia D. Evans 1, Jennifer A. Zimmer 1, Alette M. Wessels 1, Ming Lu 1, Jon david Sparks 1, Mark Mintun 1, Dawn A. Brooks 1, John R. Sims 1
1Eli Lilly and Company - Indianapolis (United States)
10.50 a.m.  LB9 - Exploratory clinical outcomes from BIIB080 (MAPT ASO) phase 1b multiple ascending dose and long-term extension study in mild Alzheimer’s disease

Nick Ziegas 1, Shuang Wu 1, Yumeng Li 1, Lin Lin 1, Amanda Edwards 1, Jessica Collins 1, Irene Tien 1, Catherine Mummery 2, Roger Lane 2, Candice Junge 3, John Beaver 1, Ying Tian 1, Jaren Landen 1, Diana Gallagher 1, Melanie Shulman 1

1Biogen - Cambridge (United States), 2Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London - London (United Kingdom), 3Ionis Pharmaceuticals - Carlsbad (United States)

11.05 a.m.  LB10 - Phase 1 safety, tolerability, and pharmacological results of ALN-APP, the first investigational RNA interference therapeutic in development for early-onset Alzheimer’s disease

Catherine Mummery 1, Simon Ducharme 2, Jared Brosch 3, Everard Vijverberg 4, Liana Apostolova 5, Alexandre Sostelly 5, Sasikiran Goteti 5, Nune Makarova 5, Andreja Avbersek 6, Weinong Guo 5, Brett Bostwick 5, Sharon Cohen 5

1University College London - London (United Kingdom), 2Douglas Mental Health University Institute, Department of Psychiatry and Montreal Neurological Institute, Department of Neurology & Neurosurgery, McGill University - Montreal, Quebec (Canada), 3Indiana University School of Medicine - Indianapolis, Indiana (United States), 4Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC - Amsterdam (Netherlands), 5Alnylam Pharmaceuticals - Cambridge, Massachusetts (United States), 6Regeneron Pharmaceuticals, Inc. - Tarrytown, New York (United States), 7Toronto Memory Program - Toronto, Ontario (Canada)

11.20 a.m.  OC1 - Clinical effects of Lewy body pathology in clinically unimpaired and cognitively impaired individuals

Oskar Hansson 1, 2, Sebastian Palmqvist 1, 2, Piero Parchi 1, 3

1Lund University - Lund (Sweden), 2University of Bologna - Bologna (Italy)

11.35 a.m.  OC2 - Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease

Gemma Salvadó 1, 2, Kanta Horie 1, 2, 3, Nicolas R Barthélémy 4, 5, 6, Jacob W Vogel 1, 3, 7, Alexia Pichert Binette 1, 3, 4, Charlie D Chen 5, 6, Brian A Gordon 5, 6, Tammie L Benzinger 6, 7, David M Holtzman 1, 2, 3, John C Morris 3, 7, Shorena Janelidze 1, 3, Rik Ossenkoppele 1, 3, 6, 7, Suzanne E Schindler 1, 2, 3, Randall J Bateman 2, 3, 7, Oskar Hansson 1, 4, 10

1Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), 2The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), 3Department of Neurology, Washington University School of Medicine - St Louis (United States), 4Eisai Inc. - New York (United States), 5Eisai Europe Ltd, Lund (United Kingdom), 6Eisai Europe Ltd, Lund (United Kingdom), 7Department of Radiology, Washington University School of Medicine - St Louis (United States), 8Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), 9Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), 10Memory Clinic, Skåne University Hospital - Malmö (Sweden)

11.50 a.m.  OC3 - The anti-amyloid beta “brain shuttle” antibody trontinemab rapidly reduces amyloid plaques in people with Alzheimer’s disease

Luka Kulic 1, Fabien Alcaraz 1, Annamarie Vogt 1, Carsten Hofmann 1, Philip Barrington 2, Maddalena Marchesi 1, Gregory Klein 1, Ruth Coney 3, David Agnew 3, João A. Abrantes 1, Silke Ahlers 4, Paul Delmar 1, Iris Wiesel 1, Hanno Svoboda 1

1Roche - Basel (Switzerland), 2TranScrip group - Wokingham (United Kingdom), 3Roche - Welwyn (United Kingdom), 4Excelya Germany GmbH - Mannheim (Germany)

12.05 p.m.  OC4 - Rapid detection of the earliest amyloid-related changes in memory consolidation: assessment of learning using daily digital testing

Kate Papp 1, 2, Roos Jutten 1, 2, Daniel Soberanes 1, 2, Emma Weizenbaum 1, 2, Stephanie HSieh 1, Cassidy Molinare 1, 2, Rachel Buckley 1, 2, Rebecca Betensky 3, 4, Keith Johnson 1, 2, Dorene Rentz 1, 2, Reisa Sperling 3, 4, Rebecca Amariglio 1

1Department of Biostatistics, Harvard T.H. Chan School of Public Health - Boston (United States), 2Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School - Boston (United States)

12.20 p.m.  OC5 - Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer’s Disease

Christopher Reading 1, 2, Clarence Ahlem 1, Joseph Palumbo 1, Nily Osman 1, 2, Marcia Testa 1, 2, Donald Simonson 3

1BioVié Inc. - Carson City (United States), 2Department of Biostatistics, Harvard T.H. Chan School of Public Health - Boston (United States), 3Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School - Boston (United States)
Wednesday, October 25

1.40 p.m.  **LATE BREAKING SYMPOSIUM 3**
Clinical and ATN Biomarker Findings on the Impact of Amyloid Removal in a 10 year prevention trial – the DIAN-TU-001
Chairman: Randall Bateman, Washington University School of Medicine - St Louis (United States)

Presentation 1: A comprehensive analysis of CSF tau following amyloid reduction recapitulates the tau-related staging of Alzheimer disease biomarkers.
Eric McDade, Washington University School of Medicine - St Louis (United States)

Presentation 2: Examining Amyloid Reduction as A Surrogate Endpoint through Latent Class Analysis Using Clinical Trial Data for Dominantly Inherited Alzheimer’s Disease
Guoqiao Wang, Washington University School of Medicine - St Louis (United States)

Presentation 3: Top-line results of gantenerumab amyloid removal in the prevention of symptom onset and dementia progression in the DIAN-TU
Randall Bateman, Washington University School of Medicine - St Louis (United States)

2.20 p.m.  **ORAL COMMUNICATIONS**
Moderators: Sandrine Andrieu, Toulouse University Hospital, Toulouse (France) and Ali Rezai, WVU Rockefeller Neuroscience Institute - Morgantown (United States)

2.20 p.m.  **OC6 - Plasma P-tau217 facilitates a two-phase screening approach for participant selection into anti-amyloid trials**
Niklas Mattsson-Carlsson 1, Lyduine Collij 1,2, Alex Pichet Binette 1, Rik Ossenkoppele 1,2, Ruben Smith 1, Olof Strandberg 1, Sebastian Palmqvist 1, Erik Stomrud 1, Nicholas Ashton 3, Kaj Blennow 3, Shorena Janelidze 1, Oskar Hansson 1
1Lund University - Lund (Sweden), 2Amsterdam UMC - Amsterdam (Netherlands), 3University of Gothenburg - Gothenburg (Sweden)

2.35 p.m.  **OC7 - Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Patients with Signs and Symptoms of Cognitive Impairment**
Will Canestaro 1, Randall Bateman 2, David Holtzman 2, Mark Monane 3, Joel Braunstein 3
1University of Washington School of Pharmacy - Seattle (United States), 2Washington University School of Medicine - St Louis (United States), 3C2N Diagnostics - St Louis (United States)

2.50 p.m.  **OC8 - A phase 2b clinical trial of neflamapimod in dementia with Lewy bodies designed to confirm the efficacy results from phase 2a**
Niels D. Prins 1, Amanda Gardner 2, Hui-May Chu 3, Kelly Blackburn 3, James E. Galvin 4, John J. Alam 2
1Brain Research Center - Amsterdam (Netherlands), 2EIP Pharma Inc - Boston (United States), 3Anoixis Corporation - Natick (United States), 4University of Miami Miller School of Medicine - Boca Raton (United States)

3.05 p.m.  **OC9 - Accelerated β-amyloid plaque reduction in Alzheimer’s disease combining aducanumab infusion with focused ultrasound blood-brain barrier opening**
Ali Rezai 1, Pierre D’haese 1, Marc Hut 1, Manish Ranjan 1, Jeffrey Carpenter 1, Rashi Mehta 1, Kirk Wilhelmsen 1, Peng Wang 1, Victor Finomore 1, Sally Hodder 1
1WVU Rockefeller Neuroscience Institute - Morgantown (United States)

3.20 p.m.  **LATE BREAKING ROUNDTABLE 1**
NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer’s disease
Chair: Laurie Ryan, National Institute on Aging/NIH - Bethesda (United States)

Panelists: Clifford Jack 1, Reisa Sperling 2,3, Oskar Hansson 4, Heather Snyder 1, Laurie Ryan 6
1Mayo Clinic - Rochester (United States), 2Brigham and Women’s Hospital - Boston (United States), 3Massachusetts General Hospital - Boston (United States), 4Lund University - Lund (Sweden), 5Alzheimer’s Association - Chicago (United States), 6National Institute on Aging/NIH - Bethesda (United States)

3.50 p.m.  Coffee break and poster session 🍵
**Wednesday, OCTOBER 25**

- **Conference Room**: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
- **Overflow room**: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

---

### 4.20 p.m.

**KEYNOTE 3**

**Alzheimer's Disease: The Drug Development Pipeline and Emerging Therapies**

*Introduction:* Bruno Vellas, Toulouse University Hospital, Toulouse (France)

**Jeffrey Cummings**, University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)

---

### 4.55 p.m.

**LATE BREAKING COMMUNICATIONS**

*Moderators:* Yan Li, Washington University St. Louis, St. Louis (United States) and Jeffrey Cummings University of Nevada Las Vegas (UNLV), Las Vegas (United States)

---

### 4.55 p.m.

**LB11 - Rapid amyloid clearance and efficacy: Results from TRAILBLAZER-ALZ 2, a phase 3 study of donanemab for treatment of early Alzheimer's disease**

Sergey Shcherbinin 1, Ming Lu 1, Jian Wang 1, Hong Wang 1, Paula Hauck 1, Ivelina Gueorguieva 1, Dawn Brooks 1, John Sims 1, Mintun Mintun 1, Emily Collins 1

1Eli Lilly and Company - Indianapolis (United States)

---

### 5.10 p.m.

**LB12 - Reduced caregiver distress associated with neuropsychiatric symptoms in EMERGE, a Phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer's disease**

Jeffrey Cummings 1, Sharon Cohen 2, Jennifer Murphy 1, Ping He 4, Carl De Moor 3, Fiona Forrestal 3, John Harrison 4, Judith Jaeger 8, 9, Catherine Jane Mummery 10, Anton P. Porsteinsson 11, Michele Potashman 12, Ying Tian 3, Lili Yang 13, John O’gorman 1, Samantha Budd Haeberlein 14

1Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV - Las Vegas (United States), 2Toronto Memory Program - Toronto (Canada), 3Biogen Inc. - Cambridge (United States), 4Takeda Pharmaceutical Company Limited - Boston (United States), 5Certara - Princeton (United States), 6Scottish Brain Sciences - Edinburgh (United Kingdom), 7Alzheimercentrum of the Amsterdam UMC - Amsterdam (Netherlands), 8CognitionMetrics, LLC - Stamford (United States), 9Albert Einstein College of Medicine - New York (United States), 10Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), 11University of Rochester School of Medicine and Dentistry - Rochester (United States), 12Biohaven Pharmaceuticals Inc - New Haven (United States), 13Alnylam Pharmaceuticals - Cambridge (United States), 14Enigma Biomedical USA - Nashville (United States)

---

### 5.25 p.m.

**LATE BREAKING SYMPOSIUM 4**

**Lecanemab for Early Alzheimer's Disease-Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration**

*Chairman:* Christopher van Dyck, Yale Alzheimer's Disease Research Center - New Haven (United States)

**Presentation 1: Clarity AD: Review of the Mechanism-Based Rationale and Results of the Lecanemab Phase 3 Trial**

Christopher van Dyck, Yale Alzheimer's Disease Research Center - New Haven (United States)

**Presentation 2: Biomarker Assessments from Clarity AD: Downstream Implications of Targeting Protofibrils and Tau as a Predictive Biomarker**

Keith Johnson, Harvard Medical School - Boston (United States)

**Presentation 3: Lecanemab for the Treatment of Early Alzheimer's Disease: The Extension of Efficacy Results from Clarity AD**

Reisa Sperling, Brigham and Women's Hospital Harvard Medical School - Boston (United States)

**Presentation 4: Preliminary Update on Lecanemab Safety in Clarity AD Open-Label Extension, Including Subcutaneous Formulation**

Michael Irizarry, Eisai Inc. - Nutley (United States)

Panel Discussion and Q&A

---

### 6.05 p.m.

**End of the Conference Day**
Thursday, OCTOBER 26

**POSTER WALKING TOUR** - Poster Hall

8:30 a.m. **LATE BREAKING COMMUNICATIONS**

**LB13 - Time Savings Estimates for Donanemab TRAILBLAZER-ALZ Phase 2 & Phase 3 Studies**

Samuel P. Dickson 1, Suzanne B. Hendrix 1, Lars Lau Raket 2, Saptarshi Chatterjee 2, Joshua Christensen 1, Benjamin Haaland 1, Jon David Sparks 2, John R. Sims 2, Dawn A. Brooks 2, Mark A. Mintun 2

1Pentara Corporation - Salt Lake City (United States), 2Eli Lilly and Company - Indianapolis (United States)

8:45 a.m. **LB14 - Evidence that Lumipulse G pTau217 Plasma measurements have the ability to quantitatively assess Tau stage and burden**

Anthony Bannon 1, Edwin Stage 1, Manu Vandijck 2, Francesca Desimone 2, John Lawson 3, Larry Ward 4, Vincent Doré 5, James Doecke 6, Chris Fowler 4, Jondavid Sparks 2, John R. Sims 2, Dawn A. Brooks 2, Mark A. Mintun 2

1AbbVie Inc - North Chicago (United States), 2Fujirebio - Antwerp (Belgium), 3Fujirebio - Malvern (United States), 4The Florey Institute of Neuroscience and Mental Health - Melbourne (Australia), 5CSIRO - Melbourne (Australia), 6CSIRO - Brisbane (Australia)

9:00 a.m. **ORAL COMMUNICATIONS**

9:00 a.m. **Emerging Solutions: Novel Approaches to Treating Alzheimer’s Disease**

Chair and introduction: Howard Fillit, Alzheimer’s Drug Discovery Foundation, New York, NY (United States)

9:15 a.m. **OC10 - Allopregnanolone Regenerative Therapeutic for Mild Alzheimer’s Disease**

Roberta Brinton 1, Gerson Hernandez 1, Claudia Lopez 1, Lon Schneider 2

1University of Arizona - Tucson (United States), 2University of Southern California - Los Angeles (United States)

9:30 a.m. **OC11 - Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in an ongoing Phase 1/2 AD study**

Terrence Fisher 2, Elizabeth Evans 1, Megan Boise 1, Vikas Mishra 1, Crystal Mallow 1, John Leonard 1, Eric Siemens 2, Raymond Turner 1, Wendy Bond 4, John Huffaker 2, Maurice Zauderer 1

1Vaccinex, Inc. - Rochester (United States), 2Siemers Integration LLC - Indianapolis (United States), 3Re-Cognition Health - Fairfax (United States), 4Neuropsychiatric Research Center of Southwest Florida - Fort Myers (United States)

9:45 a.m. **OC12 - Astrocyte reactivity biomarker for the populational enrichment of clinical trials in preclinical Alzheimer’s disease**

Bruna Bellaver 1, Guilherme Povala 1, Pamela C.I. Ferreira 1, João Pedro Ferrari-Souza 1, Douglas Teixeira Leffa 1, Firoza Z. Lussier 1, Andrea L. Benedet 2, Nicholas J. Ashton 2, Eduardo R. Zimmer 2, Henrik Zetterberg 2, Kaj Blennow 2, Ann Cohen 1, Thomas K. Karikari 1, Pedro Rosa-Neto 1, Tharick A. Pascoal 1

1University of Pittsburgh - Pittsburgh (United States), 2University of Gothenburg - Gothenburg (United States), 3Universidade Federal do Rio Grande do Sul - Porto Alegre (United States), 4McGill University - Montreal (United States)

10:00 a.m. **LATE BREAKING ORAL COMMUNICATIONS**

Moderators: Mike Rafii, Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego - San Diego (United States) and Sharon Cohen, Toronto Memory Program - Toronto (Canada)

10:15 a.m. **LB15 - An exploration of amyloid removal measures in relation to clinical benefit: a review and meta-regression of anti-amyloid trials in AD**

Marzia Antonella Scelsi 1, Josie Jackson 1, Matteo Tonietto 2, Gregory Klein 2, Christopher Lane 1, Janice Smith 1, Rachelle Doody 2, Paul Delmar 2

1Roche Products Ltd - Welwyn Garden City (United Kingdom), 2F. Hoffmann-La Roche AG - Basel (Switzerland)
Thursday, October 26

> Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

10.15 a.m.  
**LB16 - Progression analysis on cognitive, functional, and behavioral endpoints in EMERGE, a Phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer’s disease**  
Sharon Cohen 1, Jeffrey Cummings 2, Jennifer Murphy 3, Ping He 4, Mihaela Levitchi Bena 5, Fiona Forrestal 6, John Harrison 6,7, Judith Jaeger 8,9, Catherine Jane Mummery 10, Anton P. Porsteinsson 11, Michele Potashman 12, Lili Yang 13, Shuang Wu 13, Ying Tian 13, Samantha Budd Haeberlein 14  
1Toronto Memory Program - Toronto (Canada), 2University of Las Vegas - Las Vegas (United States), 3Biogen Inc. - Cambridge (United States), 4Takeda Pharmaceutical Company Limited - Boston (United States), 5Fulcrum Therapeutics - Cambridge (United States), 6Scottish Brain Sciences - Edinburgh (United Kingdom), 7Alzheimercentrum of the AUMC - Amsterdam (Netherlands), 8CognitionMetrics, LLC - Stamford (United States), 9Albert Einstein College of Medicine - New York (United States), 10Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), 11University of Rochester School of Medicine and Dentistry - Rochester (United States), 12Biohaven Pharmaceuticals, Inc. - New Haven (United States), 13Alnylam Pharmaceuticals - Cambridge (United States), 14Enigma Biomedical USA - Nashville (United States)

10.30 a.m.  
Coffee break and poster session

11.00 a.m.  
**KEYNOTE 4**  
Clinical Trials in Alzheimer's Disease Prevention  
Introduction: Paul Aisen, Alzheimer Therapeutic Research Institute, University of Southern California - San Diego (United States)  
Sandrine Andrieu, Toulouse University Hospital, Toulouse (France)

11.25 a.m.  
**SYMPOSIUM 5**  
What can we LEARN from the A4 Study? Associations among longitudinal cognitive, functional, biomarker and imaging outcomes  
Chair: Paul Aisen, Alzheimer Therapeutic Research Institute, University of Southern California - San Diego (United States)  
Presentation 1: Plasma phospho-tau217 baseline and longitudinal outcome measures in the A4 Study  
Roy Yaari, Lilly and Co. - Indianapolis (United States)  
Presentation 2: Amyloid and Tau PET in the A4 Study  
Keith Johnson, Massachusetts General Hospital, Harvard Medical School - Boston (United States)  
Presentation 3: Predictors of Cognitive and Functional Decline in the A4 and LEARN Studies  
Reisa Sperling, Brigham and Women’s Hospital Harvard Medical School - Boston (United States)

12.05 p.m.  
Lunch and poster session

1.20 p.m.  
**ROUNDTABLE 2**  
Forging the Path Forward: Capitalizing on Recent Alzheimer’s Momentum through Strategic Investments in Novel Therapeutics  
Howard Fillit 1, Philip Scheltens 3, Susan Kohlhaas 3, John Behr 4, Joe Lewcock 3  
1Alzheimer’s Drug Discovery Foundation - New York City (United States), 2EQT Life Sciences - Amsterdam (Netherlands), 3Alzheimer’s Research UK - London (United Kingdom), 4Dementia Discovery Fund - London (United Kingdom), 5Denali Therapeutics - South San Francisco (United States)
Thursday,
OCTOBER 26

1.50 p.m. ORAL COMMUNICATIONS
Moderators: Nicola Coley, INSERM-University of Toulouse UMR1295, Toulouse (France) and Lars Lannfelt, BioArctic AB - Stockholm (Sweden)

OC15 - Stress Testing the CL concept: Evaluating Centiloid Stability to Tracer, Effective Image Resolution and Quantification Method
Mahnaz Shekari1,2,3, David Vállez García4, Lyduine E Collij4, Daniel Alcolea4,5, Fiona Heeman6, Hugh Pemberton6,7, Núria Roé Vellvé6, Santiago Bullich6, Christopher Buckley6, Andrew Stephens6, Gill Farrar6, Giovanni Frisoni7, William.e Klunk9, Frederik Barkhof1,2, Juan Domingo Gispert1,2,10
1BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), 2IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), 3Universitats Pompeu Fabra - Barcelona (Spain), 4Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 5Memory Center, University Hospitals and University of Geneva - Geneva (Switzerland), 6GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), 7University College London London (United Kingdom), 8Life Molecular Imaging GmbH - Berlin (Germany), 9University of Pittsburgh - Pittsburgh (United States), 10Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN) - Barcelona (Spain)

OC16 - End-to-end automated scoring of speech-based cognitive assessments for Alzheimer’s Disease: A comparison with manual scoring in the AMYPRED-US and AMYPRED-UK studies
Jack Weston1, Udeepa Meepegama1, Caroline Skirrow1, Michael Ropacki2, Emil Fristed1
1Novoic - London (United Kingdom), 2Oryzon - Temecula (United States)

OC17 - Characterization of the synaptic blood marker β-synuclein in different stages of Alzheimer’s disease and other dementias
Patrick Oeckl1, Giovanni Bellomo2, Lorenzo Barba3, Daniel Alcolea4, Anna L Wozdala2, Juan Fortea4, Alberto Lleó4, Lucilla Parnetti1, Olivia Belbin4, Markus Otto3
1Ulm University Hospital, Department of Neurology and DZNE Ulm - Ulm (Germany), 2Section of Neurology, Department of Medicine and Surgery, University of Perugia - Perugia (Italy), 3Department of Neurology, Martin-Luther-University of Halle-Wittenberg - Halle (Saale) (Germany), 4Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain - Barcelona (Spain)

OC18 - Remote detection and characterization of cognitive performance trajectories in mild cognitive impairment and populations at-risk from the INTUITION brain health study
Monroe Butler2, Roland Brown1, Andrew Becker1, Matt Hobbs1, Paramita Saha-Chaudhuri1, Joaquin Penalver-Andres1, Daniel Roggen1, Alf Scotland1, Yuval Zabar1, Richard Hughes1, Hanson Lennyy1, Matt Bianchi2, Audrey Gabelle1, Shibeshih Belachew3
1The Intuition Scientific Study Committee
2Biogen - Cambridge (United States), 3Apple - Cupertino (United States)

OC19 - Binding profiles of lecanemab and donanemab to different amyloid-beta species
Lars Lannfelt1,2, Malin Johansson1, Patrik Nygren1, Adeline Rachalski1, Emily Button1, Anne-Sophie Svensson1, Eleni Gkanatsiou1, Nicolas Fritz1, Olof Zachrisson1, Linda Söderberg1, Christer Möller1
1BioArctic AB - Stockholm (Sweden), 2Department of Public Health/Geriatrics - Uppsala (Sweden)

3.05 p.m. ROUNDTABLE 3
What is meaningful enough for CMS to cover? – What is reasonable and necessary?
Chair: Lefkos Middleton, Imperial College - London (United Kingdom)
Discussants: Maria Carrillo1, Ron Petersen2, Lon Schneider1
1Alzheimer’s Association - Chicago, IL (United States), 2Mayo Clinic - Rochester, MN (United States), 3USC - Los Angeles (United States)

3.35 p.m. Coffee break and poster session
Thursday, OCTOBER 26

> Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

4.05 p.m. **ORAL COMMUNICATIONS**
**Moderators:** Lon Schneider, Keck School of Medicine of USC - Los Angeles (United States) and Guoqiao Wang, Washington University School of Medicine, St Louis (United States)

4.05 p.m. **OC20 - Estimating Time-Saving Treatment Effects in Alzheimer’s Clinical Trials: Exploring Alternative Approaches**
Guoqiao Wang 1, Gary Cutter 2, Lon Schneider 3, Whedy Wang 4, Brian Mangal 4, Yijie Liao 5, Yan Li 1, Chenjie Xiong 1, Jorge Libre-Guerra 1, Eric Mccade 1, Randall Bateman 1

1Washington University School of Medicine, St. Louis, MO - St Louis (United States), 2University of Alabama at Birmingham - Birmingham (United States), 3Keck School of Medicine, University of Southern California - Los Angeles (United States), 4Alector, Inc - San Francisco (United States), 5Asher Biotherapeutics - San Francisco (United States)

4.20 p.m. **OC21 - The Potential for Time Savings in Early Alzheimer Clinical Trials**
Lon Schneider 1, Guoqiao Wang 2, Richard Kennedy 3, Gary Cutter 3

1Keck School of Medicine of USC - Los Angeles (United States), 2Washington University - Saint Louis (United States), 3University of Alabama, Birmingham - Birmingham (United States)

4.35 p.m. **OC22 - Precision medicine analysis of heterogeneity in individual-level treatment response to beta-amyloid removal in early Alzheimer’s disease**
Menglan Pang 1, Audrey Gabelle 1, Paramita Saha-Chaudhuri 1, Willem Huijbers 1, Arie Gafson 1, Paul Matthews 2, Lu Tian 3, Ivana Rubino 1, Richard Hughes 1, Carl De Moor 1, Shibeshih Belachew 1, Changyu Shen 1

1Biogen - Cambridge (United States), 2Imperial College London - London (United Kingdom), 3Stanford University School of Medicine - Stanford (United States)

4.50 p.m. **OC23 - Effects of an 18-month multimodal intervention on cognitive function (J-MINT PRIME Tamba): A randomized controlled trial**
Yutaro Oki 1, Tohmi Osaki 2, Ryoko Kumagai 3, Shunsuke Murata 4, Haruhi Encho 3, Hisafumi Yasuda 1, Rei Ono 5, Hisatomo Kowa 3

1Department of Public Health, Kobe University Graduate School of Health Sciences - Kobe (Japan), 2Department of Occupational Therapy, Faculty of Rehabilitation, Kobe Gakui University - Kobe (Japan), 3Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences - Kobe (Japan), 4Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute - Suita (Japan), 5Department of Physical Activity Research, National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition - Ibaraki (Japan)

5.05 p.m. **LATE BREAKING SYMPOSIUM 6**
Implementing blood biomarkers in clinical practice and trials
Chair: Stephen Salloway, Brown Universitiy - Providence (United States)

Presentation 1: Defining the minimum acceptable performance of blood-based biomarkers of Alzheimer’s disease for clinical use in symptomatic patients
*Suzanne Schindley, Washington University School of Medicine - St. Louis (United States)*

Presentation 2: A highly accurate blood test for Alzheimer’s disease pathology has performance equivalent or superior to clinically used cerebrospinal fluid tests
*Oskar Hansson, Lund University - Lund (Sweden)*

Presentation 3: Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s Disease
*Robert Rissman, Alzheimer, University California San Diego - San Diego (United States)*

5.45 p.m. End of the Conference Day
Friday, OCTOBER 27

> Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

7.30 a.m.  
**POSTER WALKING TOUR** - Poster Hall

8.30 a.m.  
**LATE BREAKING COMMUNICATIONS**

**Moderators:** Merce Boada, Fundacio Ace, Barcelona (Spain) and Christopher Van Dyck, Yale School of Medicine - New Haven (United States)

8.30 a.m.  
**LB17 - Topline results of a Phase II Trial of Edonerpic Maleate in Patients with Early Stage Biomarker-Proven Alzheimer’s Disease**

**Niels Prins**, Charlotte Teunissen, Pieter Van Bokhoven, Sietske Sikkes 4, Willem De Haan 4, Tomohiro Okuda 5,

Philip Scheltens 6

1Brain Research Center - Amsterdam (Netherlands), 2Neurochemistry Laboratory, Department of Neurochemistry, Amsterdam UMC - Amsterdam (Netherlands), 3IAA Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), 4Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), 5FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), 6Amsterdam UMC - Amsterdam (Netherlands)

8.45 a.m.  
**LB18 - CT1812 START Study Design: Anti-Aβ Monoclonal Antibodies as Background Therapy**

**Christopher Van Dyck**, Rema Raman, Michael Donohue, Robert Rissman, Michael Rafii, Mary Hamby, Michael Grundman,

Anthony Caggiano, Paul Aisen

1Yale School of Medicine - New Haven (United States), 2Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego - San Diego (United States), 3Cognition Therapeutics Inc. - Pittsburgh (United States)

9.00 a.m.  
**KEYNOTE 5**

What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials

**Introduction:** Jacques Touchon, Montpellier University, Montpellier (France)

Cynthia A. Lemere, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (United States)

9.25 a.m.  
**LATE BREAKING SYMPOSIUM 7**

INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers

**Chair:** Diana Kerwin, Kerwin Medical Center, Dallas (United States)

**Presentation 1:** Determination of target engagement at various doses of ACU193 in INTERCEPT-AD

Miriam Trame, Certara, Boston (United States)

**Presentation 2:** Reduction in amyloid plaque load at higher doses of ACU193 in INTERCEPT-AD

Eric Siemens, Acumen Pharmaceuticals, Inc, Charlottesville (United States)

**Presentation 3:** Characteristics of Participants in INTERCEPT-AD Who Did or Did Not Develop ARIA with ACU193

Stephen Salloway, Alpert Medical School of Brown University, Providence (United States)

10.05 a.m.  
Coffee break and poster session

10.30 a.m.  
**ORAL COMMUNICATIONS**

**Moderators:** Serge Gauthier, McGill University, Montréal (Canada) and Mary Sano, Icahn School of Medicine at Mount Sinai - New York (United States)

10.30 a.m.  
**OC24 - Alzheimer’s disease in Down syndrome: Natural History, Biomarkers and Clinical Trials**

**Michael Rafii**

1Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA (United States)

10.45 a.m.  
**OC25 - Risk of Incident Cognitive Impairment Using Stages of Objective Memory Impairment (SOMI) and Neuroimaging**

Kellen Petersen, Ali Ezzati, Bhargav Nallapu, Richard Lipton, Reisa Sperling, Kathryn Papp, Dorene Rentz, Ellen Grober

1Albert Einstein College of Medicine - Bronx (United States), 2University of California, Irvine - Irvine (United States), 3Harvard Medical School - Boston (United States)
> Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

Friday, OCTOBER 27

11.00 a.m.  
OC26 - Quantitative Amyloid-PET in Real-World Practice: Lessons from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study  
Renaud La Joie 1, Ehud Zeltzer 1, Nidhi Mundada 1, Ganna Blazhenets 1, Jhonny Mejia Perez 1, Daniel Schonhaut 1, Leonardo Iaccarino 1, Maria Carrillo 1, Lucy Hanna 4, Constantine Gatzonis 4, Andrew March, Barry Siegel 6, Bruce Hillner 7, Rachel Whitmer 8, Gil Rabinovici 1  
1University of California, San Francisco - San Francisco, Ca (United States), 2Avid Radiopharmaceuticals - Philadelphia, Pa (United States), 3Alzheimer’s Association - Chicago, Il (United States), 4Brown University - Providence, Ri (United States), 5American College of Radiology - Philadelphia, Pa (United States), 6Washington University School of Medicine in St. Louis - St Louis, Mo (United States), 7Virginia Commonwealth University - Richmond, Va (United States), 8University of California, Davis - Davis, Ca (United States)

11.15 a.m.  
OC27 - Measuring Meaningful Benefit of Disease Modifying Treatment on Health-Related Resource Use  
Carolyn Zhu 1, Mary Sano 1  
1Icahn School of Medicine at Mount Sinai - New York, NY (United States)

11.30 a.m.  
OC28 - Establishing the validity of a novel electronic Clinical Dementia Rating (eCDR)  
Rachel Nosheny 1, Daniel Yen 1, Taylor Howell 1, Monica Camacho 3, Krista Moulder 1, Miriam Ashford 1, Ronald Petersen 4, Nikki Stricker 1, Erik Roberson 2, Daniel Marson 3, Walter Kukull 4, Scott Mackin 1, Michael Weiner 1, John Morris 2, Yan Li 2  
1UCSF - San Francisco (United States), 2Washington University - St. Louis (United States), 3Northern California Institute for Research and Education, Gothenburg (Sweden), 4University of Alabama at Birmingham - Birmingham (United States), 5University of Washington - Seattle (United States)

11.45 a.m.  
OC29 - AI-based enrichment tools substantially increase the efficiency of AD clinical trials  
Viswanath Devanarayan 2, Yuqiang Ye 1, Harald Hampel 1, Lynn Kramer 1, Michael Irazarry 1, Shobha Dhadda 1  
1Eisai Inc. - Nutley (United States)

12.00 p.m.  
OC30 - Timing of Biomarker Changes in Sporadic Alzheimer Disease in Estimated Years from Symptom Onset  
Yan Li 2, Daniel Yen 1, Rachel Hendrix 1, Brian Gordon 1, Sibonginkosi Dlamini 1, Nicolas Barthelemy 3, Andrew Aschenbrenner 1, Rachel Henson 1, Eric Mcdade 1, David Holtzman 1, Tammie Benzinger 1, John Morris 1, Randall Bateman 1, Suzanne Schindler 1  
1Washington University in St. Louis - St. Louis (United States)

12.15 p.m.  
Lunch break and poster session

1.15 p.m.  
LATE BREAKING ORAL COMMUNICATIONS  
Moderators: Pierre-Jean Dubset, Toulouse University Hospital, Toulouse (France) and Laia Montoliu-Gaya, University of Gothenburg - Gothenburg (Sweden)

1.15 p.m.  
LB19 - Pharmacokinetic-Pharmacodynamic (PK-PD) Relationship Between Aducanumab Exposure and Amyloid PET Over Long-term Treatment Period Including Dosing Gap in the EMBARK Phase 3b Study  
Jackson Burton 1, Kowalski Ken 2, Kumar Kandadi Muralidharan 1, R. Matthew Hutchison 1, Philip Montenigro 1, Ivan Nesterov 1  
1Biogen - Cambridge (United States), 2Kowski PMetrics Consulting LLC - Naples (United States)

1.30 p.m.  
LB20 - A mass spectrometric panel of phosphorylated and non-phosphorylated plasma tau species reveals differences in the associations with early and intermediate tau PET in sporadic Alzheimer’s disease  
Laia Montoliu-Gaya 1, Gemma Salvadó 2, Nicholas J Ashton 1, Shonen Jnelidze 1, Johanna Nilsson 3, Niklas Mattsson-Carlgen 2, Sophia Weiner 4, Sebastian Palmqvist 2, Juan Lantero-Rodriguez 1, Gunnar Brinkmalm 4, Erik Stomrud 2, Henrik Zetterberg 3, Johan Gobom 1, Kaj Blennow 4, Oskar Hansson 2  
1University of Gothenburg - Gothenburg (Sweden), 2Lund University - Lund (Sweden), 3University of Gothenburg - Gothenburg (Sweden), 4University of Gothenburg - Gothenburg (Sweden)

1.45 p.m.  
LB21 - Evaluating the Efficacy of AR1001 on Plasma ptau 181 Levels and ADAS-Cog 13 in Mild to Moderate Alzheimer’s Disease: Results from the Phase 2 Trial  
Byoung Seok Ye 1, David Greeley 1, Fred Kim 2, Jai Jun Choung 2  
1Department of Neurology, Yonsei University College of Medicine - Seoul (Korea, Republic of), 2AnBio Co., Ltd. - Seongnam (Korea, Republic of)

2.00 p.m.  
LB22 - Aducanumab Phase 3b EMBARK Study Interim Analysis: Topline Safety Results  
Gioacchino G Curiale 1, Philip Montenigro 1, Kimberly Umans 1, Tao Sun 1, John O’gorman 1, Karen Smirnakis 1  
1Biogen - Cambridge (United States)
Friday, OCTOBER 27

> Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

2.15 p.m.

**ORAL COMMUNICATIONS’ FOCUS SESSION: Phase 1 Clinical Trials**

Moderators: Robert Rissman, Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), and Oliver Peters, Charité - Berlin (Germany)

**OC31 - RG6289, a new γ-secretase modulator for the treatment of Alzheimer’s disease: Results from a phase I healthy volunteer study**

Stefan Sturm 1, Agnes Portron 1, Annamarie Vogt 1, Agnes Poirier 1, Tianxu Yang 2, Adnan Mohamed Abd Al 1, Gwendlyn Kollmorgen 3, Cory Simmons 4, Kalbinder Mahil 4, Lothar Lindemann 5, Karl-Heinz Baumann 5, Thomas Mueggler 2, Taner Vardar 7, Rosanna Tortelli 2, Irene Grass 2

1Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 3Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Beijing (China), 4Roche Diagnostics GmbH - Penzberg (Germany), 5Product Development Data Sciences, F. Hoffmann-La Roche Ltd - Mississauga (Canada), 6Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Limited - Welwyn (United Kingdom), 7Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland)

2.15 p.m.

**OC32 - A phase 1a single ascending dose study of the safety, tolerability, and brain receptor occupancy of BMS-984923 in healthy older adults**

Adam P Mecca 1, Elaheh Salardini 1, Jean-Dominique Gallezot 1, Ryan S O’de 1, Juan Young 1, Emma Cooper 2, Meghan G Donahue 2, Julia L Waszak 1, Jeanine L May 1, Joshua Spurrer 1, Timothy R Siegert 2, Richard E Carson 1, Stephen M Strittmatter 2, 1Yale School of Medicine - New Haven (United States), 2Allyx Therapeutics, Inc. - New Haven (United States)

2.25 p.m.

**OC33 - A Phase 1 Study demonstrating safety, CNS target engagement and PBMC pharmacodynamic response to ASN51, a novel and orally administered O-GlcNAcase inhibitor**

Ryan Schubert 1, Bruno Permanne 1, Rolf Potkorn 1, Pearl Fang 1, Vanessa Teachout 1, Maud Nény 1, Solenne Ousson 1, Ruhi Ahmed 1, Manfred Schneider 1, Anna Quattropani 1, Dirk Beher 1

1Asceneuron - Lausanne (Switzerland)

2.35 p.m.

**OC34 - E2511, a Novel TrkA Modulator, Engages its CNS Cholinergic Target in a Phase 1 Clinical Study**

Satya Saxena 1, Yuanqing Ye 1, Kazunari Sasaki 1, Takeo Kamakura 1, Garth Ringheim 1, Luigi Giorgi 1, Natasha Penner 1, Kanta Horie 1, Viswanath Devanarayan 1, Pallavi Sachdev 1

1Eisai Inc. - Nutley (United States)

2.45 p.m.

**OC35 - Mode of action, clinical phase Ib data in patients, and the phase II design of the orally available anti-prionic compound PRI-002 that disassembles Aβ oligomers into Aβ monomers**

Dieter Willbold 1, Nicoleta-Carmen Cosma 2, Janine Kutzsche 1, Dagmar Jürgens 1, Gerhard Tischler 2, Oliver Peters 2

1FZ Jülich - Jülich (Germany), 2Charité - Berlin (Germany), 3Prinnovation - Leipzig (Germany)

3.05 p.m.

Coffee break and poster session

3.30 p.m.

**LATE BREAKING ORAL COMMUNICATIONS**

Moderators: Suzanne Hendrix, Pentara Corporation - Millcreek (United States), Susan Landau, UC Berkeley - Berkeley (United States)

**LB23 - Results of a Phase 2 randomized withdrawal study of simufilam in mild-to-moderate Alzheimer's Disease**

Ian Cohen 1, Shishuka Malhotra 1, Paayal Patel 2, Suzanne Hendrix 3, Craig Mallinckrodt 1, Ben Murray 1, Leslie Jones 1, Antonio Hernandez 1, Emmalee Crow 1, Melissa Snyder 4, Lindsay Burns 4, James Kupiec 4, Nadav Friedmann 4

1Toronto Memory Program - Toronto (Canada), 2Brain Matters Research - Delray Beach (United States), 3Pentara Corporation - Millcreek (United States), 4Cassava Sciences, Inc. - Austin (United States)
**Program**

> Conference Room: All sessions will be held in Grand Ballroom AB - Floor 2 (Mezzanine Level)
> Overflow room: Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)

### Friday, OCTOBER 27

3.45 p.m.

**LB24 - Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-beta pathology**

Przemysław Kac 1, Armand González-Escalante 2,3,4, Marta Milà-Alomà 2,5, Nicholas Ashton 1,4,7,6, Mahnaz Shekari 2,3,4,5, Paula Ortiz-Romero 2,3, Henrik Zetterberg 1,9,10, Juan Domingo Gispert 2,5,11, Kaj Blennow 1,12, Marc Suárez-Calvet 2,3,11,13, Thomas Karikari 1,14

1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), 2BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), 3Hospital del Mar Research Institute - Barcelona (Spain), 4Universitat Pompeu Fabra - Barcelona (Spain), 5Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), 6Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London - London (United Kingdom), 7NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation - London (United Kingdom), 8Centre for Age-Related Medicine, Stavanger University Hospital - Stavanger (Norway), 9Hong Kong Center for Neurodegenerative Diseases, HKCeND - Hong Kong (China), 10School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), 11Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina - Madrid (Spain), 12Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 13Servei de Neurologia, Hospital del Mar - Barcelona (Spain), 14Department of Psychiatry, School of Medicine, University of Pittsburgh - Pittsburgh (United States)

### 4.00 p.m.

**LB25 - Elevated amyloid and tau are not associated with cognition in a diverse clinical trial cohort**

Susan Landau 1, Theresa Harrison 1, Tyler Ward 1, Prashanthi Vemuri 2, Samuel Lockhart 3, Robert Koeppe 4, Danielle Harvey 5, Laura Lovato 6, Arthur Toga 6, Sarah Tomaszewski Farias 7, Kathryn Papp 8, Heather Snyder 9, Charles Decarli 3, William Jagust 1, Laura Baker 3

1UC Berkeley - Berkeley (United States), 2Mayo Clinic - Rochester (United States), 3Wake Forest School of Medicine - Winston-Salem (United States), 4University of Michigan - Ann Arbor (United States), 5UC Davis - Davis (United States), 6University of Southern California - Los Angeles (United States), 7Harvard University - Boston (United States), 8Alzheimer’s Association - Chicago (United States)

### 4.15 p.m.

**LB26 - Feasibility of remote blood collection and plasma biomarker analyses to assess eligibility for Alzheimer’s disease preclinical clinical trials - The AlzMatch Study**

Rema Raman 1, Sarah Walter 1, Gustavo A. Jimenez-Maggiora 1, Robert Rissman 1, Alireza Atri 2, Dana Goldman 3, Joshua Grill 4, Gad A. Marshall 5, Gregory Jicha 6, Michael Racke 7, Raymond Turner 8, Christopher H. Van Dyck 9, Venky Venkatesh 10, Reisa Sperling 1, Paul Aisen 1

1Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), 2Banner Sun Health Research Institute and Banner Alzheimer’s Institute, Banner Health, Brigham And Women’s Hospital - Sun City And Phoenix, Boston (United States), 3Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California - Los Angeles (United States), 4Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), 5Massachusetts General Hospital, Harvard Medical School - Boston (United States), 6University of Kentucky - Lexington (United States), 7Quest Diagnostics - Secaucus (United States), 8Georgetown University - Washington Dc (United States), 9Yale College of Medicine - New Haven (United States), 10C2N Diagnostics - St. Louis (United States)

### 4.30 p.m.

**LB27 - Twelve-month results in FTD-C9orf72 participants from INFRONT-2: a phase 2 study of latozinemab (AL001) in FTD**

Lawrence Carter 1, Peter Ljubenkov 2, Harro Seelaar 3, Olga Kahn 1, Lori Long 1, Grace Chao 1, James Okoronkwo 1, Megan Smithey 1, Julie Huang 1, Whedy Wang 1, Gary Romano 1, Albert Ludolph 4

1Alector - South San Francisco (United States), 2University of California San Francisco - San Francisco (United States), 3Erasmus University Medical Center - Rotterdam (Netherlands), 4University of Ulm and DZNE - Ulm (Germany)

### 4.45 p.m.

**LB28 - Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology**

Benjamin Wolozin 1, Peter Ash 1, Amit Berson 1, Caroline Murphy 1, Nick Fredette 1, Ben Moore 1, Joe Vacca 1, Robert Schaub 1, Glenn Larsen 1, Aquinnah Pharmaceuticals Inc. - Cambridge (United States)

5.00 p.m.

End of the conference
POSTER PRESENTATIONS
presented in Boston
and available on the CTAD23
digital platform
Listing of CTAD23 POSTERS

All posters are available in Pdf format at all times on the CTAD23 digital platform.

Posters presented remotely are indicated with this icon:

- THEME: Clinical Trials: Methodology
  - P001 to P030 & LP001 to LP016
  - P031 to P045 & LP017 to LP034
  - P046 to P063 & LP035 to LP042
  - P064 to P097 & LP043 to LP060

- THEME: Clinical Trials: Results
  - P098 to P117 & LP062 to LP069

- THEME: Clinical Trials: Imaging
  - P118 to P137 & LP070 to LP080 & LP121 to LP123

- THEME: Clinical Trials: Biomarkers including plasma
  - P138 to P140 & LP124 to LP126

- THEME: Clinical Trials: Cognitive and Functional Endpoints
  - P141 to P143

- THEME: Cognitive assessment and clinical trials
  - P144 to P150 & LP082 to LP083 & LP127 to LP128

- THEME: Behavioral disorders and clinical trials
  - P151 to P152 & LP084 to LP089

- THEME: Health economics and clinical trials
  - P153 to P158 & LP090 to LP097 & LP129 to LP130

- THEME: Epidemiology and clinical trials
  - P159 to P178 & LP098 to LP108

- THEME: Animal Model
  - P179 to P192 & LP109 to LP117 & LP131 to LP133

- THEME: New Therapies and Clinical Trials
  - P193 to P204 & LP118 to LP120

- THEME: Proof of Concept/Translational research
  - P205 to P212 & LP134 to LP136

- THEME: Digital health/E-trials
  - P213 to P220 & LP137 to LP139

- THEME: Beyond Amyloid and Tau
  - P221 to P228 & LP140 to LP142
**Poster Presentations**

**Theme: Clinical Trials: Methodology**

**P001** Variation in the mini-mental state examination in subjects with suspected mild to moderate Alzheimer’s disease: Implications for clinical trial designs  
James Rock 1, Jessie Nicodemus-Johnson 2, Holly Wood 2, Fred Kim 1, Jongkyi Kim 1, Yoon-Seok Chun 3, Suzanne Hendrix 2  
1ArBIONC - San Diego (United States), 2Pentara - Mill Creek (United States), 3ArBIONC - Gyunggi-Do (United States)

**P002** Communicating Trial Indicators Resulting from Participants and Study Partners in a Preclinical Alzheimer’s Disease Study  
Taylor Clanton 4, Joshua D. Grill 2, Jason Karlawish 3, Karen Chilcott Holdridge 4, Roy Yaari 4, Rema Raman 1, Sarah Walter 1, Elizabeth Shaffer 1, Paula J. G. Cohen 1, Paul S. Aisen 1, Reisa A. Sperling 5  
1Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), 2UC Irvine - Irvine (United States), 3Department of Neurology, Harvard Medical School, Brigham and Women’s Hospital, Massachusetts General Hospital - Boston (United States)

**P003** Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease  
Robyn Moxon 3, Todd Feaster 1, Gopalan Sethuraman 1, Alyssa Carroll 1, Siew Tin Gan 1, Shane Ziembia 1, Kimber Price 1, Vladimir Skljarevski 1, Karen Sundell 1, Janice Hitchcock 1, Eric Siemers 1  
1Acumen Pharmaceuticals - Charlottesville (United States)

**P004** Investigating Treatment Effect Heterogeneity in Data-Driven Subgroups of TOMMORROW  
Cameron Shand 1, Neil Oxtoby 1  
1University College London - London (United Kingdom)

**P005** How should the next generation of Alzheimer’s Disease clinical trials be analyzed in the estimands framework? The GRADUATE I & II experience  
Rachid Abbas 1, Nicola Voyle 2, Giuseppe Palermo 1, Geoff Kerchner 1, Christopher Lane 3, Angeliki Thanasopoulou 1, Janice Smith 2, Rachelle Doody 1, 2, Paul Delmar 2  
1F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Roche Products Ltd - Welwyn Garden City (United Kingdom), 3Genentech, Inc. - South San Francisco (United States)

**P006** Factors Influencing Older Adults’ Intention to Participate in a Secondary Prevention Trial in Alzheimer’s Disease  
Emily Largent 1, Joshua Grill 2, Jason Karlawish 1, Amy Bleakley 3  
1University of Pennsylvania - Philadelphia (United States), 2University of California, Irvine - Irvine (United States), 3University of Delaware - Newark (United States)

**P007** Evaluation of machine learning models that predict Alzheimer’s disease progression in observational studies and randomized clinical trials  
Sofia Broomé 1, Shibeshih Belachew 1, Basten Caba 1, Enrica Cavedo 1, Jonathan Dubois 1, Audrey Gabelle 1, Refaat Gabr 1, Arie Gafson 1, Despoina Ioannidou 1, Xiaotong Jiang 2, Yan Jin 1, Neil Oxtoby 1, Menglan Pang 1, Nikos Paragios 1, Willem Huijbens 2  
1TheraPanacee - Paris (France), 2BioGen - Cambridge (United States), 3Floybox Science - Mildenhall (United Kingdom)

**P008** Study Design of POLARIS-AD, AR1001 Phase 3 Study in Early Alzheimer’s Disease  
Sharon Sha 1, SangYun Kim 2, 3, Jeffrey Cummings 4, Charlotte Teunissen 1, 2, 3, David Grecel 4, Monica Kim 4, James Rock 4, Fred Kim 4, 5, 6, Jain Choung 4  
1Stanford University - Palo Alto (United States), 2Palo Alto (United States), 3UC Irvine - Irvine (United States), 4Department of Neurology, Harvard Medical School, Brigham and Women’s Hospital, Massachusetts General Hospital, - Boston (United States), 5University of Southern California - San Diego (United States), 6Eli Lilly and Company - Indianapolis (United States)

**P009** Enrichment for clinical trial of early AD using combination of PHS and plasma p-tau181 as screening instruments  
Xin Wang 3, Xiran Wang 1, Steven Edland 1, Iris Broce 1, Sarah Banks 1  
1University of California, San Diego - La Jolla (United States), 3University of Nevada, Las Vegas - Las Vegas (United States)

**P010** Validating an automatic phone-based speech biomarker measuring cognition SB-C against PACC5 and MoCA in the Swedish H70 epidemiological cohort  
Johannes Tröger 1, Fredrik Öhman 1, Basten Caba 1, Enrica Cavedo 1, Jonathan Dubois 1, Audrey Gabelle 1, Refaat Gabr 1, Arie Gafson 1, Despoina Ioannidou 1, Xiaotong Jiang 2, Yan Jin 1, Neil Oxtoby 1, Menglan Pang 1, Nikos Paragios 1, Willem Huijbens 2  
1TheraPanacee - Paris (France), 2BioGen - Cambridge (United States), 3Floybox Science - Mildenhall (United Kingdom)

**P011** A systematic review and met-analysis of agitation trials in individuals with dementia: Are cognitive measures needed?  
Heather Belanger 1, Kativa Gohl 1, Jeffrey Finman 1, Gary Kay 1  
1Cognitive Research Corporation (CRC), University of South Florida - St Petersburg (United States)

**P012** Effects of Informant Replacement in Alzheimer’s Disease Clinical Trials  
Mikaela Nishida 1, Michelle Nuno 1, Joshua Grill 1, Daniel Gillen 1  
1University of California, Irvine - Irvine (United States), 2University of Southern California - Los Angeles (United States)

**P013** Harnessing the power of continuous time: Learnings from recent large clinical trial data  
Paul Delmar 1, Lars Lau Raket 2, John O’gorman 1, Guoqiao Wang 1, Michael Donohue 2, 3  
1F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Eli Lilly and Company, Indianapolis, USA - Indianapolis (United States), 3Biogen - Cambridge (United States), 4Washington University School of Medicine, - Saint Louis (United States), 5University of Southern California - San Diego (United States)

**P014** Internet-based insomnia intervention to prevent cognitive decline: Use of Internet-based recruitment, intervention, and assessment methods  
Meghan Matros 1, Carol Manning 1, Wen You 1, Kirsten Macdonnell 1, Lee Ritterband 1  
1University of Virginia - Charlottesville (United States)
P015 Exploring the Impact of Baseline Discordance Between Functional Scales in Early AD Clinical Trials
Alan Kott 1, Xingmei Wang 2, David Miller 1
1Signant Health - Prague (Czech Republic), 2Signant Health - Blue Bell (United States)

P016 A pragmatic, investigator-driven process for disclosure of amyloid PET scan results to ADNI4 research participants
Claire Erickson 1, Jason Karlawish 1, Joshua Grill 2, Kristin Harris 1, Susan Landau 3, Ronald Petersen 4, Paul Aisen 1, Michael Weiner 4, Emily Largent 1
1University of Pennsylvania - Philadelphia (United States), 2University of California Irvine - Irvine (United States), 3University of California Berkley - Berkley (United States), 4Mayo Clinic - Rochester (United States), 5University of Southern California - San Diego (United States), 6University of California San Francisco - San Francisco (United States)

P017 RG6289, a new γ-secretase modulator for the treatment of Alzheimer’s disease: Dose selection for a phase II trial based on population PK/PD modeling
Dominik Lott 1, Agnes Porton 2, Mizan Alam 1, Carina Cantrill 1, Ruth Coney 2, Fabien Alcaraz 1, Rosa Maria Rodriguez Sarmiento 4, Lothar Lindemann 3, Lutz Mueller 1, Thomas Mueggler 1, Taner Vardar 1, Rosanna Fortelli 1, Stefan Sturm 1, Irene Gerlach 1
1Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Roche Innovation Center Wadern, Roche Pharma Research and Early Development, Roche Products Limited - Weilheim (United Kingdom), 3Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 4Medicinal Chemistry, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 5Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland)

P018 Recruitment Source, Eligibility, and Reason for Prescreen-Fail across Sex, Race & Ethnicity: A Preliminary Analysis of Prescreening Data from the AHEAD Study
Dylan Kern 1,2,3, Shunran Wang 1, Joshua D. Grill 1, Karin Ernstom 1, Akpewoeghe Ikoba 1, Emily Sprague 1, Gustavo Jimenez-Maggiora 1, Elizabeth Shaffer 1, Reisa Sperling 1,5, Rema Raman 7
1Department of Neurology, Brigham and Women's Hospital - Boston (United States), 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), 3Center for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), 4Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)

P019 Impact of recruitment methods on racial and ethnic diversity: results from the Davis Memory and Aging Cohort at Mass General Brigham
Stephanie Moreno 1, Akpewoeghe Ikoba 1, Caitlyn Christiano 1, Juliana Aya Ussui Anzai 1, Andrea Roman 1, Dylan Kern 2, Lenore Jackson-Pope 1, Martha Cecilia Muniz 1, Jasmeer P. Chhatwal 1, Seth A. Gale 1, Gads A. Marshall 1, Reisa A. Sperling 1, Hyun-Sik Yang 1, Dennis J. Selkoe 4, Dorene M. Rentz 6
1Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital - Boston (United States), 2Department of Neurology, Brigham and Women’s Hospital - Boston (United States), 3Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 4Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital - Boston (United States), 5Department of Neurology, Brigham and Women’s Hospital - Boston (United States), 6Signant Health - Blue Bell (United States)

P020 Improving Diverse Recruitment in an Early Phase Therapeutic AD trial through a Pre-screening Study, Apheleia-001
Dawn Batchuluun 1, Katy Smith 2, Tamiko Magee-Rodgers 3, Leigh Zipke 1, John Dwyer 1, Jason Bork 1, Richard Mois 1, Julie Schwartzbard 4, Anthony Bannon 1, Shau Yu Lynch 3, Christa Lee 3, Danielle Mcgeeney 3
1Global Alzheimer’s Platform Foundation - Washington (United States), 2Aventura Hospital and Medical Center - Aventura (United States), 3AbbVie, Inc. - North Chicago (United States)

P021 On Adaptive Randomization in Time-to-Event Alzheimer’s Disease Clinical Trials
Navneet Hakhu 1, Joshua Grill 1, Daniel Gillen 1
1University of California, Irvine - Irvine (United States)

P022 Views and perceptions of amyloid imaging among racial and ethnic groups in a preclinical Alzheimer’s disease trial
Christina M. Magana-Ramirez 1, Gimarie Intzarry 1, Daniel L. Gillen 1,2, Joshua D. Grill 1,2,4
1Department of Statistics, University of California, Irvine, California - Irvine (United States), 2Department of Neurobiology and Behavior, University of California, Irvine, California - Irvine (United States), 3Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), 4Department of Psychology and Human Behavior, University of California Irvine, Irvine, California - Irvine (United States)

P023 Application of the personalized medicine approach to a behavioral intervention study: the Internet-based Conversational Engagement Clinical Trial (i-CONCET)
Chao-Yi Wu 1,2, Kexin Yu 1,2, Steven Arnold 1, Sudeshna Das 1, Hiroko Dodge 1
1Neurology, Massachusetts General Hospital, Harvard Medical School - Charlestown (United States), 2Neurology, Oregon Health & Science University - Portland (United States)

P024 Understanding Non-progressors in Alzheimer’s Disease Clinical Trials
Shuang Wu 1, Jennifer Murphy 1, Wei Feng 2, Philip Montenegro 1, Ying Tian 1
1Biogen - Cambridge (United States), 2Keros Therapeutics - Lexington (United States)

P025 A Phase 2 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Aducanumab in Subjects with Early Alzheimer’s Disease
Lloyd Tran 1, Fen Xu 1, Markku Kurkinen 1
1Biomed Industries, Inc. - San Jose

P025B A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Confirm Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer’s Disease
Lloyd Tran 1, Fen Xu 1, Markku Kurkinen 1
1Biomed Industries, Inc. - San Jose (United States)
Reducing screen failure rates due to biomarker cut-offs in early Alzheimer's disease trials using a prognostic model

Angela Tam 1, César Laurent 1, Christian Daneseau 1

1Pentel AI - Montreal (Canada)

Rationale and design of a Phase 2b trial to evaluate the efficacy of a specific inhibitor of N1B-HSDL, Xanamem®, in mild and moderate AD

Dana Hilt 5, Jack Taylor 1, Tamara Miller 1, John Harrison 5 3 4, Christopher Chen 5, Craig Ritchie 2

1Actinogen Medical - Sydney (Australia), 2Scottish Brain Sciences - Edinburgh (United Kingdom), 3King's College - London (United Kingdom), 4Alzheimercentrum, AlMtc - Amsterdam (Netherlands), 5Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore)

Impact of a Site Supplemental Funding Program to Alleviate Recruitment Burden: Experiences in the Preclinical Alzheimer's Disease AHEAD Study

Leona K Shurtn 4, Rema Ramam 1, Oliver Langford 1, Victoria Salcedo 1, Andy Liu 1, Reisa Sperling 2 3, Joshua D Grill 4, Crystal M Glover 5 6 7, Paul Aisen 1, Keith Johnson 2 3, Shobha Dhadde 4, Michael Irizarry 8, Doris Molina-Henry 1

1Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), 2Brigham and Women's Hospital, Harvard Medical School - Boston, Ma (United States), 3Massachusetts General Hospital, Harvard Medical School - Boston, Ma (United States), 4University of California, Irvine - Irvine, Ca (United States), 5Department of Neurological Sciences, Rush Medical College - Chicago, Il (United States), 6Department of Psychiatry and Behavioral Sciences, Rush Medical College - Chicago, Il (United States), 7Rush Alzheimer's Disease Center - Chicago, Il (United States), 8Eisai Inc. - Nutley, Nj (United States)

Establishing an evidence-based patient recruitment strategy through a site recruitment needs assessment for a hospice-eligible population with dementia

Karla López Aquino 1, Ariane Zokas Fritts 1, Jacobo Mintzer 1, Brigid Reynolds 1, Melanie Chadwick 1, Olga Brawman-Mintzer 1, Gregory Jicha 1, Mark Kindy 1, Branko Husa-Garate 1, Jeffrey Keller 1, Taylor Clayton 1, Brendan Smith 1, Joshua D Grill 4, Paul Aisen 1, Rema Ramam 1

1Alzheimer's Therapeutic Research Institute (ATRI) - San Diego (United States), 2Medical University of South Carolina - Charleston (United States), 3Georgetown University - District Of Columbia (United States), 4Ralph H. Johnson Veteran Affairs Medical Center - Charleston (United States), 5University of Kentucky - Lexington (United States), 6University of South Florida - Tampa (United States), 7The Neuron Clinic - San Marcos (United States), 8Pennington Biomedical Research Center - Baton Rouge (United States), 9University of California, Irvine - San Diego (United States)

Inviting Diverse Communities to Clinical Research Participation through Medical Record Retrieval and Review

Katie King 1, Erin Beck 2

1Biogen - Wilmington (United States minor outlying islands), 2SiteRx - New York (United States minor outlying islands)

Addressing Representative Alzheimer's Disease Enrollment in Clinical Research via Real-World Conversion Analysis across the Recruitment Funnel

Michael Stalder 1

1SiteRx - New York (United States)

Examining the role of community engagement in enhancing the participation of minoritized communities in Alzheimer's disease clinical trials: a rapid review

Sanaz Dabin 1, Doris Molina-Henry 1

1Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

Developing a Screening Platform for Early-Phase Clinical Trials to Prevent AD (The EPIICH Platform)

Gene Bowman 4, Hira Shrestha 1, Hiroko Dodge 2, Jody-Lynn Lupo 2, Jeremiah Momper 2, 3, Carolyn Revta 2, Kevin Rynearson 5, Steven Edland 1, Jonathan Rosand 2, Steven Arnold 2, Howard Feldman 1, Rudolph Tanzi 1

1McCance Center for Brain Health, Clinical Trials Unit and Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), 2Interdisciplinary Brain Center, Department of Neurology, Massachusetts General Brigham and Harvard Medical School - Boston (United States), 3Alzheimer's Disease Cooperative Study, University of California San Diego - San Diego (United States), 4Pennington Biomedical Research Center - Baton Rouge (United States), 5Department of Neurosciences, University of California San Diego - San Diego (United States), 6Departments of Neurology, University of California San Diego - San Diego (United States), 7Alzheimer's Disease Cooperative Study and Department of Neurosciences, University of California San Diego - San Diego (United States)

Theme: Clinical Trials: Results

Combined exercise and cognitive interventions for adults with mild cognitive impairment and dementia: A systematic review and network meta-analysis

Dandan Xue 1, Polly W.C. Li 1, Doris S.F. Yu 1, Rose S.Y. Lin 1, Yuewen Lao 1

1School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong - Hong Kong (Hong Kong), 2University of Rochester School of Nursing, New York, USA - New York (United States), 3Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Hangzhou (China)

Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium

Sudhir Sivakumaran 1, Nicholas Cullen 1, Eileen Priest 1, Corissa Lau 1, Hazel White 1, Michael Irizarry 2, Klaus Romero 1, Yashmin Karten 1

1Critical Path Institute - Tucson (United States), 2Eisai Inc. - Nutley (United States)
PO45  ARIA by Clinical Subgroup and Baseline Amyloid PET Centiloid Levels from the Lecanemab Clarity AD Study
Marwan Sabbagh 1, David Li 2, Shobha Dhadda 2, Michael Irizarry 2, Steve Hersch 2, Luigi Giorgi 2, Andre Matta 3, Lynn Kramer 2
1Barrow Neurological Institute - Phoenix (United States), 2Eisai Inc. - Nutley (United States), 3Eisai Co., Inc. - Hatfield (United Kingdom)

LP07  A Phase Ib Double Blind Multiple Ascending Dose Study of the Safety and Pharmacokinetics of NTRX-07 in Normal Volunteers and Patients with Mild Cognitive Impairment or Early Alzheimer's Disease
Joseph Foss 1, Tony Giordano 1, Mariana Kiraly 1
1NeuroTherapy, Inc. - Cleveland (United States)

LP08  Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer's disease
Philip Scheltens 1, Alireza Atri 2,3,4, Howard H. Feldman 5, Oskar Hansson 6,7, Filip K. Knop 6,9,10,11, Mary Sano 12,13, Claus Dethlefsen 14, Peter Johansson 14, Teresa León Colombo 15, Charlotte T. Hansen 14, Jeffrey Cummings 16
1Alzheimer Centre, VU University Medical Center Amsterdam - Amsterdam (Netherlands), 2Banner Health Research Institute - Sun City, Az (United States), 3Banner Alzheimer’s Institute - Phoenix, Az (United States), 4Bingham and Women’s Hospital, Harvard Medical School - Boston, Ma (United States), 5Alzheimer’s Disease Cooperative Study, Department of Neurosciences University of California San Diego - La Jolla, Ca (United States), 6Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), 7Memory Clinic, Skåne University Hospital - Malmö (Sweden), 8Center for Clinical and Experimental Sciences, University of Copenhagen - Hellerup (Denmark), 9Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), 10Steno Diabetes Center Copenhagen - Herlev (Denmark), 11Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), 12Icahn School of Medicine at Mount Sinai - New York, Ny (United States), 13James J Peters VA Medical Center - Bronx Ny (United States), 14Novo Nordisk A/S - Søborg (Denmark), 15Novo Nordisk A/S - Madrid (Spain), 16University of Nevada - Las Vegas, NV (United States)

LP09  The Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE) Study
Carol Van Hulle 1, Hanna Zylstra 1, Kate Cronin 1, Aleshsia Cole 1, Elena Beckman 1, Allison Eierman 2, Madeleine Blazel 3, Karen Lazay 4, Kevin Johnson 1, Leonardo Rivera 1, Carey Gleason 1, Henrik Zetterberg 1, Sterling Johnson 1, Cynthia Carlson 1
1University of Wisconsin-Madison - Madison (United States), 2Medical College of Wisconsin-Green Bay - Green Bay (United States), 3Case Western Reserve University School of Medicine - Cleveland Ohio (United States), 4Sahlgrenska Academy - Mölndal (Sweden)

LP20  Neurogenesis Hypothesis and Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease and Major Depressive Disorder
Lloyd Tran 1, Zung Tran 1
1Biomed Industries, Inc. - San Jose (United States)

LP22  RetiSpec’s AI-based retinal test: Results of a multi-site, prospective, validation study to predict brain Aβ pathology in a diverse population of adults with Preclinical, MCI, and Probable Alzheimer’s disease
Alon Hazan 1, Catherine Bornbaum 1, Eliai Shaked 1, Jennifer Giordano 1, Yochai Edlitz 2,3, David He 4, Diana Kerwin 5
1RetiSpec - Toronto (Canada), 2Weizmann Institute of Science - Rehovot (Israel), 3MLIA Data Science - Tel Aviv (Israel), 4Analytical Solutions Group, Inc. - North Pontomac (United States), 5Kerwin Medical Center - Dallas (United States)

LP23  Dopaminergic Therapy for Frontotemporal Dementia Patients: preliminary results from a phase 2 multi-site, Randomized Clinical Trial
Martina Assogna 1, Francesco Di Lorenzo 1, Sonia Bonni 1, ALPerto Benussi 2, Ilaria Borghi 1, Emanuele Cerulli Irelli 3, Enrico Premi 1, Valentina Cantoni 3, Valentina Pezzopane 1, Lucia Mencarelli 1, Caterina Motta 1, Clarissa Ferrari 1, Martorana Alessandro 1, Giacomo Koch 1,4
1Department of Clinical and Behavioural Neurology, Santa Lucia Foundation - Rome (Italy), 2Memory Clinic, Department of Systems Medicine, University of Tor Vergata - Rome (Italy), 3Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia - Brescia (Italy), 4Department of Human Neurosciences, University of Rome Tor Vergata - Rome (Italy), 5Department of Clinical Neurorehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT) - Ferrara (Italy)

LP24  RESULTS FROM: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1012 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimer’s Disease
Willem De Haan 1,2, Anthony Caggiano 1, Philip Scheltens 4, Michael Grundman 3, Elliz Scheijbeler 1,2, Mary Hamby 2, Everard Vijverberg 1
1Department of Clinical Neurophysiology and MEG Center, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 2Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), 3Cognition Therapeutics - Purchase (United States), 4EOT Group - Amsterdam (Netherlands), 5Global R&D Partners and Department of Neurosciences, University of California - San Diego (United States)

LP25  Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia patients (PEA-FTD): A phase 2 Randomized Clinical Trial
Martina Assogna 1, Francesco Di Lorenzo 1, Sonia Bonni 1, Ilaria Borghi 1, Emanuele Cerulli Irelli 3, Lucia Mencarelli 1, Michele Maiella 1, Elias Paol Casula 1, Valentina Pezzopane 1, Caterina Motta 1, Clarissa Ferrari 1, Carlo Caflagirone 1, Martorana Alessandro 1, Giacomo Koch 1,4
1Department of Clinical and Behavioural Neurology, Santa Lucia Foundation - Rome (Italy), 2Memory Clinic, Department of Systems Medicine, University of Tor Vergata - Rome (Italy), 3Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia - Brescia (Italy), 4Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT) - Ferrara (Italy)
POSTER PRESENTATIONS

LP026  OVERTURE Open-Label Extension Data Confirms Safety, Adherence and Durability of Treatment Benefits over 18 Months
Ralph Kern 1, Colin Kuang 1, Mihaly Hajs 1, Alex Konisky 1, Alyssa Boasso 1, Evan Hempel 1, Brent Vaughan 1, Chandran Seshagiri 1, Zach Malchano 1, Suzanne Hendrix 1, Khalil Saikali 1
1Cognito Therapeutics - Cambridge (United States), 2Pentara Corporation - Salt Lake City (United States)

LP027  Baseline risk factors for ARIA-E in the GRADUATE I and II studies of gantenerumab
Paul Delmar 1, Nicola Voyle 2, Michael Grundman 3, Stephen Salloway 4, Jakub Wojtowicz 1, Marco Lyons 2, Christopher Lane 2, Angeliki Thanasopoulou 1, Simona Rossomanno 1, Zofia Bullain 1, Gregory Klein 1, Tobias Bittner 1, Andres Schneider 1, Janice Smith 1, Rachelle Doody 5
1F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Roche Products Ltd - Welwyn Garden City (United Kingdom), 3Global R&D Partners, LLC and Dept. of Neurosciences, University of California - San Diego (United States), 4Butler Hospital and Warren Alpert Medical School of Brown University - Providence (United States), 5F. Hoffmann-La Roche Ltd and Genentech, Inc. - Basel (Switzerland)

LP028  Donanemab: Characterization of immunogenicity from the TRAILBLAZER-ALZ & TRAILBLAZER-ALZ 2 trials
Garrett Mullins 1, Paul Ardayfio 1, Ivelina Gueorguieva 1, Greg Anglin 1, Jason Bailey 1, Laiyi Chua 1, Jennifer Zimmer 1, Cynthia Evans 1, Emel Nery 1, Hong Wang 1, Rashna Khanna 1, Dawn Brooks 1, John Sims 1
1Eli Lilly and Company - Indianapolis (United States)

LP029  Donanemab: Characterizing infusion-related reactions from TRAILBLAZER-ALZ & TRAILBLAZER-ALZ 2
Paul Ardayfio 1, Garrett Mullins 1, Jennifer Zimmer 1, Cynthia Evans 1, Greg Anglin 1, Ivelina Gueorguieva 1, Emel Nery 1, Hong Wang 1, Rashna Khanna 1, Dawn Brooks 1, John Sims 1
1Eli Lilly and Company - Indianapolis (United States)

LP030  Cerebral Amyloid Angiopathy and Comorbid Cardiovascular Risk Factors in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Results from APOLLOE4 Phase 3 Trial of Oral Anti-Amyloid Agent ALZ-801
Rosalind McIntaie, Enrvin Liang 1, Susan Abushakra 1, David Watson 2, Merce Boda 3, Sharon Cohen 4, Marwan Sabbagh 5, Aidan Power 1, Susan Flint 1, Winnie Pak 1, John Hey 1, Martin Tolar 1
1Alzheon, Inc. - Framingham (United States), 2Alzheimer’s Research and Treatment Center - Wellington (United States), 3Ace Alzheimer’s Center - Barcelona (Spain), 4Toronto Memory Program - Toronto (Canada), 5Barrow Neurological Institute - Phoenix (United States)

LP031  ACI-35.030 anti-phospho-Tau active immunotherapy for the treatment of early Alzheimer’s Disease (AD): Update from the Phase 1b/2a study data and perspectives.
Olivier Sol 1, Johannes Streffer 2, Juliette Merroud 1, Marija Vukicevic 1, Eva Gollwitzer 1, David Hickman 1, Valérie Hliva 1, Julian Gray 1, Lennert Steukers 1, Andrea Pfeifer 1, Marie Kosco-Vilpois 1, Philip Scheltens 5
1AC Immune SA - Lausanne (Switzerland), 2University of Antwerp - Antwerp (Belgium), 3Janssen - Beerse (Belgium), 4Janssen - New Jersey (United States), 5Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, VUmc - Amsterdam (Netherlands)

LP033  ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay of Target Engagement for the sAβO-Selective Antibody ACU193 in INTERCEPT-AD
Erika Cline 1, Jerome Moore 1, Hao Zhang 1, Gopalan Sethuraman 1, Eric Siemers 1, Robert Dean 1, Jasna Jerecic 1
1Acumen Pharmaceuticals - Charlottesville (United States)

LP034  INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease
Hao Zhang 1, Jerome Moore 1, Hao Zhang 1, Gopalan Sethuraman 1, Eric Siemers 1, Robert Dean 1, Jasna Jerecic 1
1Acumen Pharmaceuticals - Charlottesville (United States), 2Pacific BioDevelopment - Davis (United States), 3Department of Pathology & Laboratory Medicine, Indiana University School of Medicine - Indianapolis (United States)

THEME: Clinical Trials: Imaging

PO46  Brain structure-allelic associations and networks in Alzheimer’s disease
Seokwoo Moon 1
1Konkuk University Chungju Hospital - Chungju (Korea, Republic of)

PO47  Impact of anodal transcranial direct current stimulation on white matter microstructure integrity in mild cognitive impairment patients according to effect modifiers as risk factors for Alzheimer’s disease
Dong Woo Kang 1
1Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)
P048  Measuring changes in longitudinal Tau-PET with [18F]MK-6240: group-level vs individualized ROIs definition
Nick Sidorenko 1, Matteo Tonietto 1, Antoine Leuzy 2, Gregory Klein 1
1Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Malmo (Sweden)

P049  Regional Aβ-tau interactions can predict individual-level time periods of the optimal therapeutic window for amyloid-lowering treatments
Gillhwan Lim 1, Hanna Cho 1, Chul Hyung Lyoo 1, Joon-Kyung Seong 1, 2, 3, 4, 5 Wha Jin Lee 2, ADNI: Alzheimer's Disease Neuroimaging Initiative 6
1NeuroKTX - Seoul (Korea, Republic of), 2Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), 3School of Biomedical Engineering, Korea University - Seoul (Korea, Republic of), 4Department of Artificial Intelligence, Korea University - Seoul (Korea, Republic of), 5Interdisciplinary Program in Precision Public Health, Korea University - Seoul (Korea, Republic of), 6Alzheimer's Disease Neuroimaging Initiative - Los Angeles (United States)

P050  Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome
Isabel Barroeta 1, Jordi Pegueroles 1, Victor Montal 1, Mateus Rozalem 1, Alejandra Morcillo 1, Sara Zsadanyi 1, Lidia Vaque 1, Bessy Benejam 1, Laura Videla 1, Maria Carmona-Iraqui 1, Alexandre Bejani 1, Valé Camacho 1, Albert Flotats 1, Alberto Ueo 1, Juan Fortea 1
1Unidad de Memoria, Servicio de Neurología, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona - Barcelona (Spain), 2Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain - Barcelona (Spain)

P051  Automated brain MRI segmentation using a novel AI-based method
Thomas Cægfinger 1, Joël Schaerer 1, Po-Han Chen 1, Chris Conklin 1, Madhura Ingalhalikar 1, David Scott 1, Joyce Suhy 1, Luc Bracoud 1
1Clario - Lyon (France), 2Clario - Estenfeld (Germany), 3Clario - Philadelphia (United States), 4Clario - San Mateo (United States)

P052  Assessing the Relationship Between Central Cholinergic Integrity and Amyloid Accumulation in Individuals with Down Syndrome Using [18F]-FEOBV and [11C]-PiB PET: Preliminary Data
Jason K. Russell 1, Alexander C. Conley 1, Brian D. Boyd 1, Rachel Schlossberg 1, Adam J. Rosenberg 2, Lealani Y. A. Acosta 1, Michael S. Rafii 1, Sepideh Shokouhi 1, Paul A. Newhouse 1
1Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), 2Vanderbilt University Institute of Imaging Science, Vanderbilt University School of Medicine - Nashville (United States), 3Vanderbilt University Medical Center - Nashville (United States), 4Alzheimer's Therapeutic Research Institute and Department of Neurology, Keck School of Medicine, University of Southern California - San Diego (United States), 5Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Healthcare System - Nashville (United States)

P053  Minimizing sample sizes for trials using MK-6240: impact of reference and target tissues
John Becker 1, Cristina Lois 1, Emma Thibault 1, Grace Del Carmen Montenegro 1, Justin Sanchez 2, Brian Healy 1, Fang Fu 1, Julie Price 1, Georges El Fakhri 1, Keith Johnson 1
1Massachusetts General Hospital - Boston (United States), 2Washington University School of Medicine - St. Louis (United States), 3Harvard T.H. Chan School of Public Health - Boston (United States)

P054  Cerebral Amyloid Angiopathy in APOE4/4 Homozygotes with Alzheimer’s Disease: Baseline Characteristics of Subjects Enrolled in APOLLO4 Phase 3 Trial of Oral AZ-901 in Early AD
Rosalind McIver 1, 2, Susan Abushakra 1, Earvin Liang 1, Jerome Barakos 1, Aidan Power 1, David Watson 1, Emer Macsweeney 2, Anton Porsteinsson 3, Joyce Suhy 4, John Hey 1, Martin Tolar 1
1Alzheimer, Inc. - Framingham (United States), 2California Pacific Medical Center & Claro - San Francisco (United States), 3Alzheimer's Research and Treatment Center - Wellington (United States), 4Re:Cognition Health - London (United Kingdom), 5University of Rochester School of Medicine and Dentistry - Rochester (United States), 6Claro - San Mateo (United States)

P055  Changes in cortical microstructure in brain regions associated with cognitive status and disease duration after short-term treatment with XPro1595 for Alzheimer’s disease
Parris Pope 1, Christopher Barnum 1, Raymond Tesi 1, Tom Soeder 1
1Nune Bio, Inc. - Boca Raton (United States), 2Allucent - Cary (United States)

P056  Association of cholinergic integrity to age, amyloid, cortical volume and cognitive performance in healthy postmenopausal women using [18F]-FEOBV PET
Alexander Conley 1, Jason Russell 1, Brian Boyd 1, Tonnar Castellano 1, Adam Rosenberg 1, Brittany Bosko 1, Julie Dumas 1, Paul Newhouse 1, 2
1Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center - Nashville (United States), 2Department of Radiology, Vanderbilt University Medical Center - Nashville (United States), 3Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont Larner College of Medicine - Burlington (United States), 4Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System - Nashville (United States)

P057  Real-world implementation of patient stratification with faster cognitive decline using MRI-based prediction of regional tau positivity
Yeong-Hun Song 1, Wha Jin Lee 2, Joon-Kyung Seong 1
1Korea University - Seoul (Korea, Republic of), 2NeuroKTX - Seoul (Korea, Republic of)
P059

Association of amyloid PET burden with longitudinal cognitive decline in a heterogeneous Alzheimer’s disease research cohort

Emily Johns 1, Kyan Younes 1, Shubhabrata Mukherjee 1, Christina B. Young 1, Jesse Mez 2, Timothy J. Hohman 3, Duygu Tosun 4, Sarah Biber 5, Walter A. Kukull 6, Paul Crane 7, Elizabeth C. Mormino 1

1Department of Neurology and Neurological Sciences, Stanford University - Palo Alto (United States), 2Department of Medicine, The University of Washington - Seattle (United States), 3Department of Neurology, Boston University - Boston (United States), 4Vanderbilt Memory and Alzheimer’s Center, Vanderbilt University Medical Center - Nashville (United States), 5Department of Radiology and Biomedical Imaging, University of California, San Francisco - San Francisco (United States), 6Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington - Seattle (United States)

P059 Stress-testing the Centiloid Concept: Validation of the Between-Tracer Accuracy of the Centiloid Method in an Independent Cohort

Juan Domingo Gispert 1, 2, 3, David Vázquez García 4, Lyduine e Colluij 5, Mahnaz Shekari 1, 2, 7, Lucca Presotto 4, 5, Richard Manber 7, Robin Wolz 7, 8, Henrik Zetterberg 9, 10, 11, 12, Kaj Blennow 10, 11, 12, Andrew Stephens 10, 12, Jill Farrar 10, 12, Pieter Jelle Visser 17, 18, 19, Craig Ritchie 20, Frederik Barkhof 2, 21

1Barcelona-00001 Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain - Barcelona (Spain), 2IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain - Barcelona (Spain), 3Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spain - Barcelona (Spain), 4Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117, Amsterdam, Netherlands & - Amsterdam (Netherlands), 5Universitat Pompeu Fabra, Barcelona, Spain - Barcelona (Spain), 6University of Milano-Bicocca - Milan (Italy), 7OICQ, London, UK - London (United Kingdom), 8Imperial College, London, UK - London (United Kingdom), 9Dementia Research Institute, University College London, London, UK - London (United Kingdom), 10Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK - London (United Kingdom), 11Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China - Hong Kong (China), 12Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden - Gothenburg (Sweden), 13Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden - Gothenburg (Sweden), 14Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden - Mölndal (Sweden), 15Life Molecular Imaging GmbH, Berlin, Germany - Berlin (Germany), 16GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), 17Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, Netherlands - Maastricht (Netherlands), 18Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam University Medical Center, VU Medical Center, Amsterdam, Netherlands. - Amsterdam (Netherlands), 19Department of Neurobiology, Care Sciences and Society, Division of Neurogenetics, Karolinska Institute, Stockholm, Sweden - Stockholm (Sweden), 20Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK - Edinburgh (United Kingdom), 21Institute of Neurology and Centre for Medical Image Computing, University College London, UK - London (United Kingdom)

P060

Estimating the time between Amyloid- and Tau-PET positivity: Implications for Alzheimer’s Disease Prevention trials

Alexis Mocco 1, 2, Fiona Heeman 3, Toru Duran 3, Michael Schöll 1

1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden), 2Clario - San Mateo (United States), 3Clario - Lyon (France)

P061

A Novel Tau Staging Scheme Using [18F]MK-6240 PET Visual Read Extent Scores

Eddie Stage 1, Dustin Wooten 1, John Seibyl 2, Nicholas Seneca 1, Anthony Bannoo 1, Hana Florian 1, Robert Comley 1, Qi Guo 1

1AbbVie - North Chicago (United States), 2Institute for Neurodegenerative Disorders - New Haven (United States)

P062

Cortical microstructural changes associated with RBANS scores in cognitively unimpaired and MCI in the European Prevention of Alzheimer’s Dementia (EPAD) study

Mario Torso 1, Ged Ridgway 1, Michele Valotti 1, Ian Hardingham 1, Steven Chance 1, 2

1Oxford Brain Diagnostics - Oxford (United Kingdom), 2for the European Prevention of Alzheimer’s Dementia (EPAD) Consortium

P063

Amyloid PET Scan Reads in IDEAS – Comparison of Local Clinician and Expert Reads

Charles Windon 1, Barry Siegel 2, Maria Carrillo 3, Constantine Gatsionis 4, Lucy Hanna 5, Bruce Hillner 4, Andrew March 5, Rachel Whitmer 4, Anupa Arora 9

1Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), 2Mallinkrodt Institute of Radiology, Washington University in St Louis - St. Louis (United States), 3Alzheimer’s Association - Chicago (United States), 4Department of Epidemiology and Biostatistics, Brown University School of Public Health - Providence (United States), 5Center for Statistical Sciences, Brown University School of Public Health - Providence (United States), 6Department of Medicine, Virginia Commonwealth University - Richmond (United States), 7American College of Radiology - Reston (United States), 8Department of Public Health Sciences, University of California, Davis - Davis (United States), 9Vidadiapharmaceuticals - Philadelphia (United States), 10Life Molecular Imaging GmbH - Berlin (Germany), 11GEHC - Massachusetts (United States)

LP035

Baseline Regional Flortaucipir Profiles in Preclinical Alzheimer’s Disease

Vikas Kotaru 1, Michael Case 1, Karen Holdridge 1, Roy Yaari 1, Aaron Schultz 2, Keith Johnson 3, Paul Aisen 4, Reisa Sperling 2, John Sims 1, Sergey Shcherbinin 1

1Eli Lilly and Company - Indianapolis (United States), 2Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), 3Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), 4Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States)

LP036

Interim MRI safety analysis from a 76-week Phase 3 clinical trial of simufilam in Alzheimer’s Disease

James Kupres 1, Luc Bracoud 1, Joyce Suy 2, Laura Rodriguez 3, Lindsay Burns 1

1Cassava Sciences - Austin (United States), 2Clario - Lyon (France), 3Clario - San Mateo (United States)

LP037

Advancing Practicality for the Real-World Anti-Amyloid Treatment: Application of Solitaire 12-Fluid-Attenuated Inversion Recovery-Based Brain Volumetric Analysis Model

Hye Weon Kim 1, Zunhyan Riu 1, Hyunji Lee 1, Min Woo Lee 1, Jimin Kang 2, Won-Jin Moon 3

1Research Institute, Neurophet Inc. - Seoul (Korea, Republic of), 2Research Institute of Medical Science, Konkuk University of Medicine - Seoul (Korea, Republic of), 3Department of Radiology, Konkuk University Medical Center - Seoul (Korea, Republic of)

CTAD 2023
POSTER PRESENTATIONS

LP038  Longitudinal Tau PET analysis pipeline with consistent progression measures across tracers and diagnoses in commonly used as well as subject-specific AD Regions of Interest
Ziad Saad 4, David Henley 2, 3, Ritoboratto Datta 1, Christopher Rowe 4, Hartmuth KoLP 1
1Neuroscience Biomarkers and Global Imaging, Janssen R&D, Johnson & Johnson - San Diego (United States), 2Neuroscience Clinical Development, Janssen R&D, Johnson & Johnson - San Diego (United States), 3Indiana University School of Medicine, 4Austin Health and University of Melbourne - Sao Paulo - Sao Paulo (United States)

LP039  The utility of [18F]FDG brain uptake to predict disease progression and estimations of sample and effect size compared to clinical scales to help guide clinical trial development plans
Nicholas Seneca 1, Eddie Stage 1, Sjoerd Finnema 1, Scott Gladstein 1
1Abbvie - North Chicago (United States)

LP040  Stress Testing the CL concept: Validation of Generalizable Centiloid Cut-off Values in Two Large, Independent and Representative Clinical Alzheimer Cohorts
Juan Domingo Gispert 1, 2, Christopher Buckley 2, Santiago Bullich 1, Daniele Altomare 1, Mahmoud Shekari 1, 2, 3, Lyduine Collil 4, 5, David Vállez-García 6, Andrew Stephens 1, Gill Farrar 1, Andrew March 10, Renaud La Joie 11, Gil Rabinovici 11, Giovanni Frisoni 8, Frederik Barkhof 8
1Barcelona BRAIN Program: Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain; Barcelona Brain Research Center (BBRC), 2Hospital Germans Trias i Pujol, Badalona (Spain), 3Universitat Pompeu Fabra, Barcelona, Spain, 4GE Healthcare Pharmaceutical Diagnostics - Amsterdam (Netherlands), 5Life Molecular Imaging GmbH - Berlin (Germany), 6Institute of Rehabilitative and Geriatric Medicine, University Hospitals and University of Geneva - Geneva (Switzerland), 7Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva - Geneva (Switzerland), 8Department of Radiology and Nuclear Medicine, University Hospitals of Cleveland - Westlake, OH (United States), 9Clinical Memory Research, Lund University - Lund (Sweden), 10American College of Radiology - Washington (United States), 11Department of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco - San Francisco (United States)

LP041  Improved Differential Diagnosis of Hydrocephalus Ex Vacuo and Idiopathic Normal Pressure Hydrocephalus by Integrating Radscale and Dilatation of Perihippocampal Fissure
Jung-In Lim 1, Soyeong Lee 1, Minkyung Kim 1, Sun-Won Park 2, Jun-Young Lee 1, Jung-Hyo Ryim 1, Jee-Young Lee 4, Yu Kyong Kim 5, Sang-Hyung Lee 6
1Department of Radiology, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), 2Seoul National University College of Medicine - Seoul (Korea, Republic of), 3Department of Radiology, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), 4Department of Neurology, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), 5Department of Nuclear Medicine, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), 6Department of Neurosurgery, SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of)

LP042  Characterization of distortion correction on DTI measurements in a large multi-center clinical trial
Chris Conklin 1, Stefano Radonic 1, Luc Bracoud 1, Madhura Ingallhalikar 1, Saima Rathore 1, Diana Otero Svaldi 2, Adam Fleisher 7, Dave Scott 2
1Clario - Philadelphia (United States), 2Cerilliant - Georgetown (United States), 3Eli Lilly and Company - Indianapolis (United States)

THEME: Clinical Trials: Biomarkers including plasma

P064  The ViewMind AI Solution (VIMAS) detects and characterises neurocognitive decline along the Alzheimer’s disease continuum
Mario A. Parra 1, Francisco Lopera Restrepo 2, Gerardo Fernandez 1, Daniela Verge 4
1University of Strathclyde - Glasgow (United Kingdom), 2Grupo de Neurociencias - Antioquia (Colombia), 3ViewMind - Bahia Blanca (Argentina), 4ViewMind - West Chester (United States)

P065  Predicting cognitive stage transition using p-tau181, Centiloid, and other measures
Seong-Ho Koh 1, Hyuk Sung Kwon 1, Yongkyeong Lee 1, Hyun-Jeong Yu 1, Seong Hye Choi 1, Hongil Kim 1
1Hanyang University Guri Hospital - Guri (Korea, Republic of), 2Bundang Jesaeng Hospital - Seongnam (Korea, Republic of)

P066  Relationship between brain amyloid deposition and regional electroencephalogram abnormalities in older adults
Woo Jung Kim 1, Jaesub Park 2
1Korea University College of Medicine - Yongin-Si, Gyeonggi-Do, Korea (Republic of), 2National Health Insurance Service Ilsan Hospital - Goyang-Si, Gyeonggi-Do (Korea, Republic of)

P067  Relationship between telomere shortening and early subjective depressive symptoms and cognitive complaints in older adults
Seong-Ho Koh 1, Hyun-Jeong Yu 1, Hye-Jeong Yang 1, Seong Hye Choi 1
1Department of Neurology, College of Medicine, Hanyang University - Guri (Korea, Republic of), 2Bundang Jesaeng Hospital - Seongnam (Korea, Republic of), 3Department of Neurology, College of Medicine, Gachon University Gil Medical Center - Incheon (Korea, Republic of), 4Department of Neurology, Inha University Medical Center - Incheon (Korea, Republic of)

P068  Direct Comparison of Four Blood Plasma-Based Biomarkers in Preclinical Alzheimer’s Disease
Peter Snyder 1, Jessica Alber 1, Andreas Jeromin 1, Lauren Chaby 2, Stuart Portbury 2, Louisa Thompson 1, Jennifer Stronger 1, Ashley Price 1
1The University of Rhode Island - Kingston (United States), 2ALZpath, Inc. - Carlsbad (United States), 3Alpert Medical School of Brown University - Providence (United States), 4Butler Hospital - Providence (United States)

P069  Blood RNAs as fluid biomarkers for the differentiation between Alzheimer’s disease and dementia with Lewy bodies
Katrin Beyer 1, Jorge Mena 1, David Adamuz 1, Dolores Vilas 1, Ispierto Lourdes 2, Álvaro Ramiro 2, Pastor Pau 2
1Research Institute Germans Trias i Pujol - Badalona (Spain), 2Hospital Germans Trias i Pujol - Badalona (Spain)
P070  Systematic literature review of the clinical and non-clinical value of imaging and fluid biomarker testing to diagnose, identify and monitor patients with Alzheimer’s Disease
Salwa Masud 1, Helen Hu 1, Sreeranjani Menon 1, Miya Strait 1, Christian Siegfried 1, Elizabeth Somers 2, Cathelaine Plaideau 1
1Veranex - Boston (United States), 2Eisai Inc. - Nutley (United States)

P071  Serum Tau-1 and Tau-C levels and their association with cognitive impairment and dementia progression in a memory clinic derived cohort
Tobias Melton Axelsen 1, Peter Haggh 2, 4, 5, Asger Bihløt 2, Morten Asser Karsdal 2, Kim Henriksen 2, Steen Gregers Hasselbalch 2, Anja Hviid Simonsen 2, 5
1Department of Biomedical Sciences, University of Copenhagen - Copenhagen (Denmark), 2Nordic Bioscience - Herlev (Denmark), 3Sanos Clinics - Herlev, Denmark - Herlev (Denmark), 4Regional Dementia Research Centre, Department of Neurology, Zealand University Hospital - Roskilde (Denmark), 5Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark)

P072  Biomarker responses to gamma sensory stimulation in Alzheimer’s disease patients assessed in HOPE clinical trial
Mihaly Hajos 1, Monika Shpokayte 1, Celine Houser 1, Evan Hempel 1, Chandran Seshagiri 1, Alyssa Galley 1, Zach Malchano 1, Ralph Kern 1
1Cognito Therapeutics - Cambridge (United States)

P073  A robust and specific ELISA for N-acetylated VAMP-2, a novel synaptic biomarker for Alzheimer’s disease in CSF
Charlotte De Rocker 1, Julie Goossens 1, Alba Cervantes Gonzalez 1, Alberto Lleo 1, Olivia Belbin 2, Eugeen Vanmechelen 1
1ADx NeuroSciences - Gent (Zwijnaarde), Belgium, 2CIBERNED - Madrid (Spain)

P074  Alzheimer’s disease and microbiota: the MICMALZ cohort
Germain Ulyss Busto 1, 2, Linda-Nora Mekki 1, Sylvaine Artero 1, Yves Dauvilliers 2, Audrey Gabelle 1, Karim Bennys 1, Sylvie Claesens 1
1Resource and Research Memory Center - Montpellier University Hospital, Montpellier (France), 2University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier (France)

P075  Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812
Britney Lizama 1, Eunah Cho 1, Duc Duong 2, Kiran Pandey 3, Claire Williams 1, Anthony Caggiano 1, Nicholas Seyfried 1, Valentina Di Caro 1, Mary Hamby 1
1Cognition Therapeutics, Inc - Pittsburgh (United States), 2Emory University School of Medicine - Atlanta (United States), 3Emtherapro, Inc. - Atlanta (United States)

P076  Associations between the NIH Toolbox Emotion Battery and Tau Pathology in Preclinical Alzheimer’s Disease: Analysis of data from the multi-site ARMADA study
Koon Joo Yoo 1, Jennifer Gatchel 2, Emily Ha 3, Steven Arnold 4, Hiroko Dodge 5
1Bay Aging and Alzheimer’s Disease Center, Department of Neurology, Oregon Health & Science University - Portland (United States), 2Department of Psychiatry, Massachusetts General Hospital/McLean Hospital, Harvard Medical School - Boston (United States), 3Department of Medical Social Sciences, Northwestern University Evanston (United States), 4Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)

P077  Plasma protein markers to screen for blood-brain barrier dysfunction in Alzheimer’s disease.
Betty Tijms 2
1Amsterdam UMC - Amsterdam (Netherlands)

P078  A novel plasma ONS-derived tTau assay for detection of amyloid positivity in Alzheimer’s Disease
Gallen Triana-Baltzer 1, Antonella Scaglione 1, Setareh Moughadam 1, Kristof Van Kol 2, Vanessa Raymont 3, Mark Woolrich 3, James Rowe 4, Hartmuth Kolp 1
1INmune Bio, Inc - Boca Raton (United States), 2Department of Radiology, Massachusetts General Hospital - Boston (United States), 3University of Oxford - Oxford (United Kingdom), 4University of Cambridge - Cambridge (United Kingdom)

P079  Pharmacodynamic Effects of Semorinemab on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer’s Disease (Lauriet)
Stephen Schauer 1, 2, Balaz Toth 1, Julie Lee 1, Veronica Anania 1, Lee Honigberg 1, Kristin Wildsmith 1, Vidya Ramakrishnan 1, Felix Yeh 1, Michael Dolton 1, Parris Pope 4
1Janssen R&D - San Diego (United States), 2Janssen R&D - Beerse (Belgium), 3Department of Psychiatry, Massachusetts General Hospital/McLean Hospital, Harvard Medical School - Boston (United States), 4Emtherapro, Inc. - Atlanta (United States)

P080  CSF proteomic insights into the mechanism of action of gamma sensory stimulation in Alzheimer’s Disease
Kiran Pandey 1, 3, Annabelle Singer 2, Duc Duong 3, James Lah 3, Allan Levey 3, Nicholas Seyfried 1, Monika Shpokayte 4, Zach Malchano 6, Mihaly Hajos 6
1Emtherapro, Inc. - Atlanta (United States), 2Georgia Tech - Atlanta (United States), 3Emory University - Atlanta (United States), 4Cognito Therapeutics - Cambridge (United States), 5Inmune Bio, Inc. - Boca Raton (United States)

P081  Changes in the neurology related CSF proteome after short-term treatment with XPro1595 for Alzheimer’s disease
Parris Pope 1, Christopher Barnum 1, Raymond Tesi 1
1INmune Bio, Inc. - Boca Raton (United States)
A biomarker to aid Alzheimer's disease staging: sTREM2 is decreased in Amyloid positive/Tau negative, yet increased once Tau aggregates leading to increased cognitive decline

Rodrigo Canovas 1, Christopher J. Fowler 1, Stephanie Rainey-Smith 2,4,5,6, Margherita Carboni 1, Ivonne Suridjan 1, Gwendlyn Kollmorgen 6, Chad Logan 7, Vincent Dore 1,10, Jurgen Fripp 11, Colin L. Masters 1, Qiao-Xin Li 12, Steven J. Collins 13, Paul Maruff 13, James D. Doecke 24

1Australian E-Health Research Centre, CSIRO, Parkville-Melbourne, Vic (Australia), 2The University of Melbourne, The Florey Institute-Melbourne, Vic (Australia), 3Centre for Healthy Ageing, Murdoch University - Murdoch, Wa (Australia), 4Australian Alzheimer's Research Foundation, - Perth, Wa (Australia), 5University of Western Australia - Perth, Wa (Australia), 6Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer's Disease Research & Care-Joondalup, Wa (Australia), 7Roche Diagnostics International Ltd-Rotkreuz (Switzerland), 8Roche Diagnostics GmbH - Penzberg (Germany), 9Centralised & Point of Care Solutions, Roche Diagnostics GmbH-Penzberg (Germany), 10Department of Molecular Imaging & Therapy-Austin Health-Melbourne, Vic (Australia), 11Australian E-Health Research Centre, CSIRO Brisbane, Old (Australia), 12Department of Medicine & The Florey Institute, The University of Melbourne, Parkville-Melbourne, Vic (Australia), 13Cogstate Ltd-Melbourne, Vic (Australia)

Sex Differences in Amyloid PET: A Secondary Analysis of the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Study

Charlotte Teunissen 1, Inge M.W. Verberk 1, Jolien Jutte 1,2, Maurice Y. Kingma 1,3,1, Argonde C. Van Harten 1,3,4, Anouk Den Braber 1,3,2, Sindhuja Vigneswaran 1,4, Mariam Gouda 1, Marie-Paule Van Engelen 1, Afina W. Lemstra 1, Yoland A.L. Pijnenburg 1, Wiegie M. Van Der Flier 1,3,5, Martijn Schut 2, David Wilson 6

1Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 2Translational Artificial Intelligence laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 3Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 4Center for Neurodegenerative disease research, Amsterdam (Netherlands), 5Department of Methodology & Digital Health - Amsterdam (Netherlands), 6Quanterix - Billerica (United States)

The mastermind of the Alzheimer’s blood-based biomarkers: development of cutoffs and a visualization tool for use in clinical dementia practice

Costa 1, Vigneswaran 1,4

1Mayo Clinic - Rochester (United States), 2Oxford Diagnostics - Oxford (United Kingdom), 3MGH - Boston (United States)

AD risk genes for blood-brain barrier dysfunction

1Santa Lucia Foundation IRCCS - Rome (Italy), 2Oxford Diagnostics - Oxford (United Kingdom), 3Brown University - Providence, Rhode Island (United States), 4Brown University - Providence, Rhode Island (United States), 5American College of Radiology - Philadelphia (United States), 6Washington University in St. Louis - St. Louis (United States), 7UCDAVIS - Davis (United States)

MIP-1α serum levels correlate alongside positive outcome of clinical endpoints in Alzheimer’s Disease patients receiving plasma exchange with albumin replacement

David Wilson 6

1University of California San Francisco - San Francisco (United States), 2Alzheimer Association - Usa (United States), 3Brown University - Providence, Rhode Island (United States), 4Brown University - Providence, Rhode Island (United States), 5University of Chicago - Chicago (United States), 6Quanterix - Billerica (United States)

Proteomic Analyses in the 24-week PEGASUS Trial Using the Olink Platform: Providing Insight into the Biologic Activity of Sodium Phenylbuturate and Taurursodiol in Alzheimer’s Disease

Nicholas Cullen 1, Ryan Miller 2, Marcelo Gutierrez 2, Rudolph E. Tanzi 1, Lahar Mehta 2

1BioFINDER Group, Department of Clinical Sciences, Lund University - Lund (Sweden), 2Amylyx Pharmaceuticals, Inc. - Cambridge (United States), 3Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University - Boston (United States)

Statistical considerations for assessing the relationship between disease progression biomarkers and clinical endpoints in Alzheimer’s disease

1Biogen - Cambridge, Ma (United States), 2Pentara Corporation - Millcreek, Ut (United States), 3Lund University - Malmö (Sweden), 4University of Southern California - San Diego, Ca (United States)

Validation of clinical cutoffs for the beta-amyloid (Aβ42), p-Tau181 and p-Tau181/Abeta42 Roche Elecsys Generation 2 assays

1Mayo Clinic - Rochester (United States)

1BioFINDER Group, Department of Clinical Sciences, Lund University - Lund (Sweden), 2Amylyx Pharmaceuticals, Inc. - Cambridge (United States), 3Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University - Boston (United States)

Structural and functional DMN preservation after 24 weeks of rTMS in Alzheimer’s disease patients

1University of California San Francisco - San Francisco (United States), 2Alzheimer Association - Usa (United States), 3Brown University - Providence, Rhode Island (United States), 4Brown University - Providence, Rhode Island (United States), 5VCU Health - Virginia (United States), 6American College of Radiology - Philadelphia (United States), 7Washington University in St. Louis - St. Louis (United States), 8UCDAVIS - Davis (United States), 9Centralised & Point of Care Solutions, Roche Diagnostics GmbH - Penzberg (Germany), 10Centralised & Point of Care Solutions, Roche Diagnostics GmbH-Penzberg (Germany), 11Australian E-Health Research Centre, CSIRO Brisbane, Old (Australia), 12Department of Medicine & The Florey Institute, The University of Melbourne, Parkville-Melbourne, Vic (Australia), 13Cogstate Ltd-Melbourne, Vic (Australia)

1Mayo Clinic - Rochester (United States), 2Oxford Diagnostics - Oxford (United Kingdom), 3MGH - Boston (United States)
POSTER PRESENTATIONS

P092 Associations Between Blood-Based Biomarkers and Amyloid PET measurements in Cognitively Unimpaired Presenilin 1 E280A Mutation and Non-Mutation Carriers from the API Autosomal Dominant Alzheimer's Disease Colombia Prevention Trial

Vedanshi Bhargava1,2, Mike Malek-Ahmadi1,2,3,4, Francisco Lopera5,6, Silvia Rios-Romenets2, Eugenia Cardona2, Yakeel T Quiroz-Gaviria4, Jessica Langkjaer1, Pierre Tarant3, Robert Alexander2, Yu Su1,2,3,4, Kewei Chen2,3, Tobias Bittner1, David Clayton9,9,10,1, Richele Doody9,9, Eric Reiman1,9,10,1
1University of Arizona College of Medicine Phoenix - Phoenix (United States), 2Banner Alzheimer’s Institute - Phoenix (United States), 3University of Arizona College of Medicine Phoenix - Phoenix (United States), 4Arizona Alzheimer’s Consortium - Phoenix (United States), 5Neurosciences Group of Antioquia, Universidad de Antioquia – Medellin (Colombia), 6Massachusetts General Hospital and Harvard Medical School - Boston (United States), 7Arizona Alzheimer’s Consortium - Phoenix (United States), 8Genentech - South San Francisco, CA (United States), 9Translational Genomics Research Institute - Phoenix (United States), 10Arizona Alzheimer’s Consortium - Phoenix (United States)

P093 Plasma p-tau217 as a cost-effective surrogate biomarker for clinical trials across the AD continuum

Pamela C Lukasiewicz-Ferreira1, Bruna Bellaver1, Guilherme Povala1, Joao Pedro Ferrari-Souza1, Firoza Z. Lussier1, Douglas T. Leff1, Helmet Karim1, Chang Hyung Hong2, Hyun Woong Rho2, Dana L. Tudorascu1, Thomas K. Karikan3, Beth E. Snitz2, Sang Joon Son2, Tharick A Pascoal2
1Department of Psychiatry, School of medicine, University of Pittsburgh - Pittsburgh (United States), 2Department of Psychiatry, Ajou University School of Medicine - Suwon (Korea, Republic of), 3Department of Neurology, School of Medicine, University of Pittsburg - Pittsburgh (United States)

P094 Plasma biomarkers and longitudinal cognitive decline in non-demented Alzheimer’s disease

Karly Cody1,2, Rebecca Langhough1, Lianlian Du1, Erin Jonaitis1, Nathaniell Chin3, Beckie Jeffers3, Monica Vandlenangenberg1, Sanjay Asthana1, Kris Kirsch5, Matthew Meyer2, Kevin Yarasheski2, Tim West2, Tobey Bethushean2, Sterling Johnson1
1Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin - Madison (United States), 2C2N Diagnostics - St. Louis (United States)

P095 Cerebrospinal fluid cellular transcriptomics as biomarkers of central nervous system drug-target engagement of a peripherally administered vaccine in older adults with and without cognitive impairment (BG5-AD)

Marc Weinberg1,2, Mahesh Kodali1,2, Rojasheer Jayakumar3, Denise L. Faustman3, Sudeshna Das1,2, Steven Arnold1,2
1Mass General Hospital - Boston, MA (United States), 2Harvard Medical School - Cambridge, MA (United States)

P096 Bio-Hermes study topline results: AB 42/40 and p-tau 181/217 blood-based biomarkers compared to amyloid PET and CSF in a diverse, community-based population

Douglas Beauregard2, Richard Mohs1, John Dwyer1, Sarah Hollingshead1, Jennifer Gaudioso1, Jason Bork1, Diana Kerwin2
1Global Alzheimer’s Platform Foundation - Washington, DC (United States), 2Kewin Medical Center - Dallas (United States)

LP043 Novel diagnostic platform enabling protein specific biomarker signature for the diagnosis of AD

Marien San Nicol1,2, Oliver Peters1, Hilary Wunderlich1, Timo Grimm1, Lutz Frölich4, Arno Schaepe2, Richard Metzler1, Sabine Mertzig2, Klaus Hallermayer1, Harald Waldenberger1, Thomas Heydler1, Mareike Haack1
1Noselab GmbH - Munich (Germany), 2Charite - Berlin (Germany), 3PUM - Munich (Germany), 4Zf Mannheim - Mannheim (Germany), 5GMX - Munich (Germany), 6Microcoat - Munich (Germany)

LP044 A Cross-Sectional Study of Plasma Aβ42/40 ratio, p-tau217, p-tau181, GFAP and Nf-L in a Clinical Cohort Characterized by CNS Amyloid PET Imaging

Ahmed Chen1, Yoosouf Badal1, Mintzu Lo1, Brandon Yee2, Bryan Lim3, Christopher Fowler2, Robert Martone3, Christos Petropoulos3, John Winslow4
1Labcorp-Monogram Biosciences - South San Francisco, CA (United States), 2The Florey Institute of Neuroscience and Mental Health - Parkville, VIC (Australia), 3Labcorp Drug Development - Indianapolis, IN (United States)

LP046 Analytical Validation and Initial Clinical Evaluation of a New Blood-Based Diagnostic Test for Alzheimer’s Disease

Andrew Schade1,2, Adam Abdel1, Antonio Chambers1, Jeff Fill1, Heinz Reiske1, Ming Lu1, Amanda Morris1, Michael Pontecorvo1, Emily Collins1, Mark Mintun1, Michael Hodson1
1El Lilly and Company - Indianapolis (United States), 2Massachusetts General Hospital - Boston, MA (United States)

LP047 Analytical and Clinical Validation of β-Amyloid 1-40, 1-42, and the 1-42/1-40 Ratio using a Clinical Autoanalyzer

Ayla Harris1, Tien Le1, Bradley Corlier1, Matthew Chappell1, Deborah Boles1, Russell Grant1
1Labcorp - Burlington (United States)

LP048 The Alzheimer’s Association Global Biomarker Standardisation Consortium (GBSC) plasma phospho-tau Round Robin study

Nicholas Ashton1, Ashvinie Keshavan2, Lars Grötschel2, Les Shaw1, Kaj Blennow1, Jonathan Schott3, Henrik Zetterberg4
1University of Gothenburg - Göteborg (Sweden), 2Göteborg (Sweden), 3University College London - London (United Kingdom), 4University of Pennsylvania - Philadelphia (United States), 5University of Pennsylvania - Philadelphia (United States), 6University of Pennsylvania - Philadelphia (United States), 7University College London - London (United Kingdom), 8University of Gothenburg - Göteborg (Sweden)

LP049 Gene Expression Profile of Synchronized Cells Identifies Alzheimer’s Disease in Autopsy Validated Skin and Blood Samples

Florin Chirila1,2,3,4, Ayla Harris1,2,3,4, Machtup William1, Wallace Jack1, Xu Guang1, Alkon Daniel1
1Syms Dx - Rockville (United States), 2Spot Dx - Morgantown (United States)
### POSTER PRESENTATIONS

**THEME: Clinical Trials: Cognitive and functional endpoints**

**P098** Between-Country Comparisons of Quality of Life and Activities of Daily Living in Multinational Alzheimer’s Disease Clinical Trials  
Sayaka Machizawa 1, Erica Appleman 1, Jessica Stenclick 1, Andrei Iacob 1, Ruiyi Kamat 1  
1Sigant Health - Blue Bell (United States), 2Sigant Health - Bucharest (Romania)

**P099** The Effect of Global Functioning on Participant and Study Partner Ratings of Quality of Life in Participants with Prodromal to Mild Alzheimer’s Disease  
Jessica Stenclick 1, Amanda Aedo 1, Sayaka Machizawa 1, Ruiyi Kamat 1, Erica Appleman 1, Andrei Iacob 1  
1Sigant Health - Blue Bell (United States)

**P100** Blood pressure variability via ambulatory monitoring and risk for dementia in the SPRINT MIND trial  
Isabel Sibley 1, Daniel Nation 2  
1University of Southern California - Los Angeles (United States), 2University of California Irvine - Irvine (United States)

**P101** Longitudinal resting-state EEG along the Alzheimer’s disease continuum: the road to successful clinical trial implementation  
Ellie P. Scheijbeleeer 1, Willem De Haan 1, Cornelis J. Stam 1, Jos W. R. Twisk 1, Alida A. Gouw 1  
1Amsterdam UMC location VUMc - Amsterdam (Netherlands)

**P102** The EEG as functional endpoint in AD trials  
Willem De Haan 1, Ellie Scheijbeeleer 1, Alida Gouw 1, 2, Cornelis Jan Stam 1, 2  
1Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUMc - Amsterdam (Netherlands), 2Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), 3Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUMc, - Amsterdam (Netherlands), 4Clinical Neurophysiology and MEG Center, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUMc - Amsterdam (Netherlands)

**P103** Rates of Progression in Patients with Alzheimer’s Disease Depending on Apolipoprotein E Genotype and Concomitant Medications  
Carina Wattmo 1, 2  
1Cognitive Disorders Research Unit, Department of Clinical Sciences, Malmo, Lund University - Malmo (Sweden), 2Department of Neurology, Lund University - Lund (Sweden)

**P104** Effects of Melissa officinalis extract containing rosmarinic acid for Alzheimer’s disease in human  
Moeko Shinozaki 1, Kenjiro Ono 1  
1Kanazawa University - Kanazawa (Japan)

**P105** TRAILBLAZER-ALZ 2: Heterogeneity in performance of clinical outcome assessments across geo-cultural areas  
Giulia Tronchin 1, 2, Wendy Wenyu Ye 1, Xiaojuan Mi 2, Alette M. Wessels 1  
1Eli Lily and Company - Indianapolis (United States), 2TechData Services Company - King Of Prussia (United States)

**P106** Assessing ‘true’ non-progression rate in early Alzheimer’s disease accounting for within-subject variation  
Menglan Pang 1, Willem Huijbiers 1, 2, Audrey Gabelle 1, Arie Gafson 1, Richard Hughes 1, Shibeshih Belachew 1, Shen Changyu 1  
1Biegen - Cambridge (United States), 2Department of Neurology, Zealand University Hospital - Roskilde (Denmark)

**P107** The use of composite z-scores in place of normative-based scaling to improve signal detection in clinical trials involving neurodegenerative diseases  
Erin Jacobs 1, Christopher Randolph 1, 2, Danielle Digregorio 1, Selam Negash 1, Raymond Blattner 1  
1WCG Clinical - Princeton (United States), 2Loyola University Medical Center - Chicago (United States)

**P108** Impact of study partner type on primary endpoint variability in two phase 3 registration trials in mild-to-moderate Alzheimer’s disease  
Mary Ryan 1, 2, 3, Daniel Gillen 1, 2, Joshua Grill 1, 2, 3  
1Institute for Memory Impairments and Neurological Disorders, UC Irvine - Irvine (United States), 2Department of Statistics, UC Irvine - Irvine (United States), 3Department of Biostatistics, Yale School of Public Health - New Haven (United States), 4Department of Psychiatry and Human Behavior, UC Irvine - Irvine (United States), 5Department of Neurobiology and Behavior, UC Irvine - Irvine (United States)

**P109** Timing the change in the Pre-clinical Alzheimer’s Cognitive Composite score with Amyloid-β in pre-clinical Alzheimer’s Disease  
Timothy Cox 1, Rosita Shishhegar 1, Christopher Fowler 2, Stephanie Rainey-Smith 3, 4, 5, 6, Hamid Sohrabi 3, 4, Shaun Markovic 3, 4, Vincent Dore 1, 2, Pierrick Bourget 1, Jurgen Fripp 3, Ralph Martins 3, 4, Victor Villemagne 10, Colin Masters 1, Christopher Rowe 1, 2, 3, James Doecke 1  
1Australian E-Health Research Centre, CSIRO - Parkville (Australia), 2The University of Melbourne, The Florey Institute - Melbourne (Australia), 3Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), 4Australian Alzheimer’s Research Foundation - Perth (Australia), 5University of Western Australia - Perth (Australia), 6Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer’s Disease Research & Care - Perth (Australia), 7Department of Molecular Imaging & Therapy Austin Health - Melbourne (Australia), 8Australian E-Health Research Centre, CSIRO - Brisbane (Australia), 9Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University - Sydney (Australia), 10Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States)

**P110** Longitudinal resting-state EEG along the Alzheimer’s disease continuum: the road to successful clinical trial implementation  
Ellie P. Scheijbeeleer 1, Willem De Haan 1, Cornelis J. Stam 1, Jos W. R. Twisk 1, Alida A. Gouw 1  
1Amsterdam UMC location VUMc - Amsterdam (Netherlands)

**P111** Rates of Progression in Patients with Alzheimer’s Disease Depending on Apolipoprotein E Genotype and Concomitant Medications  
Carina Wattmo 1, 2  
1Cognitive Disorders Research Unit, Department of Clinical Sciences, Malmo, Lund University - Malmo (Sweden), 2Department of Neurology, Lund University - Lund (Sweden)

**P112** Effects of Melissa officinalis extract containing rosmarinic acid for Alzheimer’s disease in human  
Moeko Shinozaki 1, Kenjiro Ono 1  
1Kanazawa University - Kanazawa (Japan)

**P113** Assessing ‘true’ non-progression rate in early Alzheimer’s disease accounting for within-subject variation  
Menglan Pang 1, Willem Huijbiers 1, 2, Audrey Gabelle 1, Arie Gafson 1, Richard Hughes 1, Shibeshih Belachew 1, Shen Changyu 1  
1Biegen - Cambridge (United States), 2Department of Neurology, Zealand University Hospital - Roskilde (Denmark)

**P114** The use of composite z-scores in place of normative-based scaling to improve signal detection in clinical trials involving neurodegenerative diseases  
Erin Jacobs 1, Christopher Randolph 1, 2, Danielle Digregorio 1, Selam Negash 1, Raymond Blattner 1  
1WCG Clinical - Princeton (United States), 2Loyola University Medical Center - Chicago (United States)
LP063  Factors associated with floor and ceiling effects in the LatAm-FINGERS neuropsychological battery
Monica Yassuda 1, Claudia Suemoto 1, Lucia Crivelli 1, Ismael Clandidi 1, Paulo Caramelli 2, Francisco Lopera 2, Sonia Brucki 2, Ricardo Nitrini 2, Ana Luisa Sosa 3, Rosa Salinas 1, Lina Velilla 4, Gustavo Sevlever 1, Mia Kivipelto 4, Maria Carrillo 2, Ricardo Allegri 3,
1Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), 2Antioquia Medical School - Antioquia (Colombia), 3Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suárez - Ciudad De México (Mexico), 4Karolinska Institutet - Stockholm (Sweden), 5Alzheimer's Association - Chicago (United States)

LP064  Robustness and generalizability of a speech based composite score for measuring disease progression in AD
Michael Spilka 1, Mengdan Xu 1, Jessica Robin 1, William Simpson 2
1Winterlight Labs - Toronto (Canada)

LP065  Cognitive Functional Composite detected time-dependent worsening of cognition and function during 18-month period in a phase II clinical trial with biomarker proven Alzheimer’s disease patients
Sietse Sikkens 2, Merel Postema 3, Niels Prins 1, Pieter van Bokhoven 1, Tomohiro Okuda 1, Philip Scheltens 5
1Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), 2Brain Research Center - Amsterdam (Netherlands), 3VU-Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), 4FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), 5Amsterdam UMC - Amsterdam (Netherlands)

LP066  Measuring What Matters Most to People Living With Alzheimer’s Disease and Care Partners: What Matters Most Qualitative Study
Carla Romano 1, Emily Bratlee-Whitaker 1, William L Herring 1, Leigh F Callahan 1, Karina Raimundo 2, Jim Taylor 2, Ge T Taylor 3, Ana Luisa Sosa 4, Rosa Salinas 1, Lina Velilla 4, Gustavo Sevlever 1, Ricardo Allegri 3,1
1Winterlight Labs - Toronto (Canada), 2Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suárez - Ciudad De México (Mexico), 3Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), 4Karolinska Institutet - Stockholm (Sweden), 5Alzheimer’s Association - Chicago (United States)

LP067  Tracking short-term cognitive changes among cognitively unimpaired older adults with different amyloid (A) and tau (T) profiles using The Boston
Keith Johnson 1, Reisa Sperling 1, 2, Sosa 5, Rosa Salinas 5, Lina Velilla 4, Lappin 7, Terry Frangiosa 7, Kajan Gnanasakthy 1, Diana Goss 1, Russ Paulsen 8, Ann Hartry 9, Dana Dibenedetti 1
1Massachusetts General Hospital, Harvard Medical School - Boston (United States), 2Brigham and Women’s Hospital, Harvard Medical School - Boston (United States), 3Remote Assessment for Neurocognitive Health (BRANCH), 4Harvard Medical School - Boston (United States), 5Scottish Brain Sciences - Edinburgh (United Kingdom), 6University of Edinburgh - Edinburgh (United Kingdom), 7Alzheimer’s Association - Chicago (United States), 8UsAgainstAlzheimer's - Washington, D.C. (United States), 9Biogen Inc - Cambridge (United States)

LP068  The Down Syndrome – Clinical Global Impression of Change (DS-CGIC)
Julian Gray 1, Andre Strydom 2, Olivier Sol 1, Juan Fortea 1, Carla Romano 1, Emily Bratlee-Whitaker 1, William L Herring 1, Leigh F Callahan 1, Karina Raimundo 2, Jim Taylor 2, Ge T Taylor 3, Ana Luisa Sosa 4, Rosa Salinas 1, Lina Velilla 4, Gustavo Sevlever 1, Ricardo Allegri 3,1
1Winterlight Labs - Toronto (Canada), 2Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suárez - Ciudad De México (Mexico), 3Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), 4Karolinska Institutet - Stockholm (Sweden), 5Alzheimer’s Association - Chicago (United States)

LP069  The Longitudinal Impact of COVID-19 Lockdown on Mild Cognitive Impairment and Alzheimer’s Disease
Hahnun Lee 1, Yoon Soo Cho 1, Jun-Young Lee 1
1Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea - Seoul (Korea, Republic of), 2Interdisciplinary Program in Cognitive Science, Seoul National University, Republic of Korea, 3Interdisciplinary Program in Cognitive Science, Seoul National University, Republic of Korea, 4Keimyung University School of Medicine & Institute for Medical Science - Daegu (Korea, Republic of)
THEME: Cognitive assessment and clinical trials

P118  The ViewMind AI Solution (VIMAS) addresses inequities and disparities in the assessment of dementia risk
Mario A. Parra 1, Alfreds Gonzalez-Hernandez 2, Jasmin Bonilla-Santos 3, Rodrigo A. Gonzalez-Monteleagle 4, Dorian Yisela-Cala 2, Gerardo Fernandez 2, Danilo Verge 5
1University of Strathclyde - Glasgow (United Kingdom); 2Universidad Surcolombiana - Huila (Colombia); 3ViewMind - Bahia Blanca (Argentinia); 4ViewMind - West Chester (United States)

P119  Clinical Dementia Rating Scale (CDR®) domain scores differ by diagnosis in Hispanic and non-Hispanic White samples
Giovanna Pilonietta 1, David Geldmacher 1
1The University of Alabama at Birmingham - Birmingham (United States)

P120  Sex bias and the association of dementia lifestyle risk factors with superager status
Matthew McPhee 1, Larissa Mcketon 2, Annalise Laplume 3, Angela Troyer 1,4, Nicole Anderson 2,4,5
1Neuropsychology and Cognitive Health, Baycrest - Toronto (Canada); 2Rotman Research Institute, Baycrest Academy for Research and Education - Toronto (Canada); 3Douglas Research Centre, McGill University and Centre for Research at the Geriatrics Institute of the University of Montreal - Montreal (Canada); 4Department of Psychology, University of Toronto - Toronto (Canada); 5Department of Psychiatry, University of Toronto - Toronto (Canada)

P121  Objective Monitoring of Instrumental Activities of Daily Living in Dementia
Ram Kinker Mishra 1, Myeounggon Lee 2, Adonay S. Nunes 3, Michele K. York 4, Mark E. Kunik 2, Ashkan Vaziri 1, Bijan Najafi 2
1Biosensics - Boston (United States); 2Baylor College of Medicine - Houston (United States)

P122  Errors in Clinical Dementia Rating administration and scoring: Identifying targets for intervention
Rujvi Kamat 1, Jacqueline Massa 1, Amanda Aedo 1, Gila Barbati 1, Sayaka Machizaiwa 1, Jessica Stenclik 1, Erica Appleman 1, Andrei Iacob 1
1Signant Health - Blue Bell (United States)

P123  Leveraging AI methods to detect cognitive decline and dementia over the telephone: a promising new screening tool
Catherine Diaz-Asper 1, Chelsea Chadwick 2, R. Scott Turner 1, Brigid Reynolds 1, Brita Elvevåg 4
1Marymount University - Arlington (United States); 2University of Colorado, Boulder - Boulder (United States); 3Georgetown University - Washington Dc (United States); 4University of Tromsø - the Arctic University of Norway - Tromsø (Norway)

P124  Influence of COVID-19 pandemic to self-perceived memory decline: contribution to cognitive change one-year later
Kenichiro Sato 1, Yoshiki Niimi 2, Ryoko Ihara 3, Kazushi Suzuki 4, Takeshi Ikawatsu 1,2
1University of Tokyo - Tokyo (Japan); 2University of Tokyo Hospital - Tokyo (Japan); 3Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan); 4National Defense Medical College - Sagamihara (Japan)

P125  Nili- Digital Health Solution for Dementia Care Coordination and Management
Ram Kinker Mishra 1, Myeounggon Lee 2,3, Michele K. York 4, Mark E. Kunik 2,3, Bijan Najafi 2,3, Ashkan Vaziri 2,3
1Biosensics LLC - Newton (United States); 2Department of Surgery, Baylor College of Medicine - Houston (United States); 3Neurology and Cognitive Health, Baycrest - Toronto (Canada); 4Department of Psychology, University of Toronto - Toronto (Canada)

P126  Using Speech Biomarkers for Detection and Monitoring of Cognitive Decline
Adonay S. Nunes 1, Gozde Cay 1, Myeounggon Lee 2, Mohammad Dehghan Rouzi 2, Nesreen El-Refaei 2, Anmol Momin 1, Ram Kinker Mishra 1, Bijan Najafi 2, Ashkan Vaziri 2,3
1Biosensics LLC - Boston (United States); 2Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine - Houston (United States)

P127  Validation of a TICS-r cutoff score for identification of cognitive impairment during telephone pre-screening assessment
Eric Fischer 1, Abigail O'connell 2, Sarah Gaussoin 1, Samuel Lockhart 1, Suzanne Craft 1
1Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States); 2Wake Forest School of Medicine, Department of Internal Medicine - Gerontology - Winston-Salem (United States)

P128  The Pre-Clinical Alzheimer’s Cognitive Composite Score: Informing Clinical Meaningfulness through the Alzheimer’s Disease Continuum
James David Doecke 1, Marcela Csendes 1, Timothy Cox 2, Rosita Shishegar 1, Christopher James Fowler 1, Stephanie Rainey-Smith 1,2,4,8, Hamid Sohrabi 9,10, Shaun Markovic 9,10, Jurgen Frip 1, Cai Gillis 11, Nancy Maserejian 11, Yen Ying Lim 12, Jason Hassenstab 13,14, Paul Maruff 15
1Australian E-Health Research Centre, CSIRO - Herston (Australia); 2Australian E-Health Research Centre, CSIRO - Canberra (Australia); 3Australian E-Health Research Centre, CSIRO - Parkville (Australia); 4The University of Melbourne, The Florey Institute - Parkville (Australia); 5Centre for Healthy Ageing, Murdoch University - Murdoch (Australia); 6Australian Alzheimer's Research Foundation - Perth (Australia); 7University of Western Australia - Perth (Australia); 8Edith Cowan University, School of Medical and Health Sciences, Centre of Excellence for Alzheimer’s Disease Research & Care - Joondalup (Australia); 9Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia); 10Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia); 11Biogen - Boston (United States); 12Turner Institute for Brain and Mental Health, School of Psychological Sciences - Monash (Australia); 13Knight Alzheimer Disease Research Center, Washington University School of Medicine - St. Louis (United States); 14Department of Neurology, Washington University School of Medicine - St. Louis (United States); 15Cognate - Melbourne (Australia)
Automated linguistic metrics from a novel, remote, smartphone-based self-assessment of cued narration and free recall correlate with brain atrophy in language and memory networks in early Alzheimer’s disease

Irma T. Kurniawan, Michal K. Kosek, Raphael M. Ullmann, Arnaud M. Wolfer, Stefan Holiga, Eduardo A. Aponte, Thanneer M. Perumal, Kirsten I. Taylor

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), Roche Global IT Solution Centre, Warsaw, Poland - Warsaw (Poland)

Characterising progressive decline across multiple cognitive domains in preclinical Alzheimer’s disease

Rosita Shishegar, Timothy Cox, Hamid R. Sohrabi, Shaun Markovic, Jurgen Fripp, Vincent Doré, Pierrick Bourgeat, Jason Hassenstab, Yen Ying Lim, Paul Maruff, Colin L. Masters, James D. Doecke

Australian E-Health Research Centre, CSIRO - Melbourne (Australia), Australian E-Health Research Centre, CSIRO - Canberra (Australia), Centre for Healthy Ageing, Murdoch University - Murdoch (Australia), Australian E-Health Research Centre, CSIRO - Brisbane (Australia), Department of Psychological and Brain Sciences, Washington University in Saint Louis - Saint Louis (United States), Turner Institute of Brain and Mental Health, School of Psychological Sciences, Monash University - Clayton (Australia), Cogstate Ltd. - Melbourne (Australia), The University of Melbourne, The Florey Institute - Melbourne (Australia)

Do Alzheimer’s Risk Genes Also Predict Cognitive Decline?


Centre for Precision Health, Edith Cowan University - Perth (Australia), Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University - Perth (Australia), Australian E-Health Research Centre, CSIRO - Melbourne (Australia), Florey Institute of Neuroscience and Mental Health, The University of Melbourne - Melbourne (Australia), Cogstate Ltd. - Melbourne (Australia), Department of Psychiatry, University of Pittsburgh, Pittsburgh (United States), Department of Molecular Imaging and Therapy and Centre for PET, Austin Health, Melbourne (Australia)

Forecasting Future Dementia Risk Using a Digital Clock Drawing Assessment in an African American Population


Linus Health, Inc. - Boston, Massachusetts (United States), Department of Neurology, Harvard Medical School - Cambridge, Massachusetts (United States), Michigan State University - East Lansing, Michigan (United States), Rowan University - Stratford, New Jersey (United States), University of North Dakota School of Medicine and Health Sciences - Fargo, North Dakota (United States), Rush Alzheimer’s Disease Center - Chicago, Illinois (United States), Department of Psychiatry and Behavioral Sciences, Rush University Medical Center - Chicago, Illinois (United States), Department of Neurological Sciences, Rush University Medical Center - Chicago, Illinois (United States), Hinda and Arthur Marcus Institute for Aging Research, Deanna and Sidney Wolk Center of Memory Health, Hebrew Senior Life - Boston, Massachusetts (United States)

Bridging the Assessment Gap: Newly Developed Neuropsychiatric Cognitive Assessments on the Cognivue® Platform Show Strong Correlation with Traditional Gold Standard Tests

James Galvin

University of Miami Comprehensive Center for Brain Health - Miami (United States)

Efficient and Automated Cognitive Pre-Screening for Clinical Trials using the Montreal Cognitive Assessment (MoCA) Xpress® Tool and Automated Report

Sivan Kil-Broni, Katie Bodenstein, Lara Kojok, Shuo Mila Sun, Yousaf Ghantous, Ziad Nasreddine

McGill University - Montreal, QC (Canada), MoCA Cognition Clinic and Institute - Montreal, QC (Canada), Harvard University - Cambridge, MA (United States)

Attaching contextual meaningfulness to CDR-SB score

Danielle Digregorio, Christopher Randolph, Dorothee Shoemaker, Selam Negash, Erin Jacobs, Raymond Blattner

WCG - Princeton (United States), Loyola University Medical Center - Chicago (United States)

Analysis of Aβ1–42 Oligomers by Cyclic Ion Mobility SPECTROMETRY in spiked HUMAN cerebrospinal fluid

Mikuláš Vlk, John Hey, Walter Korfmacher, Alexander Muck, Martin Hubálek, Josef Cvačka

Institute of Organic Chemistry and Biochemistry of the CAS, Mass Spectrometry Group - Prague (Czech Republic), Alzheon - Framingham (United States), Waters Corporation, Analytical Professional Services EMEA - Wilmslow (United Kingdom)

Sex Differences in Predicting Progression in Cognitively Unimpaired ADNI Participants Using Cognitive Test Performance

Adam Diaz, Melanie J. Miller, Marta Mila Aloma, Zack Hausle, Pamela Zobel-Thropp, Duygu Tosun, Rachel Nosheny, Leslie M. Shaw, Michael W. Weiner

Northern California Institute for Research and Education (NCIRE) - San Francisco (United States), Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases - San Francisco (United States), University of California, San Francisco, Department of Radiology and Biomedical Imaging - San Francisco (United States), University of California, San Francisco, Department of Psychiatry and Behavioral Sciences - San Francisco (United States), University of Pennsylvania, Perelman School of Medicine - Pennsylvania (United States)
LP070  Association of Speech and Language features with Biomarkers in Early Stage Alzheimer patients
Alexandra König 1, 2, Stefanie Köhler 1, Johannes Tröger 1, Elisa Mallick 1, Nicklas Linz 1, Josef Piller 2, 3, 4, 5, Markus Donix 6, 7, Jens Wiltfang 10, 11, 12, Inga Zerr 10, 11, Duzel Düzel 14, 15, 16, Anника Spotte 17, 18, Frederic Brosseuron 19, Michael Wagner 19, 20, Alfredo Ramirez 19, 20, 21, 22, Stefan Teipel 5, 23
1ki:elements GmbH - Saarbrücken (Germany), 2Cobitek (Cognition-Behaviour-Technology), Université Côte d’Azur, e- Nice (France), 3Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Standort Rostock/Greifswald, - Rostock/greifswald (Germany), 4Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Berlin (Germany), 5Department of Psychiatry and Psychotherapy, Charité - Berlin (Germany), 6School of Medicine, Technical University of Munich, Department of Psychiatry and Psychotherapy, - Munich (Germany), 7University of Edinburgh and UK DRI, - Edinburgh (United Kingdom), 8Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) - Dresden (Germany), 9Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, - Dresden (Germany), 10German Center for Neurodegenerative Diseases (DZNE) - Goettingen (Germany), 11Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen y - Goettingen (Germany), 12Neurosciences and Signaling Group, Institute of Biomedicine (ibIMED), Department of Medical Sciences, University of Aveiro - aveiro (Portugal), 13Department of Neurology, University Medical Center, Georg August University, - Goettingen (Germany), 14German Center for Neurodegenerative Diseases (DZNE) - Magdeburg (Germany), 15Institute of Cognitive Neuroscience and Dementia Research, Otto-von-Guericke University - Magdeburg (Germany), 16Institute of Cognitive Neuroscience, University College London - London (United Kingdom), 17German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany), 18Department of Neurology, University of Bonn, - Bonn (Germany), 19German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany), 20Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, - Bonn (Germany), 21Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) University of Cologne - Cologne (Germany), 22Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry, University of Cologne, Medical Faculty, - Cologne (Germany), 23University Medical Center Rostock, - Rostock (Germany)

LP071  A Blueprint for Early Detection of Cognitive Impairment in Primary Care Settings
Tim Macleod 1, Jim Murray 1, Chantale Bielak 2, Katherine Selzier 1
1Davos Alzheimer’s Collaborative Health System Preparedness - Wayne (United States), 2Bridgeable - Toronto (Canada)

LP072  Implementing cognitive assessment and RetiSpec retinal screening in community-based settings: Enhancing early detection of Alzheimer’s disease
Sharon Cohen 1, 2, Alissa Kurzman 2, 3, 4, Jennifer Giordano 3, Rozana Naureen 2, Amelie Hansen 1, Michelle Martinez 1, Mailis Bierenheder 2, Nigar Sohbat 2, Naeem Abdulla 1, Colette Cameron 1, Shmuel Estreicher 1, Sangeeta Semwal 2, Catherine Bornbaum 2
1Toronto Memory Program - Toronto (Canada), 2RetiSpec, Inc. - Toronto (Canada), 3University of California, Irvine – Irvine (United States), 4Davos Alzheimers Collaborative - Philadelphia (United States), 5Victoria Village Optometry - Toronto (Canada), 6Summerhill Optometry - Toronto (Canada), 7Alzheimer Society of Toronto - Toronto (Canada)

LP073  Concurrent Detection of Cognitive Impairment and Aβ PET Status with a Short AI-enabled Digital Cognitive Assessment
David Bates 1, Ali Jannati 1, 2, Karl Thompson 1, Claudio Toro-Serey 1, Joyce Gomes-Osman 1, 3, Russell Banks 1, Jeff Pobst 1, Connor Higgins 1, John Showalter 1, Sean Tohyne 1, Alvaro Pascual-Leone 1
1Linus Health, Inc. - Boston (United States), 2Department of Neurology, Harvard Medical School - Boston (United States), 3Department of Neurology, University of Miami Miller School of Medicine - Miami (United States), 4Hindu and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolf Center for Memory Health, Hebrew SeniorLife - Boston (United States)

LP075  A pilot test to examine the utility of the Montreal Cognitive Assessment (MoCA) in predicting Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score for eligibility in Alzheimer’s Disease (AD) trials
Elizabeth Sosa 1, Jennifer Mitolo 1, Tara Pamrithivikul 1, Jade Serrano-Sanchez 1, Corinne Karmar 1
1Irving Clinical Research - Irving (United States)

LP076  Identifying the Severity of Dementia Based on Cognitive Performance and Index of Independence in Basic Activities of Daily Living
Duong Huynh 1, Bin Huang 1, Reza Hosseini Ghomi 1, 2
1BrainCheck Inc. - Austin (United States), 2Frontier Psychiatry - Billings (United States)

LP077  Comparing Pschometric Characteristics of a Computerized Cognitive Test (BrainCheck-Assess) against the Montreal Cognitive Assessment (MoCA)
Duong Huynh 1, Bin Huang 1, Reza Hosseini Ghomi 1, 2
1BrainCheck Inc. - Austin (United States), 2Frontier Psychiatry - Billings (United States)

LP078  Cognitive effects of a randomized, double-blind, placebo-controlled, 36-week clinical trial of citrus phytochemicals in subjective cognitive decline
Elena Gatti 1, Giovanni Sgro 2, 3, Natalia Salvador Bonfiglio 2, Andrea Geviti 1, Salvatore Genovese 1, Serena Fiorito 1, Lucia Palumbo 1, Giovanni B. Frisoni 1, Michela Plevani 1, Francesco Epifano 5, Samantha Galluzzi 1
1LaboratoryAlzheimer’s Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia (Italy), 2Molecular Markers Laboratory and Clinical Trial Service, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia (Italy), 3Service of Statistics, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, (Italy), 4Laboratory of Phytochemistry and Chemistry of Natural Products, Department of Pharmacy, University “G. d’Annunzio” of Chieti-Pescara, Chieti, Italy, 5University Hospitals and University of Geneva, Geneva (Switzerland)

LP080  Eco-Exposome and Mild Cognitive Impairment: Linking Environmental and Social Vulnerability Indices to the COG-IT Clinical Trial
Alisa Adhikari 1, Adaoa Nwosu 1, Caroline Hellegers 1, Julia Phillips 1, Jeffery Petrella 1, Davangere Devanand 4, Murali Doraiswamy 1
1Neurocognitive Disorders Program, Department of Psychiatry, Duke University School of Medicine - Durham (United States), 2Department of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute - New York City (United States), 3Department of Radiology, Duke University School of Medicine - Durham (United States), 4Department of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute - New York City (United States)
**POSTER PRESENTATIONS**

**LPI21**  
memTEST, a direct-to-consumer self-administered digital cognitive test SELF completed in under 10 minutes on mobile (Android or iPhone), PC, or tablet to increase clinical trial participation and decrease screen fails for verbal screening tests and fluid biomarkers in Alzheimer’s Disease clinical trials  
David Watson 1, Sean Stanton 2, Robert Guilfoyle 3, Thomas Mareck 3, Brandon Lenox 1  
1K2 Medical Research - Maitland (United States), 2K2 Medical Research - Winter Park (United States), 3Recall Technologies - Orlando (United States)

**LPI22**  
Validating Enhanced Behavioral Measures of Word Recall Based on Underlying Cognitive Processes  
Jason Bock 1, Junko Hara 1,2, Dennis Fortier 1, Tushar Mangrola 1, Michael Lee 2  
1Embe Corporation - Newport Beach (United States), 2Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)

**LPI23**  
ARC-DS: A Digital Cognitive Outcome Measure for Down Syndrome-Associated AD Prevention Trials  
Jason Hassenstab 1, Laura Del Hoyo Soriano 2, Olivia Wagemann 3, Asaad Baksh 4, Andrew Aschenbrenner 1, Beau Ances 1, Juan Fortea 2, Johannes Levin 3, Michael Schöll 1, Ezequiel Surace 4, Andre Strydom 4  
1Washington University in St. Louis - St. Louis (United States), 2Sant Pau Hospital - Barcelona (Spain), 3Ludwig-Maximilian-University - Munich (Germany), 4King’s College London - London (United Kingdom), 5University of Gothenburg - Gothenburg (Sweden), 6FLENI Institute - Buenos Aires (Argentina)

**THEME: Behavioral disorders and clinical trials**

**PI38**  
Effects of brexpiprazole on agitation associated with dementia due to Alzheimer’s disease: analysis of pooled efficacy data from two Phase 3 fixed-dose trials by baseline agitation frequency  
Jyoti Aggarwal 1, Daniel Lee 1, Nanco Hefing 2, Daei Chen 1, Denise Chang 1, Zhen Zhang 1, Maia Miguelez 2, Saloni Behl 1  
1Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), 2H. Lundbeck A/S - Valby, Copenhagen (Denmark)

**PI39**  
Effects of brexpiprazole on agitation associated with dementia due to Alzheimer’s disease: analysis of pooled response data from two Phase 3 fixed-dose trials  
Daniel Lee 1, Jyoti Aggarwal 2, Nanco Hefing 2, Daei Chen 1, Denise Chang 1, Saloni Behl 1  
1Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), 2H. Lundbeck A/S - Valby, Copenhagen (Denmark)

**PI40**  
Design of ADEPT-2, a phase 3, parallel group study to evaluate KarXT (xanomeline–trospium) as a treatment for psychosis associated with Alzheimer’s disease  
Minsu Kang 1, Carolyn Watson 1, Jeffrey Cummings 1, George Grossberg 2, Ronald Marcus 1, Paul Yeung 1  
1Karuna Therapeutics - Boston (United States), 2Chambers-Grundy Center for Transformative Neuroscience, University of Nevada, Las Vegas - Las Vegas (United States), 3Department of Psychiatry & Behavioral Neuroscience, Saint Louis University School of Medicine - Saint Louis (United States)

**PI42**  
A review of meaningful change in agitation behaviors associated with Alzheimer’s disease and the potential impact of brexpiprazole  
Jyoti Aggarwal 1, Brian Talon 2, Pedro Such 3, Malaak Brubaker 1, David Wang 1, Alireza Atri 4,5,6,7  
1Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton (United States), 2H. Lundbeck A/S - Deerfield (Denmark), 3H. Lundbeck A/S - Valby, Copenhagen (Denmark), 4Banner Sun Health Research Institute - Sun City (United States), 5Banner Alzheimer’s Institute - Phoenix (United States), 6Bingham and Women’s Hospital - Boston (United States), 7Harvard Medical School - Boston (United States)

**PI45**  
Longitudinal Effects of Caregiving Burden on Inflammatory Biomarkers in Spousal Caregivers of Individuals with Cognitive Impairments  
So Yeon Jeon 1  
1Department of psychiatry, Chungnam National University College of Medicine - Daejeon (Korea, Republic of)

**PI26**  
Feasibility and acceptability of using technology in caregivers and Alzheimer’s disease patients with agitation  
H Okhravi 1, A Gupta 1, S Jain 1, K Maly 1, C Nesbitt 1, I El Moudden 1, S Alyaan 2  
1Eastern Virginia Medical School - Norfolk (United States), 2Old Dominion University - Norfolk (United States), 3Stony Brook University - New York (United States)

**THEME: Health economics and clinical trials**

**PI41**  
Implications of Treatment Duration and Intensity on the Value of Alzheimer’s Treatments  
Soeren Mattke 1, Tabasa Ozawa 1, Mark Hanson 1  
1USC - Los Angeles (United States)

**PI42**  
Amyloid PET: The Case for Quantification in Clinical Routine  
Phillip Kuo 2, William Jagust 2, Gill Farrar 1  
1UC Berkeley - Berkeley (United States), 2UC Healthcare - Amersham (United Kingdom)

**PI43**  
Assessing health system capacity for delivery of a disease-modifying therapy for Alzheimer’s disease: a multi-country analysis  
Ilke Murik Danaci 1, Valerie Crowell 1, Nathalie Budd 2, Haakon B Nygaard 3  
1Y. Hoffmann-La Roche Ltd - Basel (Switzerland), 2Y. Hoffmann-La Roche Ltd - Mississauga (Canada), 3Division of Neurology and Djavad Mowafaghian Centre for Brain Health - Vancouver (Canada)
**Theme: Epidemiology and Clinical Trials**

**PI44**  
State Department of Motor Vehicles clinician reporting mandates of dementia diagnoses: Evidence for risks and benefits  
Hankyung Jun 1, Ying Liu 2, Emily Chen 2, Andrew Becker 2, Soeren Mattke 2  
1Harvard Medical School - Boston (United States), 2University of Southern California - Los Angeles (United States)

**PI45**  
Age-specific relative comorbidity burden of mild cognitive impairment: A US database study  
Gang Li 1, Niccola Toschi 2, Viswanath Devanarayan 2, Richard Batra 1, Tommaso Boccato 2, Min Cho 1, Matteo Ferrante 2, Feride Frech 1, James Galvin 1, David Henley 1, Soeren Mattke 2, Susan De Santi 1, Harald Hampel 1  
1Eisai Inc - Nutley (United States), 2University of Rome Tor Vergata - Rome (Italy), 3University of Miami - Miami (United States), 4Janssen Research & Development - New Brunswick (United States), 5University of Southern California - Los Angeles (United States)

**PI46**  
Comorbidities Occurring Before and After Diagnosis of Mild Cognitive Impairment or Alzheimer’s Disease: A Large US Nationwide Electronic Health Record Cohort Study  
Lisa Vinikoor-Imler 1, Olga Sanchez-Solino 1, Emma Xiaomeng Yue 1, Isabella Borojo 1  
1AbbVie Inc. - Chicago (United States)

**PI47**  
Biomarker and clinical correlations for amyloid targeting monoclonal antibody (mAb) treatment responses  
Jonathan Wagg 1, Nicolas Fournier 1, Garance Lucken 1, Clarisse Schumer 1, Olivier Sol 1, Julian Gray 1, Marija Vukicevic 1, Marie Kosco-Vilbois 1, Andrea Pfeifer 1, Johannes Streffer 1  
1AC Immune SA - Lausanne (Switzerland), 2EPFL - Lausanne (Switzerland)

**PI48**  
High prevalence of amyloid cerebral pathology in older adults with cognitive frailty – an indication for anti-amyloid therapies?  
Sandrine Sourdet 1, Gaëlle Soriano 1, Bruno Vellas 1  
1Gérontopôle - Toulouse (France)

**PI49**  
Acculturation-related characteristics associated with research attitudes among underrepresented populations recruited to an Alzheimer’s disease preclinical trial  
Christian Salazar 1, Hye-Won Shin 1, Melanie Tallakson 1, Edwin Duran 1, Russ Eunjii 1, Maria Corona 1, Romina Romero 1  
1UC Irvine Institute for Memory Impairments and Neurological Disorders - Irvine (United States)

**PI50**  
Sildenafil is a candidate drug for Alzheimer’s disease: Real-world patient data observation  
Cheng Feixiong 1, Zhang Pengyue 2, Jeffrey Cummings 3  
1Cleveland Clinic - Cleveland (United States), 2Indiana University - Bloomington (United States), 3University of Nevada Las Vegas - Las Vegas (United States)

**LP081**  
Bridging the Gap: Enhancing Representation in Alzheimer’s Clinical Trials Through Strategic Collaboration with Primary Care Clinics in Diverse Communities  
Brina Quaning 1, Santiago Santeli 2, Sandra Carmona Torres 2, Lucy Lenox 3, Bryce Warner 2, Sheila Baez-Torres 2  
1Metro Health Inc. - Orlando (United States), 2K2 Medical Research - Orlando (United States)

**LP082**  
Predictors of Response Rate to a Mailed Invitation to Participate in a Dementia Prevention Lifestyle Intervention Trial (U.S. POINTER): Houston Site Experience  
Valory Pavlik 1, Melissa Yu 1, Hannah Shields 1, Ashley Alexander 2, Rose Trevino-Whitaker 2, John Valenta 2, Richard ELPein 3, Ann Marie Mcdonald 2  
1Bayolor College Of Medicine - Houston (United States), 2Kelsey Research Foundation - Houston (United States), 3Alzheimer’s Association - Houston (United States)

**LP083**  
Alzheimer’s disease linkage to evidence (AD-LINE) study: An analysis of concordance between clinical diagnosis and evidence of AD diagnosis in real-world US claims data  
Howard Fillit 1, 2, Sheila Seleri Assunção 1, Chris Wallick 3, Ibrahim M. Abbass 3, Carmen Ng 3, Tu My To 3, Karina Raimundo 3, Thomas Majda 3, Desilu Glazebrook 4, Oleg V. Tcheremissine 4  
1Alzheimer’s Drug Discovery Foundation - New York City (United States), 2Departments of Geriatric Medicine, Medicine, and Neuroscience, Icahn School of Medicine at Mount Sinai - New York City (United States), 3Genentech, Inc., a member of the Roche Group - South San Francisco (United States), 4Department of Psychiatry, Atrium Health Behavioral Health Charlotte - Charlotte (United States)

**LP127**  
Characteristics of adults with incident cognitive impairment in a population-based study of cognitive aging  
Khaled Ghonimi 1, Jeremiah A. Aakre 2, Anna M. Castillo 2, Mohamed Elminawy 2, Emma A. Brauer 2, Prashanthi Vemuri 2, Clifford R. Jack Jr. 2, Jonathan Graff-Radford 1, David S. Knopman 2, Ronald C. Petersen 1, Maria Vassilaki 1  
1Department of Neurology, Mayo Clinic - Rochester (United States), 2Department of Quantitative Health Sciences, Mayo Clinic - Rochester (United States), 3Department of Radiology, Mayo Clinic - Rochester (United States)

**LP128**  
Study Partner Effect on Retention in Alzheimer’s Disease Trials  
Michelle Nuño 1, Daniel Gillen 2, Joshua Grill 2  
1University of Southern California - Los Angeles (United States), 2University of California, Irvine - Irvine (United States)
THEME: Animal model

P151  Deciphering the mechanisms of action of cognitive gain using the multidomain lifestyle intervention protocol – from human RCTs to mice
        Vilma Alanko 1,2, Francesca Erolı 3, Alina Solomon 4,5, Kristier Håkansson 1, Tiia Nganu 1, Tobias Hartmann 4,6, Per Nilsson 1, Mia Kvistelto 1,4,6, Silvia Målo 1,2, Anna Mattson 1,2
        1Division of Clinical Genitrics, Department of NVS, Karolinska Institutet - Solna (Sweden), 2Division of Neurogeriatrics, Department of NVS, Karolinska Institutet - Solna (Sweden), 3Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), 4Aging Epidemiology (AGE) Research Unit, Imperial College London - London (United Kingdom), 5Population Health Unit, Finnish Institute for Health and Welfare - Helsinki (Finland), 6Deutsches Institut für Demenz Pravention (DIDP), Saarland University - Homburg (Germany), 7Department of Experimental Neurology, Medical Faculty, Saarland University - Homburg (Germany), 8Theme Inflammation and Aging, Karolinska University Hospital - Solna (Sweden)

P152  Subcellular and secretory effects of the AppNL-F knock-in in mice neurons
        Sophia Scheding-Weiss 4, Yang Yu 4, Robin Z. Zhou 4, Lars O. Tjernberg 4
        4Karolinska Institutet - Solna (Sweden)

LP054  TREM2 Agonism Affects Human Microglia Response in the Presence of Amyloid Pathology In Vivo
        Peter Fläsjö 1, Ivana Geric 1,2,3, Manuela Polidoro 1, Leen Wolfs 1,2,3, Anke Midsbær 1,2,3, Arja Nair 1,2,3, Laura Sans 1, Maria DaLPy 1, Jin Zheng 1, Tina Sommer Bisgaard 1, Lars Christian Roenn 1, Rita Balice-Gordon 1, Bart De Strooper 2,3,4, Niels Plath 1
        1Muna Therapeutics - Copenhagen (Denmark), 2Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB) - Leuven (Belgium), 3Department of Neurosciences and Leuven Brain Institute, KU Leuven - Leuven (Belgium), 4UK Dementia Research Institute at UCL, University College London - London (United Kingdom)

LP055  KIF-13, an Innovative Plasmalogen Derivative, Improved Memory and Cognition through Suppression of Neuroinflammation in Murine Models
        Md Shamim Hossain 2, Shiro Mawatari 1, Masanori Honsho 2, Takehiko Fujino 3
        1Institute of Rheological Functions of Food - Fukuoka (Japan), 2Kyushu University - Fukuoka (Japan), 3Neurocores - Boston (United States)

LP056  Protective Effects of New Combination Drug FPT-03 in Oxidative Damages and Cognitive Impairments against Traumatic Brain Injury
        William Chao 1, Bert Chen 1, Chia-Yi Tseng 2
        1Future PharmTech - Taipei (Taiwan, Republic of China), 2Chung Yuan Christian University - Taoyuan (Taiwan, Republic of China)

LP067  Nonfibrillar Dutch mutant amyloid beta (Aβ) aggregates (oligomers) revealed by anti-prefibrillar oligomer antibody AT-1001 and FITC-peptide imaging are associated with aging-related synaptic dysfunction but cause no detectable inflammation
        Sam Gandy 1, Emilie Castranio 1, Merina Varghese 1, Elentina Argyrousi 2, Kuldeep Tripathi 3, Charles Glabe 4, Efray Levy 5, Menghui Wang 1, Bin Zhang 1, William Lubell 1, Brigitte Geerinck 1, Shai Rahimipour 1, Dara Dickstein 2, Ottavio Arancio 2, Michelle Ehrlich 1
        1Icahn School of Medicine - New York (United States), 2Columbia U - New York (United States), 3Bar Ilan U - Raman Gaz (Israel), 4U Calif Irvine - Irvine (United States), 5NYU & NKI - New York (United States), 6U Montreal - Montreal (Canada), 7U Sherbrooke - Sherbrooke (Canada), 8Bar Ilan U - Raman Gaz (Canada), 9Uniformed Health Sci U - Bethesda (United States)

LP088  Humanized model to study the role of Kv1.3 blockade on microglia in neuroinflammation
        Ivana Geric 1, Lucas Baltussen 1, Leen Wolfs 2, Anke Midsbær 1, Negin Afnang 2, Laura Sans 1, Maria DaLPy 1, Anja Koustrup 1, Dorota Kuczek 1, Jorge Valadas 1, Lars Christian Roenn 1, Marianne Tenstrup Pedersen 1, Rita Balice-Gordon 1, Bart De Strooper 2,3,4, Niels Plath 1
        1Muna Therapeutics - Copenhagen (Denmark), 2Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB) - Leuven (Belgium), 3UK Dementia Research Institute at UCL, University College London - London (United Kingdom), 4Department of Neurosciences and Leuven Brain Institute, KU Leuven - Leuven (Belgium)

LP089  Impact of ‘Masked’ 40 Hz Light Therapy on Cognitive Decline and Associated Neuropathology in a Mouse Model of Alzheimer’s Disease
        Madison Browne 1, Olive Curren 1, Stephanie Ancheta 1, Lucy Jiwu 1, Stephanie Wu 1, Lynn Yang 1, Yuan-Yuan Yao 3, Marcus Carstensen 1, 2, 3, 4, Mai Nguyen 2, Daniela Kauffer 1, Lance Kriegsfeld 2
        1University of California, Berkeley - Berkeley (United States), 2Optoceutics ApS - Copenhagen (Denmark), 3Technical University of Denmark - Lyngby (Denmark)

THEME: New therapies and clinical trials

P153  Impact of adherence on cognitive outcomes in a pilot study of the Cogstim model
        Raymond L. Ownby 1
        1Nova Southeastern University - Fort Lauderdale (United States)

P154  Pivotal trial of low-intensity pulsed ultrasound therapy for early stage of Alzheimer’s disease (LIPUS-AD) – Rationale and design-
        Hiroaki Shimokawa 1, Masanori Akihita 1, Masafumi Ihara 1, Satoshi Teramukai 1, Aiko Ishiki 1, Yoji Nagai 2, Hajimu Kato 2, Masanori Fukushima 8
        1International University of Health and Welfare - Nara (Japan), 2Sound Wave Innovation Inc. - Tokyo (Japan), 3University of Tokyo - Tokyo (Japan), 4National Cerebrovascular and Cardiovascular Center - Suita (Japan), 5National Cerebrovascular and Cardiovascular Center - Kyoto (Japan), 6Tohoku Medical and Pharmaceutical University - Sendai (Japan), 7Kyoto University - Kyoto (Japan), 8Learning Health Society Institute - Nagoya (Japan)

P155  Masupirdine (A Pure 5-HT6 Receptor Antagonist) for the Treatment of Agitation in Patients with Dementia of Alzheimer’s Type - Rationale and Phase-3 Study Design
        Ramakrishna Nirogi 1, Jyothsna Ravula 1, Satish Jetta 1, Vinod Kumar Goyal 1, Pradeep Jayarajan 1, Vijay Benade 1, Anil Shinde 1, Santosh Kumar Pandey 1, Ramkumar Subramanian 1, Abdul Rashid Mohammed 1, Venkat Jasti 1
        1Suvira Life Sciences Ltd - Hyderabad (India)
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate
Linda Van Eldik, Wendy Ziai, Lauren Sansing, Daniel Hanley
University of Kentucky - Lexington (United States), Johns Hopkins University - Baltimore (United States), Yale University - New Haven (United States)

Treatment of early symptomatic Alzheimer's disease with nasal Protollin to activate monocytes and clear amyloid beta
Panayota Kolyvpetri, Patrick Da Silva, Lei Liu, Christian D. Gauthier, Taylor J. Saraceno, Tarun Singhal, Seth A. Gale, Tanuja Chitnis, Dennis J. Selkoe, Howard L. Weiner
Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)

The purely thermodynamic anti-prionic mode of action for the treatment of neurodegenerative diseases
Dieter Will Pold
Forschungszentrum Jülich - Jülich (Germany)

Rationale for a trial in type 2 diabetes and/or coronary artery disease: Combined intervention with exercise and a soluble epoxide hydrolase inhibitor
Department of Pharmacology & Toxicology – University of Toronto - Toronto (Canada), Hurwitz Brain Sciences Research Program, Sunnybrook Research Institute - Toronto (Canada), KITE Research Institute, Toronto Rehabilitation Institute-University Health Network - Toronto (Canada), Rehabilitation Sciences Institute, Temerty Faculty of Medicine, University of Toronto - Toronto (Canada), Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto - Toronto (Canada), Department of Food Science and Technology, College of Agriculture and Environmental Sciences, University of California, Davis, West Coast Metabolomics Center, Genome Center, University of California - Davis; Center for Neuroscience, One Shields Avenue, University of California - Davis, Ca (United States), Tanar Center for Research in Neurodegenerative Diseases, University of Toronto - Toronto (Canada), Department of Education, ICT and Learning, Oslo University College - Oslo (Norway), School of Epidemiology and Public Health-University of Ottawa - Ottawa (Canada), Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto - Toronto (Canada)

Personalized hippocampal network-targeted stimulation for Alzheimer's disease: A randomized controlled trial
Young Hee Jung, Hyemin Jang, Sungbeen Park, Hee Jin Kim, Sang Won Seo, Guk Bae Kim, Duk Kyun Na
Myongji Hospital, College of Medicine, Hanyang University - Goyang (Korea, Republic of), Samsung Medical Center - Seoul (Korea, Republic of), Hanyang University - Seoul (Korea, Republic of), Anymed - Seoul (Korea, Republic of), sungbkyunkwan University - Seoul (Korea, Republic of)

Efficacy and Safety Of AXS-05 in Agitation Associated With Alzheimer’s Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial
Jeffrey Cummings, George Grossberg, Candace Andresson, Graham Egli, Caroline Streicher, Herriot Tabuteau
University of Nevada, Las Vegas - Las Vegas, NV (United States), Saint Louis University School of Medicine - St. Louis, Mo (United States), Axsome Therapeutics - New York, Ny (United States)

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Escalating Single and Multiple Doses of DEX-001 in Healthy Volunteers Followed by a Stress Exposure Resilience Panel (SERP)
Monash University - Melbourne (Australia), Vige - Palo Alto (United States)

NutreRestore ACD856, a Trk-PAM in clinical development for Alzheimer’s disease shows neuroprotective and neurorestorative effects
Pontus Forsell, Veronica Ledell, Azita Rasti, Gunnar Nordvall, Johan Sandin, Martin Jonsson
AlzCure Pharma AB, Hälsovägen 7, Sweden - Huddinge (Sweden), Division of Neuroscience, Care and Society, Karolinska Institutet, Sweden - Solna (Sweden)

Phase 1 SAD/MAD data and Phase 2 study design for LHP588, a second-generation gingipain inhibitor for the treatment of P. gingivalis-positive Alzheimer’s dementia
Michael Detke, Marwan Sabbagh, Joanna Bolger, Jianhong Wang, Mark Ryder, Suzanne Hendrix, Sam Dickson, Craig Mallinckrodt, Leslie Holsinger, Casey Lynch, Stephen Dominy
Lighthouse Pharmaceuticals - San Francisco (United States), Barrow Neurological Institute - Phoenix (United States), University of California, San Francisco, CA - San Francisco (United States), Pentara Corp - Millcreek (United States)

Alzheimer’s Disease Research Recruitment in a World with Disease Modifying Treatments on Market
Ira Goodman, Daniel Gauthier, Erin Beck, Michael Stalder
SiteRx - New York (United States)

Treatment of Alzheimer’s Disease Subjects With Expanded Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity — Final Report of a Phase I Dose Escalation Study
Clemente Humberto Zuniga Gil, Bianca Isaura Acosta Gallo, Ruffman Menchaca Diaz, Cesar Alejandro Amescua, Sean Hong, Lucia Hui, Hank Lee, Juan Mata, Paul Y. Song
Hospital Angeles - Tijuana (Mexico), NKGen Biotech - Santa Ana (United States)

Anti-Abeta liposomal vaccine, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies
Emma Fiorini, Chiara Babolin, Rakel Carpentero, Stefania Rigotti, Stefanie Siegert, Catherine Monici, Maelle Verando, Jonathan Wagg, Pierrigio Donati, Saskia Delpretti, Johannes Steffen, Andrea Pfeifer, Marie Kosco-Vilbois, Marija Vukicevic
AC Immune SA - Lausanne (Switzerland), University of Antwerp - Antwerp (Belgium)
**P159**  D-peptide-magnetic nanoparticles disaggregate tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer’s disease  
Ke Hou 1, Hope Pan 1, David Eisenberg 1  
1UCLA - Los Angeles (United States)

**P160**  Structural dynamics of amyloid-β protofibrils and action of lecanemab as observed by high-speed atomic force microscopy  
Kenjiro Ono 1, Takahiro Nakayama 2, Mayumi Tsuji 3, Kenichi Umeda 2, Tatsunori Oguchi 1, Hiroki Konno 2, Moeko Shinohara 1, Yuji Kiuchi 1, Noriyuki Kodera 1, David B. Teplow 4  
1Kanazawa University Graduate School of Medical Sciences - Kanazawa (Japan), 2Nano Life Science Institute, Kanazawa University - Kanazawa (Japan), 3Showa University School of Medicine - Tokyo (Japan), 4David Geffen School of Medicine at UCLA - Los Angeles (United States)

**P161**  APOE-Targeted Epigenome Therapy for Alzheimer’s Disease: Pre-Clinical Studies  
Ormit Chiba-Falek 1,3, Boris Kantor 1,2  
1Duke University - Durham (United States), 2CLARIgene, LLC - Durham (United States)

**P162**  A Possible Pathogenic PSEN2 Glu56Ser Mutation in a Korean Patient with Early-Onset Alzheimer’s Disease  
Da-Eun Jeong 1, Min Ju Kang 1  
1Department of Neurology, Veterans Health Service Medical Center - Seoul (Korea, Republic of)

**P163**  Effect of spectral binning in x-ray scattering method for non-invasively characterizing amyloids  
Eshan Dahal 1,2, Sabri Amer 1, Karthika Suresh 1, Olivia Sandvold 3, Peter Noël 2, Aldo Badano 1  
1U.S. Food and Drug Administration - Silver Spring (United States), 2University of Pennsylvania - Philadelphia (United States)

**P164**  Novel brain shuttle platform for precision delivery of Alzheimer’s disease therapeutics  
Liqun Wang 1, João Santos 2, Amy England 1, Yife Lu 1, Amanda Graveline 1, Melinda Sanchez 2, Teresa Barata 2, Daniela Teixeira 2, Donald Ingber 1, James Gorman 1  
1Wyss Institute at Harvard University - Boston (United States), 2FaiIourney Biologics - Porto (Portugal)

**P165**  Equilibrative nucleoside transporter 1 (ENT1) as a promising therapeutic target to rescue pathological features and alleviate cognitive impairment in Alzheimer’s disease  
Chien-Yu Lin 1,2, Ching-Pang Chang 1,2, Kuo-Chen Wu 2,3, Ching-Wen Wu 1,2, Chun-Jung Lin 2,3, Yijuang Chen 1,2  
1Institute of Biomedical Sciences, Academia Sinica - Taipei (Taiwan, Republic of China), 2Biomedical Translation Research Center, Academia Sinica - Taipei (Taiwan, Republic of China), 3School of Pharmacy, National Taiwan University - Taipei (Taiwan, Republic of China)

**P166**  Study of novel copper and zinc binding analogue of GMP-1 in Tg4510 tauopathy mouse model  
Bengt Winblad 1, Zhe Zhao 1, Pavel Pavlov 1  
1Karolinska Institutet - Solna (Sweden)

**P167**  Novel small molecule poly-disaggregator therapeutics for AD, ALS and FTD reduce TDP-43 oligomerization, aggregation, and pathology  
Marcela Kokes 1, Vidhu Mathur 1, Eric Shao 1, Shruti Arya 1, Catherine Planey 1  
1Acelot - Palo Alto (United States)

**P168**  Differences in Glutaminyl Cyclase protein levels in Mild Cognitive Impairment subjects  
Xavier Morato 1, Amanda Cano 1, Sergio Valero 1, Raul Nuñez 1, Raquel Puerta 1, Jose Antonio Alluè 1, Leticia Sarasa 1, Agustin Ruiz 1, Mercè Boada 1  
1FUNDACIO ACE - Barcelona (Spain)

**P169**  White matter hyperintensity accumulation is related to cerebral amyloid angiopathy and neurodegeneration in autosomal dominant and sporadic AD  
Zabra Shirzadi 1, Stephanie Schultz 1, Wai-Ying Yau 1, Nelly Friedrichsen 2, Kejal Kantarci 3, Gregory Preboske 3, Clifford Jack Jr 1, Brian Gordon 2, Eric McLaude 2, Tammie Benzinger 2, Randall Bateman 2, Steven Greenberg 1, Reisa Sperling 1, Aaron Schultz 1, Jasmee Chhatwal 1  
1Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School - Boston (United States), 2Washington University in St. Louis School of Medicine - St. Louis (United States), 3Mayo Clinic, Radiology - Rochester (United States)

**P170**  Systematic in silico analysis of clinically tested drugs for reducing amyloid beta plaque accumulation in Alzheimer’s disease  
Sarah Head 1, Raibatak Das 1, Brian Campbell 2, Dan Zwefel 1, John Burke 1, Joshua Appgar 1, Fei Hua 1  
1Applied BioMath - Concord, Massachusetts (United States), 2Prothena Biosciences Inc. - South San Francisco, California (United States)

**P171**  In Silico Simulation of Dementia-Alzheimer-Syndrome: Application of hybrid computing approach to the study of emergent behavior  
Ara Khachaturian 1, Zaven Khachaturian 1, Jeanmarie Bouteiller 2, Eva Troppova 2, Vaclav Snášel 1, Vit Vondrák 1, Jiri Damborský 1, Stanislav Mazurenko 1, Josef Šivic 1, Vit Dočkal 3  
1Campaign to Prevent Alzheimer’s Disease - Rockville (United States), 2University of Southern California - Los Angeles (United States), 3Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University - Prague (Czech Republic), 4Technical University of Ostrava - Ostrava (Czech Republic), 5International Clinical Research Center of St. Anne’s University Hospital - Brno (Czech Republic)

**P172**  Neuroprotective and mnesic-improving effects of Fluoroethylnormemantine (FENM) in the A025-35 mouse model of Alzheimer’s disease  
Allison Carles 1, Aline Freyssin 2, Florent Perin-Dureau 2, Gilles Rubinstein 2, Tangui Maurice 1  
1MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France, 2ReST Therapeutics - Paris (France)
Nanolithium has a dual potential in Alzheimer's disease: to treat Neuropsychiatric Symptoms and modify disease course

Microglia-Specific APOE-Targeted Epigenome Therapy for Alzheimer's Disease

Unraveling the therapeutic potential of novel hyaluronic acid estradiol conjugate ND108E in Alzheimer's Disease: Mechanistic insights and future directions

Designed peptide targeting α-sheet Amyloid-β oligomers decreases toxic oligomer burden and improves behavior in AD mouse models

New Approach to Alzheimer's Disease - Novel Chimeric GAS6 Fusion Protein

Combined E2 and Christchurch Gain-of-Function Variants of the Human APOE Gene Delivered by AAVrh.10 Effectively Suppresses Both Amyloid and Tau Pathology in the CNS of Murine Models of APOE4 Homozygous Alzheimer's Disease

Structural and biochemical similarities of protofibrils and plaque fibrils: implications for anti-amyloid immunotherapy

Fosgonimeton, a small-molecule positive modulator of the HGF/MET system, attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease

Human specific α7nAChR-dependent adaptation to mechanical properties of the extracellular environment

Human restricted CHRFAM7A gene may enhance brain efficiency
**POSTER PRESENTATIONS**

**P106**  
Centiloid scale expression using Neurophet SCALE PET with diverse tracer comparison  
Choe Yeong Sim 1, Lee Min-Woo 1, Kim Ha Jin 1, Lee Jyeon 1, Moon Youngjoon 2, Lee Minho 1, Kim Donghyeon 1, Kim Regina Ey 1  
1Research Institute, Neurophet Inc. - Seoul (Korea, Republic of)

**P107**  
Simufilam’s primary mechanism of action confirmed by time-resolved FRET  
Erika Cecon 1, Julie Dam 1, Lindsay Burns 1, Ralf Jockers 1  
1Université Paris Cité, Institut Cochin, INSERM, CNRS - Paris (France), 2Cassava Sciences, Inc. - Austin, Tx (United States)

**P108**  
Prediction of global standardized uptake value ratio and amyloid status with both T1-weighted and T2-FLAIR image using deep learning  
Min-Woo Lee 1, Hyeon Sik Yang 1, Hye Woon Kim 1, Yeong Sim Choe 1, Ji Min Kang 1, Soo Hyun Jeon 1, Young Moon Moon 1, Dong Hyeon Kim 1, Min Ho Lee 1, Dong Woo Kang 1, So Yeon Jeon 1, Sang Joon Son 1, Young Min Lee 1, Regina Kim 1, Hyun Kook Lim 1  
1Research Institute, Neurophet Inc. - Seoul (Korea, Republic of), 2Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), 3Departments of Psychiatry, Chungnam National University Hospital - Daejeon (Korea, Republic of), 4Department of Psychiatry, Ajou University School of Medicine - Suwon (Korea, Republic of), 5Department of Psychiatry, Medical Research Institute, Pusan National University Hospital - Busan (Korea, Republic of), 6Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)

**THEME: Digital health/E-trials**

**P109**  
Development of a mild cognitive impairment risk prediction model using electronic health record data  
Gang Li 1, Viswanath Devanarayan 1, Rachel Halpern 2, Richard Battrla 1, Susan De Santi 1, Feride Frech 1, Jo Vanderappellen 1, Ara S. Khachaturian 1, Richard Crisilo 4, Soeren Mattke 5, Harald Hampel 1  
1Essai - Nutley (United States), 2Optum - Eden Prairie (United States), 3Prevent Alzheimer's Disease 2020, Inc. - Rockville (United States), 4OptumCare - Phoenix (United States), 5University of Southern California - Los Angeles (United States)

**P110**  
Validating a novel digital cognitive platform: sensitivity to change following an alcohol challenge  
John Dyer 1, Florentine Barbey 2, Md Nurul Islam 3, Judith Jaeger 4, 5, Brian Murphy 2, Niarm Kennedy 5  
1Camillus Neuroscience - Belfast (United Kingdom), 2Camillus Neuroscience - Dublin (Ireland), 3CognitionMetrics - Stamford, CT (United States), 4Albert Einstein College of Medicine - Bronx, NY (United States), 5University of Ulster - Coleraine (United Kingdom)

**P111**  
The effects of home-based, semi-computerized cognitive training on cognitive function in community dwelling older adults  
Geon Ha Kim 1, Bori R. Kim 2, Haenum Kim 1, Jee Hyang Jeong 4  
1Department of Neurology, Ewha Womans University, College of Medicine - Seoul (Korea, Republic of), 2Ewha Medical Research Institute, Ewha Womans University - Seoul (Korea, Republic of), 3Department of Artificial Intelligence Convergence, Ewha Womans University - Seoul (Korea, Republic of), 4Ewha Womans University - Seoul (Korea, Republic of)

**P112**  
Comparing the Effects of Combined Cognitivve and Functional Skills Training to Skills Training Alone: Burst Training Increases Training Gains without Increasing Drop-outs  
Philip Harvey 1, Peter Kallestrup 2, Sara Czaja 3  
1University of Miami Miller School of Medicine - Miami (United States), 2Function - Miami (United States), 3Weill Cornell Medical Center - New York (United States)

**P113**  
A real-world, longitudinal observational study in patients with Alzheimer’s Disease dementia and healthy controls, using frequent repeated digital measurements performed at-home on the Cumulus Platform: a preliminary report  
Alison Buick 1, Azar Alexander-Sefre 1, Shannon Diggins 1, John Dyer 1, Brian Murphy 2, Hugh Nolan 3, Laura Rueda-Delgado 2, James Rowe 3, Kinan Muhammed 4  
1Camillus Neuroscience Ltd - Belfast (United Kingdom), 2Camillus Neuroscience Ltd - Dublin (Ireland), 3Department of Clinical Neurosciences, University of Cambridge - Cambridge (United Kingdom), 4Novelfield Department of Clinical Neurosciences, University of Oxford - Oxford (United Kingdom)

**P114**  
Enhancing Automated Transcription for Speech-Based Screening in Alzheimer’s Disease  
Udeepa Meepagama 1, Caroline Skirrow 1, Michael Ropacki 2, Emil Fristed 3, Jack Weston 1  
1Novoc - London (United Kingdom), 2Strategic Global Research & Development - Temecula (United States)

**P115**  
Farida Far Poor 1, Muath Alsuhaihani 1, Mohammad H Mahoor 1, Liu Chen 2, Hiroko H Dodge 2  
1Department of Electrical and Computer Engineering, University of Denver - Denver (United States), 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)

**P116**  
Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralised trials in Alzheimer’s Disease  
Florentine Marie Barbey 1, Christopher J Barnum 2, Alison R Buick 1, John Frederick Dyer 3, Md Nurul Islam 3, Jack Fogarty 3, Hugh Nolan 3, Brian Murphy 1  
1Camillus Neuroscience Ltd - Dublin (Ireland), 2i-Function - Miami (United States), 3Weill Cornell Medical Center - New York (United States)

**P117**  
Accelerating Sustainable Adoption and Justification of Digital Clinical Detection Applications for Cognitive Impairment and Dementia into Established Healthcare Systems  
Ara Khachaturian 1, Brittany Cassin 2, Glen Finney 3, Phyllis Barkman Ferrell 4, Eric Klein 4, Malaz Boustani 2, Zaven Khachaturian 1  
1Campaign to Prevent Alzheimer's disease - Rockville (United States), 2DigiCARE Realized Inc. - Old Bridge (United States), 3Geisinger Health - Danville (United States), 4Eli Lilly and Company - Indianapolis (United States), 5Indiana University - Indianapolis (United States)
P109 Correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers
Emmanuel Steely 1, Adria Tort Merino 2, Alberto Ferrari 3, Gonzalo Sanchez-Benavides 4,5,6,7, Carolina Minguillon 4,5, Silvia Fallone Fallone 8, Robbert Harms 9, Ioannis Tarhanas 10,11, Mircea Balasa 2, M. Florencia Iuliita 11
1Altoida Inc. - Washington (United States), 2Hospital Clinic, IDIBAPS - Barcelona (Spain), 3Altoida Inc. - Rome (Italy), 4BarcelonaData Brain Research Center (BBRC) - Barcelona (Spain), 5Pasqual Maragall Foundation - Barcelona (Spain), 6Hospital del Mar Medical Research Institute - Barcelona (Spain), 7ICBERFES, Instituto de Salud Carlos III - Madrid (Spain), 8Altoida Inc. - Maastricht (Netherlands), 9Altoida Inc. - Nijmegen (Netherlands), 10Altoida Inc. - Thessaloniki (Greece), 11Altoida Inc. - Barcelona (Spain)

P109 Development and an Evidence Catalog of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer’s Disease and Related Dementias
Clinical Trials
Sarah Averill Lott 1, Emmanuel Steely 2, Piper Fromy 3, Jennifer Goldsack 4, On Behalf of The Dirme Core Digital Measures Of ADRD Project Team 4
1The Digital Medicine Society - Johnstown (United States), 2Altoida Inc. - Washington, DC (United States), 3The Digital Medicine Society - Saumur (France), 4The Digital Medicine Society - Boston (United States)

James Galvin 1
1University of Miami Comprehensive Center for Brain Health - Boca Raton (United States)

P109 The Brain Health Champion Study: A Health Coaching Intervention with Mobile Technology in Older Adults with Mild Cognitive Impairment or Risk Factors for Dementia- An Update
Kayla Riera 1, Ashley Park 1, Brittany Mcfeeley 1, Densina Babazadeh 1, Abby Altman 1, Kirk Daffner 1, Seth Gale 1
1Brigham and Women’s Hospital - Boston (United States)

P109 Development and clinical validation of icobrain aria – an AI-based assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities
Diana M. Sima 1, Thanh Van Phan 1, Simon Van Eyndhoven 1, Sophie Vercriynssen 1, Ricardo Magalhães 1, Celine Maes 1, Joshua Guo 1, Richard Hughes 1, Refaat Gabr 1, Paramita Saha-Chaudhuri 1, Giacchino G Curiale 1, Shiobeshil Belachew 1, Wim Van Hecke 1, Annemie Ribbens 1, Dirk Smeeets 2
1icometrix–Leuven (Belgium), 2Biogen Digital Health – Cambridge, Massachusetts (United States), 3Biogen - Cambridge, Massachusetts (United States)

P109 The Mobile TooLBox (MTB) as a novel outcome measure for assessing cognition remotely in Alzheimer’s disease clinical trials: Validation with in-clinic cognitive assessments and AD biomarkers
Jessa Burling 1, Roos Jutten 1, Michael Properzi 1, Rebecca Amariglio 2, Gad Marshall 2, Kathryn Papp 2, Keith Johnson 2, Reisa Sperling 2, Dorene Rentz 2
1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States), 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School & Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States), 3Department of Neurology/Radiology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)

P110 Improving cognitive testing and care processes for older adults at risk of cognitive decline in a large health care system
Darren Gitelman 1, 2, 3, 4, 5, 6, Jennifer Mishos 1, 2, Cristybelye-Marie Candia 1, Patti Padel 1, 2, Lisa Dimitris 1, Michael Malone 1, 4, 5
1Advocate Health, Neuroscience Service Line - Midwest Region - Downers Grove, IL (United States), 2Rosalind Franklin University of Medicine and Science, Department of Medicine - North Chicago, IL (United States), 3Northwestern University / Feinberg School of Medicine, Department of Neurology - Chicago, IL (United States), 4Aurora Health Care, Department of Senior Services - Milwaukee, WI (United States), 5University of Wisconsin School of Medicine & Public Health - Madison, WI (United States)

P110 Feasibility and acceptability of a remote and fully-automated phone screening for cognitive impairment in the Auτonomy Phase II study
Simona Schafer 1, Stephen Ruhme 1, Johannes Tröger 1, Felix Dürr 1, Jannic Warken 1, Nicklas Linz 1, Janna Herrmann 1, Kai Langel 1, Alexandra König 1
1ki elements GmbH - Saarbrücken (Germany), 2Janssen Research & Development, LLC - Raritan (United States)

P110 Older people with mild cognitive impairment exhibit lower semantic impairment after six months of frequent social conversations
Liu Chen 1, Meyesam Asgari 1, Hiroko Dodge 2
1Department of Pediatrics, Oregon Health & Science University - Portland (United States), 2Massachusetts General Hospital, Harvard Medical School - Boston (United States)

P112 Development and Preliminary Validation of a Virtual Reality Memory Test for Assessing Visuospatial Memory
Ko Woon Kim 1, Jong Doo Choi 2, Juhee Chin 3, Byung Hwa Lee 1, Choi Jee Hyun 4
1Jeonbuk National University Medical School and Hospital - Jeonju (Korea, Republic of), 2Seers Technology Company Ltd - Seongnam (Korea, Republic of), 3Samsung Medical Center - Seoul (Korea, Republic of), 4Korea Institute of Science and Technology - Seoul (Korea, Republic of)

P113 Assessing the Impact of Donepezil on Visuospatial Abilities in Individuals with Mild Cognitive Impairment: A Preliminary Study Utilizing Eye-Tracking Metrics
Ko Woon Kim 1, Qi Wang 1, Byoung Soo Shin 1
1Kim - Jeonju (Korea, Republic of)
POSTER PRESENTATIONS

LP16  The Effect of Robot-Based Digital Cognitive Training on Cognitive Performance of Dementia Patients
Jae Won Oh 1, Ji Hyun Lee 3, Myeong Hun Hong 4, Won Sub Kang 1, Jong Woo Kim 5, 1
1Department of Neurology, Brigham and Women’s Hospital - Boston, Massachusetts (United States), 2Whydots Inc. - Bucheon (Korea, Republic of), 3Department of Psychiatry, Kyung Hee University Hospital - Seoul (Korea, Republic of), 4Seodaemun-gu Center for Dementia - Seoul (Korea, Republic of), 5Department of Psychiatry, Kyung Hee University College of Medicine - Seoul (Korea, Republic of)

LP17  The digital literacy predicts the quality of life in normal old age group but not in dementia group
Lee So-Yeong 1, Lim Jung-In 2, Lee Jun-Young 1, 2
1SMG-SNU Boramae Medical Center - Seoul (Korea, Republic of), 2Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of)

LP131  Observer-reported outcome of functional decline using continuous experience sampling: Findings from the RADAR-AD Study
Sietske Sikkes 1, 2, Merel Postema 1, Mukrabe Tewolde 1, Merike Verrijp 1, Casper De Boer 1, Sanivasan Vairavan 1, Dag Aarsland 1, Anna-Katharina Brem 1, Gayle Wittenberg 1, Pieter Jelle Visser 1, Wiesje Van Der Flier 1
1Amsterdam UMC - Amsterdam (Netherlands), 2VU University - Amsterdam (Netherlands), 3Brain Research Center - Amsterdam (Netherlands), 4Janssen Neuroscience R&D - Titusville, Nj (United States), 5Kings College London - London (United Kingdom), 6Brigham and Womens Hospital - Boston, Ma (United States), 7Harvard Medical School - Boston, Ma (United States)

LP133  A One-Stop-Shop for Telehealth Guided APOE Testing, Blood Based Biomarkers, and Multi-Domain Lifestyle Intervention: Early Learnings From a Proof-of-Concept
Anitha Rao 1, Leyla Anderson 1, Travis Wilkes 1, Steven Verdooner 1
1Neurovision Inc - Sacramento (United States)

THEME: Beyond Amyloid and Tau

P193  Angiogenic Mechanisms in Alzheimer’s Disease: A Systematic Review of Neuropathological Evidence
Arunima Kapoor 2, Daniel Nation 1
1University of California, Irvine - Irvine (United States), 2Wake Forest University School of Medicine, Gerontology and Geriatric Medicine - Winston-Salem (United States)

P194  Do Mouse Data Lie? For Buntanetap They Totally Predict Human Outcomes All the Way to Clinical Efficacy
Maria Macccechini 1, Cheng Fang 2
1Annovis Bio - Berwyn (United States)

P195  Fluid Biomarker Results from an Open-Label Pilot Study of Senolytic Therapy for Alzheimer's Disease, StoMP-AD
Miranda E. Orr 1, Valentina R Garbarino 4, 3, Juan Pablo Palavici 4, Tiffany F. Kautz 4, 5, Shiva K Dehkordi 6, 5, Habil Zare 6, 5, Peng Xu 7, 8, Justin Melendez 9, 10, Nicolas Barthelemy 9, 10, Randall J Bateman 9, 10, Mitzi M Gonzales 11, 5
1Wake Forest University School of Medicine, Gerontology and Geriatric Medicine - Winston-Salem (United States), 2Wake Forest Alzheimer’s Disease Research Center - Winston-Salem (United States), 3Salisbury VA Medical Center - Salisbury (United States), 4University of Texas Health Science Center at San Antonio, Department of Medicine, - San Antonio (United States), 5Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases - San Antonio (United States), 6University of Texas Health Science Center at San Antonio Department of Cell Systems and Anatomy - San Antonio (United States), 7Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences - New York (United States), 8Mount Sinai Center for Transformative Disease Modeling - New York (United States), 9Washington University School of Medicine, Department of Neurology - St Louis (United States), 10The Tracy Family SiLO Center - St Louis (United States), 11University of Texas Health Science Center at San Antonio, Department of Neurology - San Antonio (United States)

P196  Plasma and cerebrospinal fluid proteome association during Alzheimer’s disease (AD) progression suggests possible new targets for treating AD patients
Ying Wang 1, Ricardo Gonzalo 2, Carla Minhuet 1, Ana Maria Ortiz 3, Scott Lohr 1, Mercè Boada 1, Oscar Lopez 3, Antonio Paez 4, Jorge Loscos 5, Jesus Canudas 1, Maria Pascual 5, Jose Terencio 1, Montserrat Costa 2, Chunmiao (mia) Feng 1, Benoit Lehallier 1
1Alkahest, a Grifols company - San Carlos (United States), 2Grifols - Barcelona (Spain), 3Universitat Internacional de Catalunya - Barcelona (Spain), 4University of Pittsburgh - Pittsburgh (United States), 5Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences - New York (United States)

P197  Whole transcriptomic cell free messenger RNA characterization of Alzheimer’s disease in cerebrospinal fluid compared to plasma from human subjects
Rhys De Sota 1, Robert Rissman 2, James Brewer 2, Samantha Khoury 1, Shusuke Toden 1, John Sninsky 2
1Molecular Stethoscope - South San Francisco (United States), 2University of California, San Diego - San Diego (United States)
P198 CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
Charlotte Teunissen 1, Emma L. Van Der Ende 2, Sjors In ‘t Veld 1, Iris Hanskamp 1, Sven Van Der Lee 3, 4, Janna Dijkstra 5, John C. Van Swieten 5, David J. Irwin 1, Alice Chen-Plotkin 7, William T. Hu 1, Alina Lemstra 3, Yolande A.L. Pijnenburg 4, Wiesie M. Van Der Flier 4, 6, Marta Del Campo 4 6, Lisa Vermunt 4, 9
1Amsterdam UMC - Amsterdam (Netherlands), 2Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 3Erasmus University Medical Center - Rotterdam (Netherlands), 4Alzheimer Center and Department of Neurology, Erasmus University Medical Center - Rotterdam (Netherlands), 5Department of Neurology, Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), 6Department of Neurology, Emory University School of Medicine - Atlanta (United States), 7Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 8Department of Epidemiology and Data Science, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 9Barcelona Brain Research Center (BBRC) - Barcelona (Spain)

P199 Lipid Dicarbonyl Scavengers for the Prevention of Alzheimer’s Disease
John A. Rathmacher 1, Naji N. Abumrad 2, Paul A. Newhouse 2
1MTI BioTech Inc - Ames (United States), 2Vanderbilt University Medical Center - Nashville (United States)

P200 Translation Studies and Clinical Development of THN391, a Novel Anti-Fibrin Antibody for the Treatment of Dementia
Jeffrey Stavenhagen 1, Mathias Rickert 1, Kenneth Flanagan 1, Hank Cheng 1, Anjana Suppaphia 2, Vasudha Salgotra 1, Jae Kyu Ryu 2, Katerina Akassoglou 2
1Therin Bio - San Francisco (United States), 2Glладstone Institute - San Francisco (United States)

P201 The temporal relationship between neuropsychiatric symptoms, physical activity, and sleep: A three cohort study
Adrian Noriega De La Colina 1, Meishan Ai 2, Nikolaos Scarmeas 3, Arthur F. Kramer 4, Maiya R. Geddes 1
1Department of Neurology and Neurosurgery, The Montreal Neurological Institute-Hospital, McGill University - Montreal (Canada), 2Center for Cognitive and Brain Health, Department of Psychology, Northeastern University - Boston (United States), 31st Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens - Athens (Greece)

P202 Cerebrospinal Fluid Proteomic Analysis Reveals Reversal Effects on Glucose Dysmetabolism in Alzheimer’s Disease after Treatment with Atomoxetine
Eric Dammer 1, Lingyin Peng 1, Duc Duong 1, Erica Modeste 1, Nicholas Seyfried 1, James Lah 1, Allan Levey 1, Erik Johnson 1
1Emory University - Atlanta (United States)

P203 Blood-Based small RNA Biomarkers and the ATN(1) Framework: Predicting Neurodegeneration and Vascular Profiles in the EPAD Cohort
Bruno Steinkraus 1, Marco Heuvelman 1, Luigi Lorenzini 2, Julia Jehn 1, Tobias Sikosek 1, Rastišlav Horos 1, Kaja Tikk 1, Jeffrey Cummings 1, Jean Manson 2, Craig Ritchie 1
1Hummingbird Diagnostics GmbH - Heidelberg (Germany), 2Department of Clinical Research, Northwell Health - New Hyde Park, New York (United States)

P204 Evaluation of GLP-1 analogue, Liraglutide in the treatment of Alzheimer’s disease
Paul Edison 1
1Imperial College London - London (United Kingdom)

LP118 An open-label, pilot study of daratumumab SC in patients with mild to moderate Alzheimer’s disease (DARZAD)
Marc Gordon 1, Erica Christen 1, Lynda Koechlin 1, Michelle Gong 1, Fung Lam 2, Luca Gilberto 1, 4, Jesus Gomar 1, Jeremy Koppel 1, 3, 5
1Lewy-Zucker Research Center, Feinstein Institutes for Medical Research, Northwell Health - Manhasset, New York (United States), 2Departments of Neurology and Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell - Hempstead, New York (United States), 3Feinstein Institutes for Medical Research, Northwell Health - Manhasset, New York (United States), 4Institute for Neurology and Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell - Great Neck, New York (United States), 5Department of Psychiatry, Zucker Hillside Hospital, Northwell Health - Glen Oaks, New York (United States)

LP119 Association of Serum Leptin with in vivo brain Alzheimer’s disease pathologies in cognitively normal older adults
Seunghoon Lee 1, Min Soo Byun 2, 3, Dahun Yi 1, Dongyoung Lee 2, 3, 4
1Department of Psychiatry, Myongji hospital, Hanyang University College of Medicine - Goyang (Korea, Republic of), 2Department of Neuropsychiatry, Seoul National University Hospital - Seoul (Korea, Republic of), 3Department of Psychiatry, Seoul National University College of Medicine, - Seoul (Korea, Republic of), 4Institute of Human Behavioral Medicine, Medical Research Center Seoul National University - Seoul (Korea, Republic of)

LP120 Misfolding Of Biomarkers Stratifies Proteinopathies
Klaus Gerwert 1
1Rohr-University Bochum - Bochum (Germany)
Practical Details

Conference Venue
BOSTON PARK PLAZA
50 Park Plaza at Arlington
Boston, MA 02116

> Meeting Rooms
> Conference Room
All sessions will be held in Grand Ballroom AB – Floor 2 (Mezzanine Level)
> Overflow room
Due to space constraints in the ballroom, a livefeed is available in Avenue 34 at Lobby Level (Floor 1)
> Posters Sessions and Coffee Breaks
Meet our poster presenters during the coffee breaks. A poster assistance desk will be available to locate the posters.

Free WiFi available at CTAD
Network: CTAD2023 - Password: CTAD2023

> Mobile App
Download the vFairs mobile app on the Apple Store or Google Play. Login with the email address used to register, then click on CTAD2023 and enjoy the conference at your fingertips, you can watch the livestream from the Ballroom, access the virtual poster hall and connect with your colleagues!

> CTAD23 digital platform
To access our digital platform simply go to www.ctad23.com and enter with your email address.

> Lunch on your own at CTAD23
Several restaurants and take out options are available close to the Boston Park Plaza!

> CTAD Welcome Reception with the Support of the Alzheimer’s Association
Tuesday, October 24 from 6:50 p.m. to 7:50 p.m.
CTAD Level - Floor 2 - Mezzanine
CTAD would like to thank its 2023 privileged partners for their continued support.

Ultimate Sponsor

Alzheimer’s Drug Discovery Foundation

Platinum Sponsors

Eisai
Lilly

Gold Sponsors

Alzheimer’s Association
Biogen
GSK
Lantheus Cerveau
Landbeck
Novo Nordisk
Otsuka
Follow us on social media!

@CTADConference  
#CTAD23

CTAD Conference

CTAD Alzheimer

Contact us: ctad@ant-congres.com
www.ctad-alzheimer.com
CTAD 2024
Clinical Trials on Alzheimer’s Disease

October 29 - November 1, 2024
Madrid, Spain

www.ctad-alzheimer.com
Email: ctad@ant-congres.com